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Abstract 
The design of advanced biomaterials is a promising strategy to aid the 
regeneration of oral soft tissue which can be lost during surgery or disease. 
Bacterial infection is a common surgery-associated complication which 
could prevent successful tissue integration. Misuse of antibiotics has led to 
the concerning spread of antimicrobial resistance (AMR) so alternative 
antibiotic-free treatments need to be explored.  PhotoTherixTM is a product 
concept based on a bioresorbable electrospun polymer scaffold equipped 
with antimicrobial photodynamic therapy (aPDT) technology aimed for use 
in maxillofacial applications. Typically, in aPDT, a photosensitiser (PS) is 
loaded in its inert form and then activated on-demand through a light 
source to enable its antibacterial function and this principle is central to the 
PhotoTherixTM concept. To enable translation to clinical use, this thesis 
aims to investigate how the scaffold architecture, antimicrobial functionality 
and selectivity can be controlled via variation of chemical and physical 
properties of the polymer as well as process electrospinning parameters. 
Fibrous scaffolds based on Food and Drug Administration (FDA)-approved 
biodegradable polyesters (poly(ε-caprolactone) (PCL) and poly(lactic-co-
glycolic acid) (PLGA)) were obtained via electrospinning. Electrospinning 
parameters were investigated to establish defined structure-function 
relationships. The incorporation and controlled release of two PS 
(methylene blue and erythrosin B) from the material was studied with 
regards to scaffold bactericidal effectiveness against two model bacterial 
strains (Streptococcus mutans and Escherichia coli). Evaluation of the 
viability of cells populating the scaffold was performed using L929 
fibroblasts to determine cell-scaffold relationships. Finally, the selectivity 
achievable between the bacterial and mammalian cells was determined 
through in vitro models. The resulting prototype, PhotoTherixTM, could be 
further developed into a commercial medical device aimed to improve 
patient outcomes, reduce the health economic burden and control the 
spread of AMR.  
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 Literature Review 
1.1 Clinical Needs 
The field of regenerative medical devices began to gain momentum in 
the 1980s[1]. This rise in popularity was due to the shortage of donors for 
organ/tissue transplantation causing an increasing demand from surgeons to 
regenerate a range of damaged tissue within the human body[2]. The 
combined efforts of scientists and engineers towards this common goal has 
led to the development of a range of biomaterial scaffolds which can be used 
alone[3,4] or in combination with cells[5,6] and bioactive agents[7,8]. 
The field of dentistry requires medical device products to aid 
regeneration of hard and soft tissue in the oral cavity[9]. Difficulties arise here 
as the mouth is a moist environment made up of lytic enzymes and over 700 
bacterial species as well as having a complex structure with distinct regions 
owing different patterns of keratinisation[10,11].  Biomaterials used in this 
context would need to tolerate the harsh, high moisture environment without 
degrading before repair and neotissue formation has occurred[12]. 
A commonly occurring issue with oral surgeries is bacterial infection[9]. 
One study found that up to 10% of dental implant surgeries result in 
postoperative bacterial infection[13]. These infections could lead to graft loss or 
the need for further surgical interventions[14]. Current infection treatments rely 
on oral antibiotics but, due to the alarming rise in antimicrobial resistance 
(AMR), antibiotic-free infection control techniques are being explored[15–17].  
Antimicrobial photodynamic therapy (aPDT) is an alternative treatment 
which uses photosensitisers (PS) to kill bacterial cells locally following 
application of convenient light sources without the need to administer 
antibiotics[18]. There now arises an opportunity to develop a new regenerative 
medical device in the form of a biomaterial scaffold with controlled 
degradability and the ability to support the formation of new soft tissue whilst 
displaying on-demand bactericidal activity through incorporated PS. 
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1.1.1 Oral Soft Tissue Loss 
The oral cavity consists of a range of soft and hard tissues[19]. The oral 
mucosa is the mucous membrane of soft tissue lining the oral cavity and can 
be divided into three main sections[20]: 
• Sensory mucosa e.g. taste buds on the tongue[20] 
• Lining mucosa e.g. cheeks and soft palate[20]  
• Masticatory mucosa e.g. gingiva[20] 
The oral mucosa is a very specialised tissue covering under 5% of the 
total human body and has a structure more similar to skin than any other 
mucous membrane[21,22]. The main differences between the oral mucosa and 
skin are that the oral mucosa is moist, it does not contain hair follicles or 
sweat glands, it is more permeable than skin, it has different keratinization 
patterns and it appears more pink in colour due to a greater degree of 
vascularisation[19,23–25]. There are two main structural components which make 
up the oral mucosa; the epithelium and the lamina propria (Figure 1.1)[26]. 
 
 
Figure 1.1 - The structural components of the human oral mucosa[26] 
 
The upper, stratified epithelial layer is predominantly made up of 
epithelial cells[10,22]. The lower lamina propria comprises of a combination of 
connective tissues, fibroblasts, capillaries and extracellular matrix (ECM)[10,22]. 
Below this lies the sub-mucosa. 
The function of the oral mucosa is to provide protection to the 
periodontal tissues from harmful environmental (e.g. chemical or mechanical) 
 3 
 
stimuli and bacterial infections[27,28]. The physiological conditions within the 
oral cavity are unlike those on the skin[29,30]. This is largely due to the 
presence of saliva[29,30] (Table 1.1).  
 
Parameter Value 
pH 5.5-7.0 
Continuous available volume (µl) 696±312 
Viscosity (mPa.s) 1.1±0.1 
Protein Present (mg/ml) 0.7±0.3 
Table 1.1 - The physiological components of saliva[29,30] 
 
Wounds within the oral mucosa heal more quickly and result in less 
scarring than those within the skin[31]. In a study directly comparing oral 
mucosal healing to skin healing in pigs, small gingiva wounds showed no scab 
formation at day 7 and were clinically closed by day 14[31]. At day 28, the oral 
wound was hard to distinguish from the rest of the oral mucosa[31]. 
Comparatively, even after 49 days the same sized skin wounds were clearly 
visible[31].  
However, complications arise when large amounts of oral mucosa 
tissue are lost through disease, accidents and congenital defects[32–37]. Large 
tissue defects cannot be healed naturally which results in a loss of barrier 
function, resulting in a potentially negative physiological and psychological 
impact on the patient due to the aesthetic and functional importance of the 
maxillofacial tissues[38].  
Common causes of oral mucosa damage or loss include oral cancer, 
congenital defects, periodontal disease and peri-implantitis[39,40]. In the UK, 
oral cancer incidence rates are continually increasing[41]. 7591 new oral 
cancer cases were reported in the UK in 2013 and cases have increased by 
68% over the last 20 years[42,43]. Oral surgery is required to remove cancerous 
tissue within the oral cavity, which causes the release of tissue fluid[44]. Due to 
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this, bacteremia (a condition in which bacteria are found present in the blood) 
is a common occurrence[45,46]. 
Cleft lip and palate is a congenital condition which affects 
approximately 7 in every 100 live births[35,47]. If left untreated, it can have a 
great impact on speech, appearance and psychology of the affected 
individual[35,48]. Dental surgeons are required to close the opening in the palate 
or lip, but this procedure is limited by the amount of oral mucosa available for 
transplantation[49]. It is hoped that tissue engineering will produce a material 
that can provide the correct amount of graft material of sufficiently high quality 
for these surgeries to allow fully functional and aesthetic healing post-
surgery[50]. 
Periodontal diseases such as gingivitis or periodontitis are worldwide 
public health problems[32]. These diseases are classified as infections of the 
periodontium which consists of the tissues supporting the teeth, namely the 
gingiva, cementum, periodontal ligament and alveolar bone[38,51]. The bacterial 
destruction of these tissues ultimately results in tooth loss[32,52]. In the US, 
prevalence of periodontitis ranges from 38-53% of the total population[53]. As 
this condition is more common in older age, ageing populations in the 
Western world are likely to demonstrate a continuing increase in 
prevalence[32,54]. Bacteria such as Porphyromonas gingivalis and 
Steptococcus mutans have been associated with the occurrence of tooth 
decay and periodontitis[55,56]. Consequently, clinical treatments able to 
eradicate bacterial contamination or limit bacterial growth are greatly needed 
to reduce the spread of periodontal disease[55,57]. 
Peri-implantitis is a disease which is caused by an infection of the hard 
and soft tissue supporting dental implants[51,58]. A report by National Health 
Service (NHS) England found that half a million adults now have at least one 
dental implant[59]. This is thought to occur in 10% of all dental implants 
between 5-10 years following application in vivo[60]. If implants become 
infected, they need to be removed completely before the site can be cleared 
out and new implants can be fitted[61,62]. This can be time-consuming, costly 
and painful for the patient[63]. Although antibacterial coatings designed for 
implants are currently being studied and progress is being made towards a 
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solution to prevent this disease from occurring, there is still no effective 
treatment in clinical practice[64,65]. 
1.1.2 Antimicrobial Resistance 
A serious complication with dental surgery to repair oral soft tissue loss 
is bacterial infection[66,67]. Should a post-operative oral infection occur, graft 
survival rates are low, with reported values of 65% of grafts needing to be 
removed[68]. The current management of bacterial infections in oral surgery is 
the administration of antibiotics, in some cases as a precaution prior to 
detection of an infection arising[69,70]. A major issue with this treatment route is 
the onset of antibiotic resistance, which is encompassed within the more 
general term of antimicrobial resistance (AMR)[15]. AMR covers resistance to 
current treatments for bacterial, fungal, virulent and parasitic infections[71]. In 
the past 10 years, several large organisations including the World Health 
Organisation (WHO) and the Centers for Disease Control and Prevention 
(CDC) have filed reports on the importance of minimising AMR[16,72]. In April 
2014, WHO declared the issue as a “threat to modern medicine”[16]. CDC have 
stated that in excess of 2 million people become infected with antibiotic 
resistant bacteria each year[73]. O’Neill reported in 2014 that at least 50,000 
people die in Europe and the US each year due to the acquisition of 
antimicrobial-resistant infections[74]. As well as being a serious clinical 
condition AMR poses a great economic burden as well, with yearly costs of up 
to $30 billion being reported in the US alone[75]. 
The most frequently used antimicrobials for use against bacterial 
infections (i.e. antibiotics) can be classified into four main classes based upon 
their chemical structure (Table 1.2)[76]. 
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Class Example Function 
β-lactams Penicillins Inhibit protein synthesis 
Cephalosporins Interfere with cell wall 
synthesis 
Tetracyclines Tigecyclines Inhibit protein synthesis 
Macrolides Erythromycin Inhibit protein synthesis 
Aminoglycosides Gentamicin Inhibit protein synthesis 
Table 1.2 – Four main classes of antibiotic agents[76,77] 
 
Bacteria typically develop resistance against these antibiotics through 
three main mechanisms (Table 1.3)[78]. 
 
Resistance Mechanism Class of Antibiotics 
Modification or degradation of the antimicrobial 
agent 
β-lactams and 
aminoglycosides 
Mutation of the bacterial target site resulting in a 
lower affinity for the antimicrobial agent 
β-lactams, 
tetracyclines, 
macrolides, and 
aminoglycosides 
Decreased uptake or increased efflux of the 
antimicrobial agent resulting in a decreased 
accumulation within the bacteria 
Tetracyclines and 
macrolides 
Table 1.3 –Antimicrobial Resistance (AMR) mechanisms of bacteria 
against the main classes of antibiotics[78] 
 
The causes of AMR are known to be complex, with several interlinking 
factors[79]. Despite ongoing research, the precise relationship between 
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humans and microbes is still unknown[72]. The main drivers are thought to be 
the inappropriate use of antibiotics, both in medicine and agriculture[15,79]. The 
term ‘inappropriate use’ is related to the overuse of antibiotics through 
unnecessary, preventative or incorrect prescriptions, unregulated use within 
agriculture, and through not following prescription guidelines[15,79,80]. This has 
led to the urgent and ongoing need to treat infections via means which do not 
involve administering antibiotics, in the hope that the scaling-back in 
widespread use will reduce this dangerous spread of AMR[75,81]. 
1.2 Regenerative Biomaterials for Oral Soft Tissue Loss 
Regenerative biomaterial scaffolds provide one option to encourage 
repair of oral mucosa. They are required to support neotissue formation by 
being physically, biologically and chemically suitable for the application[82,83].   
1.2.1 Current Biomaterials for Oral Mucosa Regeneration 
Biomaterial scaffolds are supporting structures which aim to aid tissue 
regeneration by providing support for in vivo cell proliferation and tissue 
growth within large defect sites[84]. Current scaffolds to aid regeneration of oral 
mucosa can be categorised into two main groups; tissue grafts and polymeric 
scaffolds. 
1.2.1.1 Tissue Grafts 
Tissue grafts can be in the form of autogeneic (same individual 
human), allogeneic (other humans) or xenogenic (other species) tissue[85]. 
Each of these tissue graft sources has associated advantages and 
disadvantages and, where commercially available, have been associated with 
various degrees of clinical success[86–88] (Table 1.4). 
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Tissue 
Graft  
Advantages Disadvantages Examples of 
Commercial 
Products for 
Soft Tissue 
Repair 
Autograft • No adverse 
immune response 
• Lack of tissue 
availability  
• Donor site morbidity 
N/A 
Allograft • Greater availability 
than autograft 
• Possible adverse 
immune response 
• Disease transmission 
risk 
• Relies on donated tissue 
• Ethical/religious issues 
• Alloderm® 
(BioHorizons) 
• SureDerm® 
(Hans 
Biomed) 
Xenograft • Greater availability 
than 
autograft/allograft 
 
• Possible adverse 
immune response 
• Disease transmission 
risk 
• Ethical/religious issues 
• OASIS® 
Wound 
Matrix (Smith 
and Nephew) 
Table 1.4 - Advantages and disadvantages of different soft tissue graft 
sources used in tissue engineering and example commercial 
products[86–88] 
 
1.2.1.1.1 Autograft 
Autologous connective tissue graft transplants commonly taken from 
the gingiva or the hard or soft palate are the current ‘gold standard’ for the 
treatment of oral soft tissue loss[89–93]. The main issue with this method is the 
lack of available oral mucosa for transplantation to the wound site[94]. Due to 
this, sources of autologous skin tissue have been attempted from the thigh[93], 
the forearm[95] or the pectoralis[95]. Further disadvantages of the use of 
autologous tissue including unwanted hair growth within the oral cavity[96], 
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wound contraction[97,98] and donor site morbidity[99] have led to the search for 
alternative sources of tissue. 
1.2.1.1.2 Allograft/Xenograft 
A well-researched and documented skin or oral mucosa graft is the 
commercially available product, ‘Alloderm®’ (BioHorizons)[26,36,92,98,100–112]. 
This product consists of a donated and processed human cadaveric dermis 
which can be preoperatively processed ex vivo into an oral mucosa equivalent 
to improve clinical success[98]. This process involves obtaining and culturing 
oral mucosa keratinocytes from the dental patient which are then seeded onto 
the Alloderm® scaffold prior to implantation[98]. The use of this technique 
compared to using the acellular scaffold showed a reduction in re-
epithelization time from 46±2.8 days to 27.4±1.2 days[98]. The obvious 
drawback to this technique is the cost of treatment and the time taken to 
produce the oral mucosa equivalent prior to surgery and the need for immune 
suppression drugs to prevent rejection[113,114]. 
A similar approach has been used by a competitor, SureDerm® (Hans 
Biomed)[115,116]. This also consists of a human cadaveric dermis[115]. Good 
healing rates and vascularisation were observed in several in vivo studies in 
athymic mice when compared to an autogenic graft treatment group and 
clinical safety and efficacy have been demonstrated[26,36,92,98,100,101,103,107–112].  
Freeze-dried human amniotic membranes (HAM) donated by women 
undergoing elective caesareans have also been used in oral mucosal 
surgery[5,117–119]. This has the advantage of being a good use for a common 
biomedical waste substance[117]. HAM processing typically involves 
cryopreserving or dehydrating the tissue. A full tissue engineered oral mucosa 
construct can be produced by removing the epithelial layer, decellularising 
and sterilising the remaining membrane, and then using this in combination 
with oral mucosa epithelial cells[118]. The resulting graft has been shown to 
have favourable mechanical properties and has been shown through 
histological analysis to be successfully integrated in mouse and rabbit animal 
models[5,117,118]. However, the use of HAM still has the same complications 
related to those with the cadaveric dermis products in terms of ethical 
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considerations and the need to administer immune suppression drugs to 
prevent rejection[114]. 
Studies have been reported on the use of porcine small intestinal 
mucosa (SIS) seeded with human oral mucosa fibroblasts and epithelial cells 
in an in vitro study that resulted in successful cell infiltration and 
revascularisation upon histological analysis[120]. Another more recent in vitro 
xenograft study demonstrated the ability of acellular urinary bladder matrix 
from porcine sources to successfully treat oral soft tissue loss in rat 
models[121]. 
However, ethical or religious complications with the use of cadaveric or 
animal tissue and the time taken to obtain a biopsy and to culture the cells are 
the main problems with the use of allograft and xenograft tissue sources[122]. 
Another risk factor is that no matter how trustworthy the source of donor 
tissue, there is always a risk of viral transmission or host rejection[123]. 
Therefore, it can be concluded that there is no ‘perfect’ graft material available 
currently for use as an oral mucosa regenerating scaffold[122]. 
1.2.1.2 Polymer Scaffolds 
Polymeric scaffolds can be made of naturally-derived polymers, 
synthetic polymers, or a combination of the two[124]. Again, each of these has 
associated advantages and disadvantages[86–88] (Table 1.5). 
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Polymer  Advantages Disadvantages Commercial Products 
Natural • Readily available 
• Inherent cell adhesion motifs 
• No ethical/ religious concerns 
• Possible adverse immune response 
• Disease transmission risk 
• Limited control of degradation 
• Batch to batch variation 
• Bio-Gide® and Bio-GidePro® 
(Geistlich) 
• CollaTape® (Zimmer Dental)  
• MucoGraft® (Geistlich) 
• Collagene AT® (Sistema AT)  
• INTEGRA® Dermal (Integra)  
Synthetic • Readily available 
• Relatively cheap 
• No disease transmission risk 
• Scaffold properties can be finely tuned 
to suit application 
• No ethical/ religious concerns 
• Possible adverse immune response 
• No adhesion cell adhesion motifs 
• Possible toxicity 
• BioMesh® (Samyang) 
• Vicryl (Ethicon, Johnson and Johnson 
Medical) 
• Costar® (Corning) 
Hybrid • Scaffold properties can be finely tuned 
to suit application 
• Readily available 
• Inherent cell adhesion motifs 
• Possible adverse immune response 
• Possible toxicity 
• Potentially non-uniform degradation 
• BIOBRANETM (Smith and Nephew) 
Table 1.5 – Advantages and disadvantages of the different polymer types used in tissue engineering[86–88] 
 
1
1
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1.2.1.2.1 Natural Polymers 
Naturally-derived polymers (e.g. proteins such as collagen or elastin, or 
polysaccharides such as chitosan) are commonly used as building blocks of 
regenerative devices in light of their higher biocompatibility and lower toxicity 
compared to synthetically produced polymers[125,126].  
One of the most commonly studied natural polymers for oral mucosa 
regenerating scaffolds is collagen[2,88,89,127–133].  Several processes have been 
used to form collagen scaffolds, such as electrospinning, freeze drying and 
chemically crosslinked hydrogel formation[6,134]. Many of these collagen-based 
matrices are available commercially, including Bio-Gide® and Bio-GidePro® 
(Geistlich)[120], CollaTape® (Zimmer Dental)[37,90,91,135,136], MucoGraft® 
(Geistlich)[91], Collagene AT® (Sistema AT)[115], INTEGRA® Dermal 
Regeneration Template Single Layer (Integra)[137], TissuFoil E (Baxter)[137] and 
CelTx® (Organogenesis)[138]. However, concerns with the use of bovine 
collagen remain as despite being approved for use by the US Food and Drug 
Administration (FDA), there have been outbreaks of bovine spongiform 
encephalitis after implantation of these scaffolds[123]. Blending collagen with 
other natural polymers has been attempted to improve parameters such as 
cell viability (e.g. with chitosan)[23,139,140], and mechanical stability in 
physiological conditions (e.g. with elastin)[141].  
Histological analysis confirmed successful integration following the use 
of pure chitosan scaffolds implanted in the hard palate of dog animal 
models[142]. However, despite new methods for crosslinking[143], chitosan has 
been found to have low mechanical stability[144].  
Nanofibrous gelatin can be generated by thermal-induced phase 
separation followed by porogen leaching[145]. These scaffolds were analysed 
using confocal microscopy to demonstrate favourable cell-cell and cell-matrix 
interactions with human gingival fibroblasts[145]. 
Another natural biomaterial which has been explored for oral mucosa 
regenerative devices is based on a blend of fibrin and agarose[145–151]. Fibrin 
has been found to have many favourable properties such as biocompatibility 
and controllable degradation, but the key disadvantage was the limited 
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mechanical properties of the protein[152]. When combined with agarose and 
autologous cells, the properties of the resulting biomaterial product become 
more favourable which has led these prototypes to be moved into clinical 
trials[66,153]. The concerns found in these case studies were the time taken to 
produce the scaffolds seeded with autologous cells (limiting suitability of this 
technique to non-oncological cases due to the time pressure to treat these 
patients) and observed wound contracture[66,153]. 
1.2.1.2.2 Synthetic Polymers 
Synthetic polymers such as poly(ethylene glycol) (PEG), poly(lactic 
acid) (PLA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL) and 
poly(lactic-co-glycolic acid) (PLGA) are all commonly used in oral medical 
devices[82,154–157]. PLA is used due to many desirable properties such as it 
being biocompatible, having good mechanical strength and it being able to be 
shaped easily[82,154]. PGA has good biocompatibility and is readily 
biodegraded so it is used frequently in applications such as resorbable 
sutures[154]. PEG is used as a biomaterial as it is non-toxic, hydrophilic, 
biocompatible and only causes a minimal immune response[82]. PEG has also 
been blended with PLA to make a more hydrophilic final product compared to 
the polyester alone[82]. The challenge with the use of synthetic polymers in 
vivo is that cell adhesion is often low due to the lack of cell-binding sites along 
the polymer backbone[82]. This issue can be overcome through alteration or 
treatment of the polymers, for example, PCL nanofibres displayed significantly 
increased cell adhesion following NaOH-soaking for 1 hour prior to cell 
seeding[158]. 
A commercially available scaffold as a dental membrane, BioMesh® 
(Samyang), consists of a blend of PGA, PLA and PLGA polyesters[115]. This 
was determined to be less effective for cell growth than a collagen scaffold[115]. 
A further study compared three synthetic commercial products based on 
either poly(ethylene terephthalate) (Greinier Bio-One), PCL (Costar® 
(Corning)) or collagen-based scaffolds[136]. This also found that the collagen 
scaffolds were superior with regards to cell growth and ECM deposition 
despite the faster degradation shown by the latter products[136]. This would 
suggest that more work is needed to enhance the cell-scaffold interactions in 
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the above-mentioned synthetic scaffolds. One commonly used technique is 
the inclusion of peptide sequences within polymer scaffolds, such as the 
tripeptide Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences 
which are known to increase cell binding affinity[159–167]. For example, cell 
growth and differentiation on PLGA films with grafted RGD/YIGSR protein 
motifs were shown to be significantly greater than for the native PLGA 
films[168]. However, modified synthetic polymers would require additional 
testing before gaining regulatory approval which is likely to increase the cost 
and time taken before the polymer scaffold can be approved for clinical 
use[169]. 
Despite this, nonwoven pure PGA scaffolds have been shown to 
successfully support cell growth of human dental pulp cells and gingival 
fibroblasts when implanted into mice[170]. Scaffolds produced with degradable, 
hydrophobic polyurethane were also determined to be useful for repair of oral 
mucosa by seeding with human gingival fibroblasts[171,172] and have been 
electrospun into functional biomaterials[173].  
Overall, synthetic products could be the ideal choice for tissue 
engineered biomaterials due to their already widespread clinical use, fine-
control of macroscopic properties, with no ethical or religious implications, and 
the removed risk of disease transmission[86]. They are also cost-effective and 
versatile as they can be highly tuneable to their applications[174]. 
1.2.1.2.3 Hybrid Polymer Systems 
An interesting advancement in polymer science has been the use of 
hybrid polymer systems consisting of synthetic and natural polymer blends[175–
177]. Hybrid polymer systems have the advantage of being highly tuneable yet 
displaying the necessary cell adhesion motifs and biocompatibility found with 
naturally derived biopolymers. Studies have been performed with a nonwoven 
gelatin/PCL scaffold[178,179]. This hybrid polymer structure was found to be able 
to successfully mimic the ECM fibrous architecture and not stimulate an 
inflammatory response whilst being used to repair mini-pig oral mucosa[178]. 
As these hybrid polymer systems contain ECM-mimicking sequences at 
the molecular scale, they would result in the same associated disadvantages 
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as described previously such as ethical or religious issues as well as the 
increased expense and time taken for regulatory approval. The production of 
a purely synthetic polymeric oral mucosa substitute made entirely from 
polymers with regulatory approval would be preferable to completely avoid 
these associated issues if optimisation of the desired properties was 
successfully achieved. 
1.2.2 Desirable Properties of Polymeric Biomaterials for Oral 
Mucosa Regeneration 
In manufacturing a new biomaterial to be used as a regenerative 
medical device, several factors should be taken into consideration. The 
biomaterial should[180]: 
• Support cell growth by having good biocompatibility[181]  
• Have fibrous scaffold architecture to allows for tissue 
ingrowth[182,183] 
• Be appropriately biodegradable[124] 
• Have suitable mechanical properties[184] 
• Be compliant with industrial manufacturing processes to allow 
for commercialisation[185–187] 
Each of these features will be discussed in more detail below. 
1.2.2.1 Biocompatibility 
It is crucially important for all medical devices to be non-toxic to the 
native in vivo environment[174]. This is essential not only for clinical success, 
but also to ensure approval by the regulatory bodies prior to 
commercialisation[188–190]. For any medical device, the ISO (International 
Organization for Standardization) 10993 standards are the main 
consideration, with a <30% mammalian cell cytotoxicity needed to be proven 
in vitro[188,191,192]. For this reason, a range of in vitro cytotoxicity tests have 
been developed as an initial indicator of the tolerability of a new biomaterial in 
biological settings[193]. These include quantitative measurements which 
involves growing a monolayer of mammalian cells (commonly L929 mouse 
fibroblast cells) and introducing the new biomaterial to see the effect on 
morphology and confluence of the cells[192,194]. Common studies to estimate 
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the cytotoxicity results from these assays include the determination of the 
metabolic activity of the cells via MTT assays[195], AlamarBlueTM assays[196] or 
ATP (adenosine triphosphate) luminosity assays[197,198]. These assays use 
either dyes which change colour, or proteins which luminesce, when they are 
reduced by enzymes present in living cells[197]. 
Any biomaterial to be made commercially available as a medical device 
needs to be approved by the relevant regulatory bodies[124]. Using FDA-
approved polymers in the scaffold would facilitate the expensive and lengthy 
process of applying for medical device approval [199]. The FDA-approved 
synthetic polymers which have previously been used for oral mucosal repair 
include PCL[200], PGA[201], PLA[202] and PLGA[203]. 
Aside from not harming the cells, it is also important that regenerative 
scaffolds encourage cell adhesion to promote neotissue formation[204]. Many 
material properties are known to affect cell attachment, including biomaterial 
architecture (such as fibre diameter and pore size)[205,206], shape[207], 
environmental responsiveness[208], mechanical properties[209], 
biodegradation[116], chemical functionality[210] and biological motifs[211]. 
1.2.2.2 Biodegradability 
Biodegradation is a term used to describe polymers which lose mass 
over a period of time in a biological environment[124]. There are concerns with 
the use of slowly degrading polymers in medical devices as these could cause 
adverse biological effects when present in vivo for prolonged periods of time 
and prevent full neotissue formation as cells cannot infiltrate the polymer 
structure[82]. Alternatively, if the degradation occurs too quickly, there will be a 
rapid loss of mechanical stability at the site of regeneration before neotissue is 
formed which could lead to further injury[212]. An additional concern with 
polymers (i.e. polyesters) degrading too quickly is that this could lead to the 
formation of acidic and potentially toxic degradation by-products in a localised 
area within the body[154]. Therefore, the degradation profile of each polymer 
needs to be tailored to fall within an appropriate timescale for the proposed 
clinical application[201].  
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In biological environments, polymers can undergo chemical 
degradation through hydrolysis or enzyme-catalysed cleavage[154]. Synthetic 
polymers (such as polyesters) are more likely to be degraded via hydrolysis 
whilst biopolymers typically degrade through enzymatic reactions[154].  
Hydrolytic polymer degradation occurs through a series of events. 
Firstly, water enters the polymeric structure and causes swelling[213]. Water 
molecules cleave covalent bonds between repeating units resulting in the 
formation of oligomers[214]. This process causes the architecture of the 
polymer to become irregular and more porous[215]. As these oligomers typically 
contain acidic functionality, a pH drop is usually observed locally within these 
pores, which accelerates the polyester degradation via autocatalysis[213]. 
Controlled degradation of a polymeric building block is important as this will 
ensure that the biomaterial structure, toxicity and clearance rate is uniform 
and controlled[194,216]. Hydrolysis results in the decrease in molecular weight at 
the molecular scale and a drop in mechanical strength at the macroscopic 
scale of the polymer scaffold[217]. Both molecular weight and mechanical 
strength of the polymeric scaffold can be monitored in vitro to investigate the 
degradation kinetics[154,218]. 
Hydrolytic reactivity of the chemical bonds present in the polymer is an 
important consideration with respect to degradation kinetics (Table 1.6)[219]. 
 
 
 
 
 
 
 
 
 
 18 
 
Polymer Type Functional Group Relative Hydrolytic 
Reactivity 
Polyether -CH2-O-CH2- Low 
Polyurethane -O-CO-NH-C-  
Polyester (aromatic) -CO-O-C-  
Polyamide -CO-NH-C  
Polyanhydride -(CH2-CO)2-C-O-  
Polyester (aliphatic) -CO-O-C- High 
Table 1.6 - The relative reactivity of different polymer types increases 
from the top to the bottom of the table[219] 
 
Aliphatic polyesters are commonly used as building blocks for medical 
devices as they are most hydrolytically active and their degradation products 
have low toxicity[220]. It is also possible to cap end groups of polymers, 
chemically cross-link polymer chains or synthesise co-polymers in order to 
fine tune the hydrolytic degradability and hydrophilicity as well as thermal and 
morphological properties of the resulting material[24,221–223]. 
Within a polymer structure, polymer chains can arrange into crystalline 
or amorphous configurations. Amorphous structures consist of randomly 
arranged polymer chains[224,225]. Contrastingly, crystalline structures are highly 
regular, closer to the structural arrangements within a crystal structure[224,225]. 
Semi-crystalline structures contain both of these structural regions[226] (Figure 
1.2).  
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Figure 1.2 - The states of polymer arrangement: crystalline, 
amorphous and semi-crystalline 
 
If a second monomer type is incorporated within the polymer backbone, 
a change in the morphology and thermal properties such as the crystallinity 
and glass transition temperatures of the resulting copolymer are expected[154]. 
The different degree of crystallinity within a polymer will alter the rate of 
biodegradation[227]. For example, crystalline PGA sutures are known to 
degrade in dental surgery within 7-10 days[228]. Therefore, the use of pure 
PGA scaffolds in oral mucosal repair may be unsuitable as it could degrade 
too quickly (< 1 month) to support the neotissue formation[229,230]. To 
overcome this problem, PGA can be copolymerised with PLA to generate 
PLGA copolymers[231]. This is advantageous as the tuning of the glycolide to 
lactide ratio can be used to alter the crystallinity and thus tune the degradation 
rate to suit the desired application[123]. It has been demonstrated that an 
increase in the lactide component decreases the rate at which degradation 
occurs[123,232,233]. One study evaluated cell viability on electrospun scaffolds to 
help heal skin using the synthetic polymers PLA, PGA and PLGA[123]. In this 
study, it was concluded that PLGA 85:15 (85% lactide to 15% glycolide 
monomers) and 75:25 (75% lactide to 25% glycolide monomers)  were optimal 
in terms of the polymer biodegradability and biocompatibility to be used for 
this application[123]. 
A structural characteristic which affects many properties such as 
degradation, mechanical properties and the water uptake (WU) is the scaffold 
porosity[234]. The more porous the scaffold, the easier it would be for the 
scaffold to take in water, and therefore a greater surface area would be 
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exposed for potential hydrolytic degradation[234]. In tissue engineered 
products, porosity is also important for cell infiltration[235,236]. Another factor is 
the hydrophilicity of the polymer, as if the polymer is less hydrophilic, the WU 
will be slower and thus the degradation rate will also be decreased[237]. 
Therefore, both the porosity and hydrophilicity of the scaffold need to be 
controlled to tune the degradation[238]. 
The molecular weight of the polymer also impacts on the degradation 
behaviour. A polymer with an increased molecular weight displays a decrease 
in degradability[239,240]. This is because a greater molecular weight polymers 
would require more chemical bonds to be broken during the break down of the 
polymer chain[240]. 
1.2.2.3 Mechanical Properties 
The thermal properties and crystallinity of polymers (section 1.2.2.2) 
have been shown to have an influence on the mechanical properties of the 
material[241]. Tensile properties of polymer scaffolds are typically established 
via uniaxial tensile testing, which can be used to calculate the elastic modulus, 
toughness and percentage elongation for a particular scaffold[242,243].  
Improvements in the mechanical properties of polymers can be 
achieved through techniques such as heat treatments to alter the degree of 
crystallinity[226]. 
The properties of oral biomaterials are not only important in vivo but 
also for the dental practitioner during surgery[244,245]. If the device is difficult to 
handle, the product may be at increased risk of being implanted incorrectly, 
ultimately resulting in poor clinical performance[90]. It is therefore desirable for 
the product to be pliable and relatively adhesive when moist[246]. The adhesion 
here would prevent the biomaterial from ‘springing back’ when put in 
place[246,247]. If the product was too adhesive however, it would be difficult to 
initially position or reposition if required[246]. 
1.2.2.4 Manufacture of Fibrous Scaffolds 
Nonwoven fibrous scaffolds are frequently used in regenerative 
scaffolds as the fibre diameter and pore size can be tuned for the desired 
application[125]. Pores present within the structure are also inter-connected 
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which can be useful for cell infiltration[125]. This three-dimensional porous 
structure produced within nonwoven scaffolds mimics the ECM of biological 
tissues, such as the lamina propria layer of the oral mucosa[127,248,249]. 
As scientific research has progressed, it has become possible for 
biodegradable regenerative biomaterials to be combined with additional 
functionality through drug loading to aid new tissue formation[250–254] such as 
antimicrobial functionality[255,256]. Depending on the polymeric building blocks, 
nonwoven fibrous scaffolds generated can be used for both hydrophobic and 
hydrophilic drugs[257–259]. For delivery of antimicrobials into the oral cavity, the 
antimicrobials would ideally be steadily released from the biomaterial until 
complete mucosal relining had occurred, as by this point the risk of infection 
would be lower[260]. This has been shown to take up to 4 weeks[260]. Fibrous 
scaffolds could be suitable for this as the release profile for the scaffolds can 
be highly tuned by varying the composition and porosity of the structure[254,261]. 
There are a range of commonly used techniques to generate fibrous 
scaffolds, each with inherent advantages and disadvantages. These include 
wet spinning, melt spinning and electrospinning. 
1.2.2.4.1 Wet Spinning  
Wet spinning is a technique which involves the extrusion of a polymer 
solution into a coagulation reservoir, upon which solid fibres form through non-
solvent induced phase separation[193]. This is a useful technique if there are 
concerns about the use of high voltages (such as those used with 
electrospinning techniques) degrading the polymer solution or biomolecules 
contained within this solution[193,262]. When using synthetic polyesters, it is 
unlikely that the polymer solution would be susceptible to degradation at high 
voltages, so this would not be a concern. Therefore, as wet spinning is a 
relatively complex manufacturing technique, it would not be the preferable 
choice of manufacturing for polyester solutions[262]. 
1.2.2.4.2 Melt Electrospinning 
Melt electrospinning is a technique which avoids the use of toxic 
solvents as a polymer solution is generated through the direct melting of the 
polymer into a viscous solution[263]. Therefore, it is commonly chosen for 
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polymers with limited solubility in water to allow for a ‘greener’ manufacturing 
method to be chosen[264]. However, this technique is less frequently used that 
electrospinning due to the increased complexities and associated costs[264]. 
1.2.2.4.3 Electrospinning 
Electrospinning is a relatively simple technique which is used to 
efficiently produce micro- to nano-scale fibres of polymer solutions at a high 
production rate with low associated costs[125,265,266]. Although the principle of 
the technique was discovered over 120 years ago[267], it has only become 
widespread in the last 10-15 years, possibly due to the increased interest in 
nanoscience and tissue engineering applications[125]. The size of the fibres 
can be smaller than with most other techniques such as self-assembly and 
phase separation[125,268].  
The electrospinning apparatus consists of a syringe with metal 
spinneret, a voltage supply and a grounded collector (Figure 1.3)[125,248]. 
 
 
Figure 1.3 - The basic electrospinning apparatus[125,248] 
 
A polymer solution is fed into the needle of the syringe, and held at the 
tip by surface tension[248]. A voltage is applied to the system, commonly 
between 10 – 50 kV, which causes charge repulsion within the polymer 
droplet and causes it to stretch away from the needle[248,266]. Once a sufficient 
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charge repulsion has been transferred, this overcomes the electrostatic 
repulsion and causes the droplet to stretch into a Taylor cone (Figure 1.4)[269].  
 
 
 
Figure 1.4  - The process of applied voltage resulting in a Taylor 
cone being generated at the needle tip of electrospinning 
apparatus[269] 
 
 
This charged cone is then pulled into a jet of polymer solution[125,248]. As 
the voltage is increased this causes the charges within the polymer to repel 
each other[266]. This, along with the evaporation of the solvent, causes the 
polymer stream to stretch from the needle tip towards the grounded collector 
electrode[125,266]. This voltage gradient causes the stream to be stretched and 
whipped to elongate and narrow the fibres[248,266]. The products produced 
therefore have inherent porosity and have a large surface area to volume 
ratio[266]. It was initially hypothesised that the jet splayed into several smaller 
jets when the charge repulsion caused movement in the jet[270]. The use of 
high speed photography has since shown that the stream remains a single jet, 
subject to rapid whipping[271]. 
One of the most important parameters which can be altered is the 
polymer solution used[272–274]. Different properties of the resulting scaffold can 
be a result of changes to the viscosity, conductivity, surface tension and the 
molecular weight of the polymer solution[125]. The difficulty with varying these 
parameters is that there is often an interplay between different factors [248].  
The solvent system needs to be optimised depending on the polymer 
used[125,275]. The volatility of the solvent has a key role in the process; the 
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more volatile the solvent, the earlier the jet will dry, and therefore the jet will 
have a slower speed[248,270]. Volatile organic solvents are commonly used for 
the process, but the most volatile of these are often also highly flammable, 
which may limit their use in commercially produced scaffolds[276]. In order to 
optimise the process of selecting the optimum solvent, a ‘spinnability-solubility 
map’ has been produced, but this study concluded a higher solubility does not 
always produce better electrospun scaffolds[277]. Although there are concerns 
with the use of toxic solvents in electrospinning, vacuum drying the 
electrospun scaffolds for prolonged periods of time can remove any potentially 
toxic solvent residues[254,263,264]. Thermogravimetric analysis (TGA) can be 
used to confirm the removal of all residual solvent[254].  
The electrical field applied, the type and size of needle tip used, the 
flow rate and the distance between the tip and the collector will also alter the 
product of electrospinning[125]. Various electrospinning techniques such as 
coaxial, multiaxial, needleless or emulsion electrospinning could also be used 
to tune the final product[125,266]. The ambient environment of the 
electrospinning rig can also affect the final nonwoven scaffold structure, which 
includes the temperature, humidity and air velocity[278]. 
It has been found that the morphology and density of fibres is changed 
upon the incorporation of additives such as hydrophilic antibiotics due to the 
charge effects on the process, i.e. an increase in solution charge would result 
in an increased whipping action and a narrowing of resulting fibres[254].  
A key benefit of electrospinning for the production of a commercially 
available tissue engineered regenerative medical device is the ease and 
relative low cost of the apparatus setup[248]. As only a small size is needed for 
the oral cavity, a large amount of the product can be produced at once, and 
product homogeneity is easily achieved due to the repeatability of the 
technique[248]. Therefore, for oral applications, electrospinning could be the 
preferred choice of manufacturing technique. 
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1.3 Antimicrobial Strategy 
Bacterial susceptibility to antimicrobials can be tested with bacteria in 
planktonic (suspended in solution) or biofilm form[279,280]. Testing with 
planktonic bacteria is commonly used initially as it allows for faster screening 
of antimicrobials[281]. The use of biofilms is a more accurate way of testing 
antimicrobials as bacteria commonly exist in this form in vivo in the oral cavity, 
particularly in dental plaque[282,283]. It is worth noting that biofilms have been 
shown to be up to 1000 times less susceptible than planktonic bacteria to 
certain antimicrobials[281,283]. 
There are two classes of bacteria; gram-negative and gram-positive, 
which are distinguished due to the cell wall structure (Figure 1.5). 
 
 
(A) (B) 
Figure 1.5 – General membrane structure of (A) Gram-negative and (B) 
Gram-positive bacteria[284] 
 
Gram-positive bacteria have a thick porous layer of peptidoglycan and 
an inner cytoplasmic membrane, whereas Gram-negative bacteria have both 
an outer and an inner membrane which are separated by a thin layer of 
peptidoglycan[285]. This additional outer membrane on Gram-negative bacteria 
means that typically they are less permeable to uptake antimicrobials and are 
therefore more resistant[284–286]. 
 
 
 26 
 
1.3.1 Types of Antimicrobials 
The severe consequences of AMR (section 1.1.2) has led to research 
into a host of antibiotic-free antimicrobial strategies[287–290]. These alternative 
antimicrobial approaches include organic substances (e.g. chitosan[126], 
cinnamaldehyde[291–293], carvacrol[291] and manuka honey[294], fatty acids[295] 
and chlorhexidine[296,297]) inorganic substances (e.g zinc[255,298], titanium 
oxide[299], silver nitrate[300] and gold or silver nanoparticles[290,301–303]), and a 
host of either organic or inorganic PS for use with light resulting in aPDT 
effect[304–306]. 
There are several examples of nonwovens being used for the delivery 
of antimicrobial agents in the oral cavity[307]. These include zein/chitosan blend 
electrospun scaffolds[308], chlorhexidine polytetrafluoroethylene scaffolds[297], 
chlorhexidine glycolide fibre scaffolds[297], and zinc carbomer (Carbopol®) 
scaffolds[298]. 
Chitosan is inherently antimicrobial, and this polymer has proven to be 
effective on oral pathogens[309]. Common oral pathogens Actinobacillus 
actinomycetemcomitans and Streptococcus mutans were shown to be 
inactivated by a 0.1% chitosan solution with a 2-log reduction in colony 
forming units (CFU) after 30 minutes, which increased to 4.5-log reduction 
after 120 minutes[310]. Antimicrobial activity was also demonstrated on the 
periodontal pathogen Porphyromonas gingivalis upon exposure to 
chitosan[309].  However, chitosan is a naturally occurring polymer so has the 
associated disadvantages (section 1.2.1.2.1). 
Inorganic components such as nanoparticles of silver, titanium dioxide 
and silica dioxide have been compared to the commonly used dental 
antibacterial chlorohexidine in biochemical assays to determine their use as 
antimicrobial agents within the oral cavity[303].  Both silver nanoparticles and 
silver nitrate were shown to be more bactericidal than chlorohexidine in this 
case, but titanium dioxide and silica dioxide were not as effective as 
chlorohexidine[303]. Similarly, silver zeolite (AgZ), silver zirconium phosphate 
silicate (AgZrPSi) and silver zirconium phosphate (AgZrP) were all shown to 
be effective at deactivating Streptococcus mutans, Lactobacillus casei, 
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Candida albicans and Staphylococcus aureus[311]. However, in a report 
published by the Scientific Committee on Emerging and Newly Identified 
Health Risks for the European Union (EU), it was concluded that due to gaps 
in knowledge, it is not yet known whether nanosilver is harmful for the 
environment or could lead to further AMR[312]. Another issue raised in this 
report was the risk of occurrence of argyria, a permanent bluish-grey skin 
discoloration resulting from exposure to silver[312].  
aPDT is a promising alternative strategy to the antimicrobial agents 
discussed above, with the additional benefit of the on-demand capability of the 
treatment. 
1.3.1.1 Antimicrobial Photodynamic Therapy 
PDT originates from observations made over 100 years ago that the 
combination of light and photosensitising dyes can lead to the death of 
microorganisms[18,313]. It has since been used throughout medical science, 
predominantly for the treatment of cancer[313–315] but also in dermatology and 
eye disorders[18,316]. Recently, applications have moved back towards the 
original use of PDT by using PS to target bacterial infections locally[313,317–319]. 
As oral infections can be treated through localised antimicrobial action, this 
technology would be a good alternative to antibiotics[320]. 
The key advantages are that it is possible to have the same killing 
effect upon all bacteria, regardless of resistant strains, and that there is no 
further induction of resistance triggered[18,321,322]. Another benefit of aPDT is 
that both the PS and the light are non-toxic alone, but when combined in the 
correct dose levels they can be tuned for selective toxicity to bacteria[323].  
A main issue in the use of this technology for infectious diseases is that 
it is yet to be fully established[18,281]. This is due to the lack of knowledge on 
the delivery of the PS to bacteria, the role of uptake and the selectivity 
achievable between the bactericidal effect and the sparing effect upon host 
cells[18]. 
1.3.1.1.1 Photochemical Mode of Action 
In a non-activated PS, a pair of electrons exist in the PS ground state 
(0PS)[313]. To activate a PS, light of a specific wavelength needs to be applied. 
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This is normally light in the visible or near-infrared region of the 
electromagnetic spectrum and is PS-specific[313]. This light provides the 
energy to excite one of these electrons from the highest occupied molecular 
orbital (HOMO) into the lowest unoccupied molecular orbital (LUMO) of the 
excited singlet state (1PS*) (Figure 1.6) [313].  
 
 
Figure 1.6 - Jablonski diagram showing the movement of electrons 
upon light stimulation within a photosensitiser (PS). 0PS: PS Ground 
State; 1PS*: PS Excited Singlet State; 3PS*: PS Excited Triplet State; 
hv: Light Energy; ISC: Inter-System Crossing; ROS: Reactive Oxygen 
Species[313] 
 
The spin state of the electron remains unchanged[313]. The electron is 
relatively unstable, so only remains in the LUMO of the 1PS* for a few 
nanoseconds[313]. As this state is short-lived, it is important to localise the PS 
to the site of infection before activation as it will only affect cells in the 
immediate vicinity[313]. From the 1PS* LUMO, there are three routes which the 
electron can take[313]. The first is that it can fall back to 0PS and release the 
absorbed energy as heat[313]. The second is that this fall back to 0PS can 
result in the emission of fluorescence energy as the wavelength of light 
emitted is slightly different to the wavelength absorbed[313]. The third is that the 
electron will reverse spin, known as inter-system crossing (ISC) which will 
convert it to the excited triplet state (3PS*)[313]. 
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From the 3PS* state, the electron can fall back to 0PS, this time with the 
energy being emitted as phosphorescence[313]. The final route for the energy 
of this electron is the course which provides the PDT activity, which involves 
the electron reacting with oxygen to produce reactive oxygen species 
(ROS)[313]. The interaction of this electron from the 3PS* with oxygen can 
occur through two different photochemical reactions: Type I PDT and Type II 
PDT[313]. Both of these mechanisms occur concurrently, with the ratio of the 
two depending on the type of PS used and the local environment of the PS in 
vivo[324]. 
Type I PDT involves an electron transfer reaction from 3PS* to generate 
free radicals[313]. For example, hydrogen peroxide (H2O2) can diffuse easily 
through cell membranes, and once within cells, this molecule can use the 
electron from the excited triplet state of the PS to undergo homolytic fission to 
produce hydroxide ions inside cells[313]. These will react with small amounts of 
transition metals such as Fe2+ or Cu+ via homolytic fission and produces 
hydroxide ions (HO-) and hydroxyl radicals (.OH)[325]. These hydroxyl radicals 
are very damaging inside cells, initiating radical chain reactions with fatty 
acids, cholesterols and lipids, ultimately resulting in cell death[313]. 
Type II processes involve the transfer of energy from the electron in 
3PS* directly to the ground triplet state of a molecule of dioxygen (O2) to 
produce reactive species of singlet oxygen (1O2)[313]. This is a highly reactive 
ROS which oxidises sulphur atoms or double bonds in macromolecules and 
can also react with DNA to create unstable and reactive products, again, 
resulting in cell death[326]. The half-life of this singlet oxygen is less than 0.04 
µs and it will only deactivate cells within a 0.02 µm radius[327]. 
1.3.1.1.2 Photodynamic Therapy in Antimicrobial or Anticancer Strategies 
Type I PDT reactions are commonly associated with the killing of 
microbes, and Type II reactions are typically used to target cancer cells[328,329]. 
However, this is not always the case as some studies have found that Type II 
reactions can kill bacteria and particular PS such as a Pd-
bacteriopheophoribide target cancer cells but act via a Type I mechanism[330–
332]. Attempts have been made to use one PS (such as erythrosin B) for both 
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anticancer and antimicrobial PDT[55,318,333]. This PS has been tested on 
malignant and pre-malignant oral epithelial cells and did trigger toxicity on 
cancerous cells[333]. However, erythrosin B is more commonly used in aPDT 
treatments[55,334,335]. 
In the early stages of aPDT, the same PS being used for anticancer 
PDT were used for aPDT to deactivate microbes[313]. It was then discovered 
that optimisation of PS could provide greater selectivity of bacteria over 
mammalian cells, by controlling the ratio of Type I to Type II reactions[313]. The 
PS selectivity is based primarily on a PS ‘dosage window’, within which 
bacterial cells are primarily targeted over mammalian cells[313,336]. This optimal 
dose applies to both the PS concentration and the light source, i.e. time and 
intensity of light exposure[313,336]. Another factor to consider is that in severe 
infections there will be a much larger number of bacterial cells to host tissue 
cells, so as the PS is applied locally, it is likely to be taken up preferentially by 
bacterial cells[313]. 
1.3.1.1.3 Choice of Photosensitiser 
The main classes of PS can be grouped according to their chemical 
structure (Table 1.7). 
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Class Example Peak Wavelength 
(λmax) 
Reference 
Phenothiazinium Methylene blue 610 and 670 nm [337,338] 
Toluidine blue O 630 nm [339,340] 
Porphyrin, chlorin 
and 
phthalocyanine 
5,10,15,20-tetrakis(4- 
sulfonatophenyl)-
21H,23H-porphine 
(TPPS) 
Porfimer sodium 
(Photofrin) 
420 nm [341] 
Xanthene  Erythrosin B 530 nm [335,342] 
Fullerene  Decacationic 
functionalized 
fullerene (LC15) 
Strong absorption 
in UV and visible 
region 
[343,344] 
Phenalenone  7-perinaphthenone 
(PN) 
356-418 nm [345] 
Riboflavin  Riboflavin 450 nm [346] 
Curcumin Curcumin 420 nm [347,348] 
Table 1.7 – Summary of the main classes of photosensitisers for 
antimicrobial photodynamic therapy 
 
The two PS of main interest for this study were methylene blue (MB) 
and erythrosin B (ER) due to their being readily available and having 
previously been screened for use in scaffolds with aPDT functionality 
proposed for this project[349]. These PS are both FDA-approved and have also 
been studied previously in the context of PDT for oral infections[334]. 
1.3.1.2 Existing Antimicrobial Photodynamic Therapy Biomaterials 
The use of PS for the treatment of infections via aPDT is established as 
a possible solution to treat infections whilst avoiding unnecessary antibiotic 
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prescriptions[317]. However, the delivery of these PS to the site of infection is 
an area which is currently of interest[350]. A steady release of PS is required, 
and as the activation of the PS is short-lived, the PS needs to target the site of 
infection whilst in the active state[284,351]. Several research papers have 
reported PS-encapsulation within various scaffolds and respective PDT 
functionality (Table 1.8). 
 
Photosensitiser Scaffold 
Curcumin 
PLGA nanoparticle scaffolds[348] 
Alginate foams[244] 
Methylene Blue 
PVA and PEO electrospun scaffolds[352] 
Wool keratin films[353] 
Poly(siloxane) polymers[354] 
Erythrosin B 
Electrospun polyvinyl pyrrolidone/ hydroxypropyl-β-
cyclodextrin (PVP/HPβCD) scaffolds[355] 
Toluidine Blue 
Poly(methyl vinyl ether/maleic anhydride) and 
Tripropyleneglycol methyl ether blended 
mucoadhesive patches[356] 
Zinc 
tetraphenylporphyrin 
N-isopropylacrylamide (NIPAA) and 
hydroxyethylmethacrylate (HEMA) hydrogels[357] 
Table 1.8 – Examples of photosensitiser and scaffold combinations 
aimed to treat infections via antimicrobial photodynamic therapy 
 
Despite several scaffold and PS systems being researched, additional 
attention needs to be given to oral treatment applications to ensure that both 
the PS-release profile and degradation of the scaffold suit the harsh and moist 
oral environment[11]. One interesting additional aspect to the study in Table 
1.8 by Jones et al[357] which loaded a porphyrin based PS into hydrogels was 
the addition of a thermoresponsive element to the scaffold which allowed for a 
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switchable release of the PS depending on the temperature of the gel[357]. If 
the scaffold was adapted for use in oral applications, this ‘switch’ could be 
achieved through rinsing the oral cavity (and therefore the scaffold) with hot or 
cold water[357]. 
1.3.1.2.1 Antimicrobial Photodynamic Therapy in Dentistry 
The use of antimicrobial PS in dental surgery is the largest growth of 
PDT in clinical infection treatment[18,358]. This is due to the many advantages 
that PDT offers over traditional routes of treating bacterial infections, both in 
practicality and in the effectiveness of the treatment[18]. The inexpensive and 
quick to use treatment method suits dental surgery[18,359]. The oral cavity can 
be easily accessed with a light source by the dental practitioner which allows 
specific targeting of only the affected areas of the mouth. Importantly, the use 
of PDT for antimicrobial activity has not been found to induce AMR[18,360]. In 
terms of effectiveness, aPDT will not just kill bacteria, but can target all 
microbes including viruses, virulent factors, fungi and bacteria present within 
biofilms[18,361,362]. This is a great advantage in the human oral cavity as the 
microflora is known to be complex and diverse[11]. 
It has long been known that PDT could be used to target bacteria in 
oral biofilms[363–366]. Over 20 years ago, an in vitro study demonstrated the 
action of toluidine blue and MB on Streptococcus sanguis, Porphyomonas 
gingivalis, Fusobacterium nucleatum and Actinobacilius 
actinomycetemcomitans[367]. Aside from bacteria, MB has also been used to 
successfully destroy oral fungal infections in a murine animal model[368].   
With regards to treatment of oral diseases, aPDT activity using MB has 
been used to successfully treat oral mucositis infections in clinical 
applications[369]. The use of PDT for the treatment of chronic periodontitis has 
been explored, and porphycene–poly(lysine) conjugates combined with a light 
source have been used to successfully kill bacteria associated with 
periodontal disease in vitro[370,371]. A clinical study on 27 patients with 
periodontitis showed successful outcomes following aPDT treatment[372]. 
However, it has been suggested that the use of this aPDT is particularly 
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effective when combined with mechanical debridement for extreme cases of 
periodontitis[373,374]. 
A consideration for the use of PDT in dental surgery is the source of 
light as to purchase a new light could result in additional costs for the end 
user. A dental chair light is commonly set at a wavelength of 420-480 nm 
(blue light) to be used for curing[246]. This blue light has the advantage of not 
transferring heat which could damage the periodontal tissues, and is known to 
be inherently bactericidal[246,313,375]. However, a longer wavelength red light 
between 650-800 nm would prevent the light being absorbed by typical 
chromophores within the tissue so is known to have greater tissue penetration 
which would help to activate PS deeper in the wound bed[322,376]. The light 
wavelength required will be dependent upon the requirements for the peak 
absorbance of the PS used. 
There are several commercially available systems for treating oral 
infections using aPDT. PeriowaveTM (Ondine Biopharma) is an antimicrobial 
PDT system for the treatment of periodontal disease with a thin plastic light tip 
to be used with MB in solution form[377]. This device has been demonstrated to 
be successful in the treatment of periodontal disease without the need to 
administer antibiotics[57,378]. Another approved treatment on the market 
involves the use of a solution of the PS tolonium chloride with a SaveDent® 
lighting system (Denfotex)[379][380]. This light system has also been used to 
show that bacteria can be destroyed with aPDT techniques in the oral 
cavity[380]. Finally, HELBO 3D EndoProbe (HELBO Photodynamic Systems) 
uses the PS toluidine blue with a 635nm wavelength light to treat infected root 
canals[379,381]. 
The main issue currently with the use of PDT to kill bacteria in 
regenerative products, is the difficulty in specifying the toxic effects to 
selectively target the microbial cells[382]. Tissue regeneration relies on new cell 
proliferation, so if the PDT harms these new cells, the product will not fulfil the 
purpose for which it was designed[87]. A limited number of studies in the 
published literature have explored mammalian cell toxicity caused by aPDT. 
The literature reports one preliminary study which tested the effect of aPDT 
 35 
 
upon human periodontal ligament cells and human gingival fibroblasts, and 
concluded that no harmful effects were observed[383]. 
There are limited recent examples in the literature of combining aPDT 
technology with oral hard tissue regeneration[384,385]. However, there is 
presently no published research which demonstrates the use of a soft tissue 
regenerating scaffold designed specifically for oral applications with aPDT 
capability. 
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 PhD Research Aim 
There is a clinical need for a regenerative medical device made from 
a finely tuned synthetic bioresorbable polymer which can manage infections 
through aPDT. 
The aim of this project was to develop a prototype of a biocompatible 
scaffold with incorporated aPDT capability. The prototype should support cell 
integration and trigger optional bactericidal effect following activation with 
light. The loaded antimicrobial PS should be released from the scaffold 
through controlled release kinetics and be selectively taken up by bacteria. 
In a clinical setting, if the clinician sees necessary, a specific frequency of 
light could then be applied to activate the PS and to selectively kill any 
bacteria present in the wound bed (Figure 2.1). 
 
 
Figure 2.1 - The light activation of the incorporated PS 
(photosensitiser) within the biodegradable polymer scaffold initiating 
antimicrobial activity 
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If the light source is not deployed, the PS should be broken down 
through normal biochemical pathways and excreted harmlessly from the 
body[386]. The scaffold would need to support new tissue growth for a 
clinically relevant period of time before it was biodegraded and removed 
from the body, again through normal biochemical pathways which ends in 
the product being released through excretion or through respiration 
processes as water or carbon dioxide[386]. This would prevent the need to 
painfully remove the scaffold after wound healing has occurred (Figure 2.2). 
 
 
Figure 2.2 – Design and clinical applicability of photodynamically-
active electrospun fibrous scaffolds for antibiotic-free infection 
control 
2.1.1 Research Strategies 
Prior to the start of this project, a proof of concept study was 
performed with a range of scaffolds loaded with antimicrobial PS, namely 
ER, tin (IV) chlorin e6, haematoporphyrin IX and MB[387]. A patent was then 
filed for the concept of a polymer scaffold loaded with antimicrobial PS for 
use in soft tissue regeneration[349]. From the results of this study it was 
concluded that the optimal product for skin regeneration was the ER-loaded 
PGA scaffold system for which sustained release of the PS, bactericidal 
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effect and cell survival upon bactericidal activation of the PS were 
demonstrated[387].  
However, changes need to be made to the methodology used in the 
initial research to optimise the scaffold for use in the oral cavity. Degradation 
of PGA sutures within the oral cavity has been found to take <10 days which 
would not be long enough to ensure full mechanical support and cell 
integration[228]. Other FDA-approved polyesters (PLGA and PCL) should 
therefore be examined. Specific scaffold requirements identified in this 
literature review are summarised below (Table 2.1). 
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Scaffold Characteristic Reason 
Fibrous and porous To allow for tissue integration 
Appropriate mechanical properties 
for the oral mucosa (e.g. elastic 
modulus of 0.9-11 MPa[388]) 
For comfort of the patient and 
ease of implantation by the dental 
practitioner 
Capable of loading PS and 
releasing steadily for up to 4 weeks 
To allow for repeated activation of 
aPDT activity until oral mucosa 
epithelial layer has healed 
Demonstrates stability and 
maintains porous structure in 
aqueous environments 
To ensure it is suitable for 
implantation in moist oral 
environment 
Maintains integrity up to 8 weeks To support full neotissue 
formation 
<30% cytotoxicity to mammalian 
cells in dark or light conditions 
To ensure mammalian cells can 
populate the scaffold and for 
potential conformity with ISO 
10993 
Minimal bactericidal activity in dark 
conditions but ability to kill bacteria 
upon light activation 
To allow for the dental 
practitioner to activate the aPDT 
in the scaffold ‘on-demand’ and 
selectively kill bacteria 
Table 2.1 – Summary of scaffold requirements for oral applications 
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2.1.2 Research Objectives 
• To determine suitable FDA-approved bioresorbable polyesters (e.g. 
PCL or PLGA) from which to manufacture a suitable electrospun 
scaffold for use in oral mucosal repair 
• To investigate the effect of encapsulation within, and release of, PS 
(e.g. ER or MB) from the scaffold fibres on the biomaterial properties 
of the scaffold in an aqueous environment 
• To investigate the selectivity achievable between human cells and 
bacterial cells 
• To investigate the feasibility of commercialising the lead prototype as 
PhotoTherixTM 
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 Manufacture and Characterisation of Photosensitiser-
Loaded Electrospun Scaffolds 
3.1 Introduction 
The aim of the work described in this chapter was to manufacture and 
characterise the biomaterial properties of electrospun scaffolds with PS 
inclusion. This should address structure-function relationships for the desired 
therapeutic effects of an oral soft tissue regenerating medical device with 
antimicrobial capability. 
3.2 Materials and Methods 
3.2.1 Materials 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) solvent was sourced from 
Fluorochem Ltd. Poly(ε-caprolactone) (PCL) (Mn: 80,000 g·mol-1) was 
sourced from Sigma Aldrich, whilst poly(rac-lactide-co-glycolide) 
(PLGA7525) (Mn: 63,000 g·mol-1, 75:25 molar ratio of lactic and glycolic acid 
units) was purchased from Purac Biomaterials (PURASORB® PDLG 7507) 
(Figure 3.1A and Figure 3.1B). Methylene Blue (molecular mass of 319.85 
g·mol-1) and Erythrosin B (molecular mass of 835.90 g·mol-1) PS were both 
sourced from Sigma Aldrich (Figure 3.1C and Figure 3.1D). 
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(A) 
 
 
(B) 
 
 
 
(C) (D) 
Figure 3.1 - (A-D): Chemical structure of selected polymers and PS. 
(A): Poly(ε-caprolactone) (PCL); (B): Poly[(rac-lactide)-co-glycolide] 
(PLGA7525) with 75:25 monomer ratio; (C): Methylene Blue (MB); (D): 
Erythrosin B (ER). 
 
Sample nomenclature is as follows: samples of either fibres or 
electrospinning solutions were coded as Polymer-YY, whereby ‘Polymer’ 
identifies the type of polymer, i.e. either PCL or PLGA7525, whilst YY 
indicates the PS encapsulated in the sample, either MB or ER. Control 
samples without PS (‘No Dye’) will be called either PCL-ND or PLGA7525-
ND throughout the results. 
3.2.2 Electrospinning Solution Preparation 
PCL and PLGA7525 were tested initially at 6 wt.%, 9 wt.% and 12 
wt.% to determine the most optimal starting viscosity. Both MB and ER were 
used at a concentration of 2.2 mM in the electrospinning solution based on 
previous reports on MB and ER-induced aPDT[334,389]. Polymer, PS and HFIP 
were weighed together into sealed flasks and covered with foil to protect 
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from ambient light. They were stirred at room temperature for 48 hours to 
allow for dissolution of all components.  
3.2.3 Viscosity Measurements 
Viscosity measurements were taken at room temperature as per 
manufacturer’s instructions using a Brookfield DV-E bench top viscometer 
(Brookfield Engineering Laboratories, Inc., Middleboro, MA, US). Briefly, 9.0 
ml of electrospinning solution was loaded into the sample holder, and 
spindle SC4-31 was placed into the solution. A steady shear stress reading 
was recorded from shear rates ranging from 0.68-6.8 sec-1 for each sample. 
These were then converted to viscosity readings by dividing the shear stress 
value by the corresponding shear rate value. 
3.2.4 Surface Tension 
Density of solutions were calculated by weighing 1 ml of 
electrospinning solution in triplicate (and plotting mass versus volume) with 
the density calculated as 1.52±0.04 g/ml.  Each electrospinning solution was 
loaded into a 2ml syringe with 18-gauge blunt-ended needle. The solution 
was ejected manually until a stable droplet was formed at the needle tip. 
KSV Pendant Drop equipment was used with Attension Theta Software 
Version 4.1.9.8 to analyse the droplet with 60 images taken over one minute. 
3.2.5 Electrospinning 
Polymer solutions were transferred into a 10 ml plastic syringe with an 
18-gauge blunt-ended needle, which was then loaded into a syringe pump. A 
pump rate of 0.03 ml/min was used with an applied voltage of 16 kV. A 
cylindrical grounded mandrel (height = 125 mm, diameter = 75 mm) was 
coated with aluminium foil at 100 mm distance away from the needle tip and 
rotated at 30 RPM. Scaffolds were electrospun for 55±5 minutes, with both 
relative humidity (33±7%) and temperature (21±1 °C) being recorded for 
each experiment (88±54 µm thickness, measured using a digital fabric 
thickness testing gauge). Scaffolds were dried under reduced pressure in a 
vacuum desiccator for 72 hours to remove residual solvent. Scaffolds were 
 44 
 
sealed in foil/poly bags (Sigma Aldrich) and frozen until use to prevent 
degradation. 
3.2.6 Scanning Electron Microscopy 
Dry samples were attached to metal stubs using carbon double-sided 
stickers and sputter coated with gold twice before being analysed on a 6-
sample multi-stub holder on a Hitachi Scanning Electron Microscope (SEM) 
at 4000x magnification. Scaffolds were sensitive to high vacuum settings so 
VP-SEM (variable pressure-SEM) low vacuum setting was used (270 Pa) 
when required. Randomly selected locations were chosen to produce five 
images of each scaffold, and ten fibre diameters were taken from each 
image using ImageJ. 
3.2.7 Loading Efficiency 
Dry samples were cut into round discs (diameter = 1 cm) and weighed 
individually on an analytical balance. These were then incubated in glass 
vials with 5 ml of HFIP and rolled at 60 RPM for 48 hours to ensure full 
dissolution. A standard UV-vis (ultraviolet-visible) curve was drawn with the 
PS dissolved in HFIP over an appropriate concentration range using a 
photometric plate reader at wavelength of 610nm for MB and 530nm for ER. 
The loading efficiency (LE) value was calculated for each PS according to 
(Equation 3.1).  
  
𝑳𝑬 =
𝒎𝒅
𝒎𝒆
× 𝟏𝟎𝟎 Equation 3.1 – Loading Efficiency 
 
where md and me are the determined and expected values of PS mass 
loaded in the electrospun scaffold, respectively. 
3.2.8 Brunauer–Emmett–Teller Analysis 
To quantify the average surface area of the scaffolds and therefore 
give supporting information on the porosity of the scaffolds, Brunauer–
Emmett–Teller (BET) analysis was performed. Micrometrics FlowPrep 060 
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was used to flush samples (approximately 0.4 g) with N2 at 40 ºC for 4 hours 
prior to analysis. Micrometrics TriStar 3000 Surface Area and Porosity 
Analyzer used along with complementary Tristar 3000 software to analyse 
the sample. A full isotherm was produced for each sample. 
 
 
3.2.9 Porometry 
Samples were soaked in a low surface tension Galpore125 
(perfluoroether, surface tension 15.6 mNm-1) solution before being displaced 
with air at a specific pressure within the POROLUX™ 100FM porometer.  
The Young-Laplace equation was used to convert this pressure into the 
diameter of the capillary (Equation 3.2).  
 
Pore diameter =
4 × 𝑐𝑜𝑠 𝜃 × 𝛾
𝑃
 Equation 3.2 – Young-Laplace 
 
with P representing the pressure required to displace the liquid from pore, θ 
representing the contact angle of the wetting fluid with the scaffold and γ 
representing the surface tension of Galpore125[390]. 
The associated POROLUX™ software was used to calculate the 
largest and smallest pores, mean flow pore size, and the distribution of pore 
sizes in the scaffold. 
3.2.10 Scaffold Colour Measurements 
Further to PS-inclusion (and scaffold colouration), samples were 
analysed using an SF600 Plus-CT machine and the associated ColorTool © 
QC software. Prior to measurements being taken, the machine was 
calibrated using the provided white and green reference tiles. LAB readings 
were converted to on-screen colour using the RGB selection tool on MS 
Word. 
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3.2.11 Differential Scanning Calorimetry 
A Differential Scanning Calorimeter (DSC) (Q100 – TA Instruments) 
was loaded with two metal cups. The first empty as a reference, and the 
second containing 6-12mg of sample (which was weighed out using an 
analytic balance). The machine was then programmed to run on a cycle from 
20 °C to 200 °C for PLGA7525 scaffolds and 20 °C to 100 °C for PCL 
scaffolds to remove thermal history of the polymer at a heating rate of        
10 °C/minute and a cooling rate of 5 °C/minute and then repeating to take 
the measurement. The glass transition and melting temperature were 
calculated using the operating software Thermal Advantage for Q Series 
Version 2.5.0.256 (©Thermal Instruments-Waters). The glass transition 
temperature was taken as the mid-point of the shift decrease in the DSC 
graph, and the maxima of the endothermic peak was taken as the melting 
point value. The DSC heat flow plots were plotted as ‘exothermic up’, with an 
increasing heat flow up the y-axis.  
3.2.12 Tensile Testing 
Dry scaffolds were cut into 10x30 mm strips and clamped into a 
James HealTM Titan5 Universal Strength Testing machine with a 100 N 
loading cell and T27 jaw scheme. The equipment was used with TestWise 
2017 test analysis software. A pretension of 0.5 N was applied to the 
material, and then the material was elongated at a speed of 100 mm/min 
until the material failed. Force against elongation measurements were 
recorded for each sample five times. Stress-strain curves were plotted, and 
the elastic modulus calculated as the slope of the linear region of the curve. 
The toughness was measured as the integral under the stress-strain curve. 
3.2.13 Statistical Analysis 
Significant differences in the results were evaluated using an 
unpaired Student's t-test. Data was deemed to be significantly different at p 
< 0.05. All data were collected in triplicate and presented as Mean ± 
Standard Deviation. 
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3.3 Results and Discussion 
3.3.1 Characterisation of Electrospinning Solutions 
3.3.1.1 Initial Concentration Determination 
PCL and PLGA7525 were expected to be suitable polymers for this 
project due to their frequent use in regenerative electrospun scaffolds and 
drug delivery devices in the published literature[125,391]. PCL has been 
reported to biodegrade slowly in the body due to hydrophobicity[218]. This 
could be advantageous for use in the harsh and moist oral environment as 
the polymer selected would need to resist degradation until neotissue 
formation has occurred. PLGA has highly tuneable properties depending on 
the selection of lactide to glycolide monomer ratio[203]. The 75:25 monomer 
ratio used in this study has previously been used for both soft tissue 
regeneration and drug delivery purposes[392–394]. A racemic mixture of D- and 
L-stereoisomers of the lactide component is more commonly chosen than 
the enantiomerically pure version of PLGA in drug delivery devices due to an 
increase in amorphous regions in the racemic polymer[395]. These 
amorphous regions allow for greater drug dispersion resulting in a more 
even distribution[395]. A commonly used volatile solvent to produce 
electrospinning solutions is HFIP,  as it readily dissolves the polyesters 
through hydrogen bonding of the hydroxyl hydrogen to carbonyl groups[396] 
and traces of the solvent can be removed from the finished product to safe 
levels with adequate drying[195,397,398].  
The viscosity of the electrospinning solution is known to affect fibre 
formation and to alter the resulting diameter of the electrospun fibres[193,399], 
which could ultimately impact the scaffold degradation and PS release 
kinetics. Therefore, the viscosity of the electrospinning solutions both with 
and without PS for each polymer was determined. Initial screening of the 
polymer solutions in HFIP was performed to gain comparable viscosities and 
spinnability between polymer groups (Figure 3.2).  
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Figure 3.2 - Viscosity of electrospinning polymer solutions at 
different concentrations in HFIP. (■): PCL-ND-6 wt.%; (■): PCL-ND-9 
wt.%; (●): PLGA7525-ND-6 wt.%; (●): PLGA7525-ND-9 wt.%; (●): 
PLGA7525-ND-12 wt.%. Lines are guidelines to the eye 
 
A typical shear thinning behaviour was observed in all electrospinning 
solutions, whereby the solution viscosity was found to be inversely related to 
the shear rate, as expected for non-Newtonian liquids. The PCL and 
PLGA7525 polyesters were chosen for this study due to their comparable 
molecular weight (Mn: 63,000-80,000 g·mol-1). Comparable viscosities were 
found between PCL-ND and PLGA7525-ND solutions at a shear rate of 6.8 
s-1 at concentrations of 6 wt.% PCL and 12 wt.% PLGA7525 in HFIP (η = 1.5 
and 1.4 Pa.s respectively) (Figure 3.2). Similar polymer concentrations have 
been reported for the formation of electrospun fibres with or without soluble 
factors[400–403]. 
Each of these polymer solutions were electrospun to ensure that the 
selected concentrations were suitable to produce bead-free fibres (Figure 
3.3).  
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Figure 3.3 - Scanning Electron Micrographs to determine fibre 
morphology from electrospinning different concentrations of 
PLGA7525 and PCL solutions. Electrospinning was not possible for 
the PCL-ND 12 wt.% formulation due to high viscosity 
 
The PCL-ND and PLGA7525-ND solutions which were chosen based 
on their viscosities produced smooth fibres. The increased viscosity in the 
PCL scaffolds produced a clumped non-fibrous structure. Any further 
increase in the viscosity prevented electrospinning. The reduction of the 
concentration and consequent viscosity of the PLGA7525 solution resulted 
in beaded fibre formation in the resulting scaffolds. This has been observed 
numerous times in previously published work[273,277,308,404–406]. This confirmed 
that appropriate polymer solution concentration had been selected and the 
influence of PS-inclusion could be studied. 
 
3.3.1.2 Viscosity and Surface Tension with Photosensitiser Inclusion 
Following this initial decision on the concentration of the polymer in 
the scaffold, a concentration of 2.2 mM of either MB or ER was employed in 
the electrospinning solutions. The aim of this was to achieve electrospun 
fibres with prolonged PS release and antimicrobial effect. Each PS was 
combined separately with each polymer type, and the resulting solutions 
were electrospun (Figure 3.4). 
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Figure 3.4 - Viscosity of native and PS-loaded electrospinning 
polymer solutions. (■): PCL-ND; (■): PCL-MB; (■): PCL-ER; (●): 
PLGA7525-ND; (●): PLGA7525-MB; (●): PLGA7525-ER. Lines are 
guidelines to the eye. 
 
Again, shear thinning behaviour was observed in all electrospinning 
solutions regardless of the selected PS and polymer. Compared to 
respective PS-free polymer solutions, loading of PS did not induce 
detectable changes in the viscosity of the PCL-MB, PCL-ER or PLGA7525-
MB polymer solutions (p = 0.10-0.12), whilst the viscosity of solution 
PLGA7525-ER proved to be significantly decreased (p = 5.5x10-16) (Figure 
3.4). Previous studies reported that low concentrations of additives (< 12 
mg·ml-1) do not significantly change the viscosity of the electrospinning 
polyester solution[407], in agreement with the majority of the results obtained 
in this study. The significantly-decreased value of viscosity measured in 
PLGA7525-ER solutions with respect to solutions PLGA7525-ND and 
PLGA7525-MB may hint at secondary, e.g. hydrophobic, interactions 
between the PS and the fibre-forming polymer, as indirectly observed in ER-
loaded PLGA nanoparticles[408]. Such secondary interactions between ER 
and PLGA7525 are expected to compromise the polymer chain 
entanglements leading to a decrease in solution viscosity, as observed 
previously with different polymer and additive formulations[174,398,400,409].   
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The surface tension of solutions was also determined, since surface 
tension is expected to inversely relate to the electrospinnability of a given 
solution (Table 3.1)[410]. 
 
Electrospinning Solution Surface Tension (mN/m) 
PCL ND 32.0±0.6 
MB 28.2±0.5 
ER 32.2±0.3 
PLGA7525 ND 32.5±2.8 
MB 32.4±0.8 
ER 33.2±1.9 
Table 3.1 – Electrospinning Solution Surface Tension. Results 
reported as Mean±SD (n=3) 
 
The surface tension appeared to be comparable between PCL- (σ = 
28±1–32±1 mN·m-1) and PLGA7525-based (σ = 32±1–33±2 mN·m-1) 
electrospinning solutions, whilst the range of surface tension values was 
found to be in agreement with the one observed in previously-reported 
electrospinning polyester solutions[231]. There has been great interest into 
elucidating the relationship between surface tension and viscosity of 
electrospinning solutions and their effects on scaffold microarchitecture [411–
413], since the fluid viscosity concerns the molecular interactions in the bulk of 
the solution, whereas the surface tension reflects the interactions of the 
solution at the air-liquid interface[411]. The above-mentioned surface tension 
results would therefore suggest that any change in the characteristics of the 
electrospun scaffolds are likely due to the PS-polymer-solvent secondary 
interaction in the bulk of the solution rather than at the air-liquid interface of 
the Taylor cone and subsequent jets during electrospinning[414]. 
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3.3.2 Characterisation of Electrospun Scaffolds 
3.3.2.1 Scaffold Formation 
Obtained polymer solutions successfully led to the formation of bead-
free fibrous scaffolds (Figure 3.5), confirming that previously-measured 
solution viscosities and surface tensions were compatible with the 
electrospinning of selected polymers and PS. 
 
 
Figure 3.5 - Microstructural analysis of PS-encapsulated scaffolds 
and electrospun controls. SEM images taken at 1000x magnification 
and Specific Surface Area (SSA) measurements obtained via BET 
analysis. 
 
To elucidate the scaffold loading efficiency and demonstrate the fibre 
encapsulation with either MB or ER, respective electrospun scaffolds were 
dissolved in HFIP to induce full release of incorporated PS (Table 3.2). 
 
 
 
 
 53 
 
Sample ID PCL PLGA7525 
MB ER MB ER 
LE /wt.% 103±16 103±31 110±16 97±30 
Table 3.2 - Loading efficiency (LE) and percent release measured in 
PCL and PLGA7525 scaffolds electrospun in the presence of either 
MB or ER. Results reported as Mean±SD (n=3). 
 
Photometric analysis of the resulting solution revealed a loading 
efficiency in the range of 97±30–110±16 wt.% therefore confirming that all 
the PS dissolved in the electrospinning solution was successfully 
encapsulated in the resulting fibres. Certain samples showed a greater than 
100% loading efficiency, which would indicate that there was a greater mass 
of PS than would be expected. This could be due to the PS interacting 
strongly with the polymer. 
SEM, BET analysis and porometry were performed on the scaffolds 
enabling quantification of fibre diameter as well as scaffold specific surface 
area and pore size, respectively. Despite employing the same molar 
concentration of PS, there was a significant reduction in fibre diameter upon 
encapsulation of either PS molecules in both scaffold systems (Figure 3.5 
and Figure 3.6A).  
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(A) (B) 
Figure 3.6 - (A) Average Fibre Diameter determined from SEM images 
for each electrospun scaffold. (B) Average Mean Flow Pore Size 
determined from porometry analysis for each electrospun scaffold. 
Grey bars: Control scaffolds; Blue bars: MB-included scaffolds; Red 
bars: ER-included scaffolds. Results reported as Mean±SD (n=3). ‘*’ 
denotes significantly different means (p <0.05, t-test). 
 
For PCL scaffolds, encapsulation with either MB or ER resulted in 
54% and 49% averaged reduction of fibre diameter, respectively, and similar 
values (51-69%) were also observed with PLGA7525-based samples. Such 
reduction of fibre diameter has been observed in other fibrous systems, 
deriving from electrospinning of PCL solutions containing peptides[415]. 
Introduction of ionically-charged PS, such as MB and ER, is likely to cause 
increased electrostatic repulsion between fibre-forming polymer jets in the 
electrospinning process[416]. For the PLGA7525-ER scaffolds, there was a 
further significant reduction in fibre diameter with respect to PS-free and MB-
encapsulated PLGA7525 scaffolds. This additional reduction in fibre 
diameter is in agreement with the significant decrease in viscosity observed 
in ER-loaded electrospinning solutions (Figure 3.4), since electrospinning 
solutions with reduced viscosity typically generate fibres with reduced 
diameter [273,417].  
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Porometry was next performed to determine the pore size among the 
fibres within the fibrous structure (Figure 3.6B and Figure 3.7).  
  
(A) (B) 
Figure 3.7 - Pore size distribution of scaffold types. (A) PCL 
scaffolds; (B) PLGA7525 scaffolds. Black lines: Polymer-ND 
scaffolds; Blue lines: Polymer-MB scaffolds; Red lines: Polymer-ER 
scaffolds. Values of mean flow pore size (µm) are given for each 
scaffold type. Results reported as Mean±SD (n=3). 
 
The pore size between fibres is an important characteristic for a 
regenerative scaffold, as delivery of soluble factors, e.g. encapsulated PS, 
and cell infiltration have been shown to be altered by the pore size, with 
fibroblast cells being unable to bridge pores larger than 20 µm[418]. A pore 
size in the range of 0.7-3 µm was measured among the different scaffolds, 
whereby the scaffold formulation proved to induce variations in pore size 
comparable to those found with the fibre diameter, i.e. PS-encapsulated 
fibres were associated with scaffolds of decreased pore size.  It is expected 
that an increased number of fibres with decreased diameter will be required 
to fill the same scaffold volume compared to fibres with an increased 
diameter. Previous porometry measurements therefore confirm the direct 
relationship between the fibre diameter and pore size in electrospun 
scaffolds [4]. The observed trends in fibre diameter is consistent with the 
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variations in specific surface area of the scaffolds (Figure 3.5), since fibres 
with reduced diameter are expected to lead to scaffolds with increased 
specific surface area [419]. Overall, the averaged pore size was measured to 
be below 4 µm in all samples, suggesting that cell should be able to bridge 
these distances. Furthermore, this range of pore size is likely to promote the 
release of the PS molecule via a predominant diffusion mechanism through 
the scaffold, given the relatively low molecular weight of selected soluble 
factors (M < 900 g·mol-1). 
Interestingly, a narrow pore size distribution was found in PS-
encapsulated scaffolds, in contrast to the broader range of pore size 
measured with the PS-free electrospun controls (Figure 3.7). Given the 
electrostatic charge of the PS molecules employed, this observation 
provides supporting evidence of the PS-induced electrostatic repulsion 
between polymer electrospinning jets. This ultimately results in PS-
encapsulated scaffolds with more regular porous architectures with respect 
to the case of PS-free electrospun controls, as previously reported with other 
electrostatically-charged additives [416]. 
3.3.2.2 Polymer Scaffold Colour 
Together with the photometric analysis, PS encapsulation proved to 
induce fibre colouration effects on the resultant scaffolds (Figure 3.8).  
 
 
Figure 3.8 - Macroscopic images of PS-free and PS-encapsulated 
scaffolds. 
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As would be expected, PS-free and ER-encapsulated fibres appeared 
‘white’ and ‘pink’ respectively. Unusually, MB-incorporated scaffolds 
displayed either a ‘purple’ or ‘blue’ colour depending on whether fibres were 
made of PCL or PLGA7525. This was quantified through the use of LAB 
Colour Space equipment to convert the macroscopic colour observed into 
LAB values to provide specific colours regardless of print or screen effects 
(Table 3.3).  
 
  L A B 
PCL-MB 68.55 24.6 -20.24 
PCL-ER 81.66 32.03 -6.94 
PLGA7525-MB 72.08 -19.95 -24.81 
PLGA7525-ER 86.08 30.38 -6.24 
Table 3.3 – LAB colour space results for PS-loaded scaffolds. 
Colours of associated rows represent the colour of the scaffold as 
per the LAB result. 
 
Although the colouration of PS-loaded materials is mainly determined 
by the specific PS and respective loading efficiency, as in the case of ER-
encapsulated samples, the above-mentioned observations on MB-
encapsulated samples suggest that secondary interactions between PS 
molecules and the polymer carrier may also play a role. With regards to MB, 
it has been described in previous publications that loading of cellulosic 
derivative with MB species typically results in a blue colouration; however, 
when the PS concentration was increased, a purple colouration was 
observed in respective MB-encapsulated polymer [420]. This is said to be due 
to the aggregation of MB molecules via non-covalent pi-pi stacking 
interactions between aromatic rings of MB (Figure 3.9). 
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(A) (B) 
Figure 3.9 – (A) Encapsulation of MB in the monomeric state 
results in a blue colour of respective fibres. (B) Aggregation of 
MB molecules results in a purple colour of PS-encapsulated 
fibres[420] 
 
In this study, the higher viscosity measured in MB-loaded PCL 
solutions with respect to the corresponding PLGA7525 variant (Figure 3.4) 
suggests a different state of MB molecules in the PCL solutions and 
resulting fibres. In the aggregated MB configuration, a lowered energy is 
required for the electrons to be excited, resulting in a red shift in the 
wavelength of visible light being absorbed and in a distinct fibre colouration 
effect. It is worth noting that UV-vis spectrophotometry experiments were 
conducted to determine whether this change was observable in the 
electrospinning solution, but no differences were found prior to scaffold 
formation. Aggregation is therefore expected to increase upon solvent 
evaporation during the electrospinning process. 
3.3.2.3 Crystallinity 
Crystallinity is known to effect many properties of polymeric 
scaffolds[241,300,421–426]. It was therefore deemed important to determine the 
crystallinity of the polymers prior to processing, and then once again when in 
scaffolds either with or without PS-inclusion (Figure 3.10).  
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(A) (B) 
Figure 3.10 – Differential Scanning Calorimetry heat flow plots of (A) 
PCL scaffolds and (B) PLGA7525 scaffolds. (―): Unprocessed 
polymer; (―): Pol-ND scaffolds; (―): Pol-MB scaffolds; (―): Pol-ER 
scaffolds 
 
The results in this study suggest that PCL samples were 
predominantly crystalline, as only a sharp melting peak was observed (Table 
3.4).  
 
Scaffold Type Tm (ºC) ΔHm (J/g) Tg (ºC) 
PCL 
Raw 59.1 187.7 - 
ND 57.5 118.2 - 
MB 56.4 89 - 
ER 54.8 71.9 - 
PLGA7525 
Raw - - 36.7 
ND - - 40.2 
MB - - 40.1 
ER - - 47.3 
Table 3.4 – DSC Thermal Analysis Values for PCL or PLGA7525 
samples of either ‘Raw’ polymer pellets, PS-free (ND) control 
scaffolds, MB-incorporated scaffolds or ER-incorporated 
scaffolds 
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The crystallinity of PLGA is known to be affected by the monomer 
ratio of the two monomer components[427–429]. PLGA7525 samples in this 
study were predominantly amorphous as no melting peak was observed but 
there was a clear glass transition point for all samples. These characteristics 
have been reported previously in the literature[430]. 
Another key observation in these results is that there was a 
noticeable shift in both the melting point and the glass transition state of 
each polymer upon inclusion of PS. In the PCL samples, the melting point 
decreased from unprocessed polymer (Tm = 59.1oC), to the control 
electrospun PCL scaffolds (Tm = 57.5oC), to the MB and ER PS-included 
scaffolds (Tm = 56.4oC and 54.8oC respectively). This phenomenon is 
commonly known as a ‘melting point depression’[431]. The more the 
contaminant, i.e. PS, interacts with the polymer, the greater the depression 
in the melting point. This would imply that the ER is interacting most strongly 
with the polymer.   
A similar trend was observed in the glass transition state of the 
PLGA7525 samples, with the unprocessed PLGA7525 having the lowest 
glass transition temperature (Tg = 36.7 °C), then the PLGA7525-ND and 
PLGA7525-MB scaffolds having the same increased glass transition 
temperature (Tg = 40.2 °C), and the PLGA7525-ER scaffolds having the 
greatest transition temperature (Tg = 47.3 °C). This increase in glass 
transition temperature is again normally indicative of a distinct interaction 
between the polymer and contaminant, in this case the PLGA7525 and the 
ER molecules[432]. This is further supporting evidence towards the secondary 
interaction which was suggested in the increased fibre diameter reduction 
effect (section 3.3.2.1). 
3.3.2.4 Mechanical Properties of Scaffolds 
The mechanical properties of the scaffolds were measured on the 
samples to investigate the potential effect of PS encapsulation on tensile 
properties (Figure 3.11 and Figure 3.12). This characteristic is important to 
explore as it will change the surgical handling capability and the scaffold 
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applicability in vivo, e.g. for oral soft tissue applications, because the 
elasticity of the fibrous matrix has been shown to alter cell adhesion[433].  
 
 
 
(A) (B) 
Figure 3.11 - (A): Stress-strain curve of PS-encapsulated scaffolds 
and electrospun controls. (―): PCL-ND; (―): PCL-MB; (―): PCL-ER; 
(···): PLGA7525-ND; (···): PLGA7525-MB; (···): PLGA7525-ER. (B): 
Experimental setup employed during tensile testing 
 
When comparing the elastic modulus of PCL-ND (E = 1.4±0.3 MPa) 
and PLGA7525-ND (E = 18.7±1.9 MPa) control scaffolds, the PLGA7525-ND 
scaffold has a significantly greater elastic modulus (p = 0.00005) (Figure 
3.12A). This comparison of the two polyester types has been observed 
previously in the literature[434]. 
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(A) 
  
(B) (C) 
Figure 3.12 (A) Elastic Modulus (E) and (B) Strain at Break (ε) 
measured in PCL or PLGA7525 samples (C) Ultimate Toughness (UT). 
Grey bars: control polymer scaffolds; Blue bars: MB-loaded 
scaffolds; Red bars: ER-loaded scaffolds. Results reported as 
Mean±SD (n=3). ‘*’ denotes significantly different means (p <0.05, t-
test) 
 
The elastic modulus values reported for the scaffolds are in 
agreement with previously reported values[184,435]. PCL-MB (E = 4.2±0.5 
MPa) and PCL-ER (E = 2.0±0.4 MPa) scaffolds both showed a significant 
increase in comparison to PCL-ND controls (p = 0.00004 and 0.04 
respectively). In the literature, it has been previously reported that inclusion 
of drugs increases the elastic modulus of fibrous PCL scaffolds[436]. For the 
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PLGA7525 samples, the PLGA7525-MB (E = 26.2±1.8 MPa) elastic modulus 
was significantly increased (p = 0.0004) as found with the PCL scaffolds, but 
the PLGA7525-ER scaffolds (E = 24.4±3.7 MPa) did not highlight a 
significant difference to the control scaffolds (p = 0.4). 
The elastic modulus of the natural oral mucosa is thought to be 
approximately 3 MPa, but this varies between 0.9-11 MPa depending on the 
location within the oral cavity[178,388,437]. While the PCL scaffolds exhibited a 
comparable modulus to that of the native tissue, PLGA7525 scaffolds 
displayed increased tensile modulus with respect to the natural tissue. 
Consequently, these electrospun fibres may prove advantageous to enable 
easy surgical handling of the graft material during implantation minimising 
risks of material breakdown. The elasticity of the scaffold will also influence 
the interactions with contacting tissue in vivo[184]. 
There was no significant difference between the elongation at break 
(ε) values between the PCL-ND (ε = 299±36%) and PLGA7525-ND (ε = 
303±44%) control scaffolds (p = 0.9) (Figure 3.12B).  
PCL-MB scaffolds (ε = 255±18%) did not show a significant difference 
when compared to the PCL-ND control (p = 0.08) but PCL-ER scaffolds 
showed a significant reduction in elongation at break (ε = 132±8%) (p = 
0.001). Comparatively, both PLGA7525-MB (ε = 128±11%) and PLGA7525-
ER (ε = 74±27%) displayed a significant reduction in elongation at break (p = 
0.0009 and 0.01 respectively) when compared to the PLGA7525-ND 
controls.  
The difference between polymer types and the effect of PS 
encapsulation is also reflected in the toughness values (UT) obtained 
through integrating the area under each stress-strain curve (Figure 3.12C). 
The toughness value represents the energy required to fracture the material, 
so the higher the value, the more tough this sample proved to be[438]. As with 
the elastic modulus, PLGA7525-ND samples (UT = 28.0±7.1 J.m-3) had a 
significant increase in toughness when compared to PCL-ND scaffolds (UT = 
13.8±2.2 J.m-3) (p = 0.01). This increase in toughness and elasticity would 
make the polyester desirable for use biomaterial scaffolds. 
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For the PCL scaffolds, interestingly, there was a large significant 
increase in toughness for the PCL-MB scaffolds (UT = 30.4±2.5 J.m-3) (p = 
0.000009) but a significant decrease for PCL-ER scaffolds (UT = 8.9±2.0 J.m-
3) (p = 0.01). The increase in toughness and elasticity for the PCL-MB 
scaffolds is unexpected, as normally an increase in one of these properties 
reduces the other[439,440]. However, other reports of this phenomenon have 
been reported in previous literature with fibrous scaffolds[441]. 
There was no significant difference in the toughness of the 
PLGA7525-MB scaffolds (UT = 18.3±2.0 J.m-3) (p = 0.05) but the PLGA7525-
ER scaffolds (UT = 8.6±4.8 J.m-3) displayed a significant decrease in 
toughness (p = 0.01). Again, these changes in mechanical properties with 
the addition of soluble factors have been observed in previous studies[434], 
providing further indirect evidence of the development of secondary, e.g. 
hydrophobic, interactions between the PS molecule and the fibre-forming 
polymer.  
3.4 Conclusion 
This study has successfully used viscosity measurements to find 
suitable polymer concentrations to manufacture smooth, bead-free fibrous 
scaffolds of two different FDA-approved polyesters via electrospinning. 
These polymer solutions have then been loaded with two different PS. 
Despite shear-thinning behaviour being observed in all electrospinning 
solutions, there was only a significant reduction in the PLGA7525-ER 
polymer solution, which suggested a secondary interaction being present 
between the polymer and the ER molecules. 
After electrospinning these polymer solutions, it was confirmed that 
the loading efficiency in each scaffold was ~100%. Another key finding was 
that PS-inclusion significantly reduced both the fibre diameter and pore size. 
This was expected to have implications on cell adhesion in later studies. 
There was an additional reduction in both fibre diameter and pore size in the 
PLGA7525-ER scaffolds, which was expected to be due to the reduced 
viscosity of the electrospinning solution.  
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The macroscopic colour of the MB-containing scaffolds depended on 
the polymer carrier, with the PCL scaffolds being purple-like and the 
PLGA7525 being blue-like. This was expected to be due to the secondary 
interactions in the PLGA7525-MB scaffold which caused the MB to be in the 
monomeric form along each fibre, whereas in the PCL scaffolds, the MB had 
aggregated upon electrospinning resulting in the purple colouration. 
The characterisation of the thermal properties of the scaffolds 
revealed that the PCL scaffolds were all crystalline and the PLGA7525 
scaffolds were all amorphous. The inclusion of each PS in the PCL scaffolds 
resulted in a melting point depression, which is expected with contaminant 
interaction disrupting the crystal structure of the polymer chains. The 
increase in glass transition temperature for the PLGA7525-ER scaffold also 
indicates secondary interactions between the polymer and ER molecules, 
which confirms the finding with the reduced viscosity, fibre diameter and 
pore size. 
Finally, the mechanical properties of the scaffolds were studied. In all 
scaffolds, the PLGA7525 had a greater elastic modulus than the PCL 
scaffolds. The inclusion of PS increased the elastic modulus between control 
and PS-containing scaffolds. The only exception to this was the PLGA7525-
ER scaffold which showed a small but insignificant increase. These 
mechanical properties may affect the clinical use of the scaffold in terms of 
handleability and comfort for the patient. 
To summarise, a number of scaffold characterisation techniques were 
adopted to elucidate the scaffold morphology and physical behaviour. The 
next stage in the study analysed these scaffolds in terms of their interactions 
to an aqueous environment. 
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 Interactions of Photosensitiser-Loaded Electrospun 
Scaffolds with Aqueous Medium 
4.1 Introduction 
The aim of the research in this chapter was to determine the 
interactions between PCL or PLGA7525 electrospun scaffolds with MB or 
ER PS in aqueous environments. These interactions will be influenced by 
the structural characteristics determined in Chapter 3. The choice of 
materials will affect the hydrophobicity of the scaffolds, which has been 
shown to influence cell integration in tissue regenerating devices[442]. The 
release profile of the PS from the scaffolds will be a vital characteristic for 
the functionality of the antimicrobial PDT, as a slow release will prevent 
cytotoxic concentrations of PS from accumulating and allow for repeat 
activations of the PS. The degradation profile is also important as the 
scaffold is required to maintain integrity in an oral environment for a 
sufficient time to allow for new tissue formation to occur[443].  
4.2 Materials and Methods 
4.2.1 Contact Angle 
Static contact angle measurements were recorded in triplicate for 
each scaffold using an FTA 4000 Contact Angle Goniometer and the 
associated software package. The scaffolds were attached to glass slides to 
hold them flat for analysis. A microsyringe was used to drop deionised water 
onto the surface of the scaffold. After a few seconds, an image was taken, 
and the shape of the droplet was analysed to calculate the contact angle. As 
the scaffolds are fibrous, additional analysis was performed on films 
produced from the electrospinning solutions to compare contact angles 
without interference from pore size and fibre diameter discrepancies. To 
produce the films, glass slides were coated in the corresponding 
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electrospinning solution and left for the HFIP to evaporate for 7 days. 
Following this time, the films were analysed in the same way. 
4.2.2 Release Kinetics 
Samples were cut into discs and weighed (ca. 20 mg) before being 
incubated with 5 ml of phosphate-buffered saline (PBS) solution at 37°C for 
up to 4 weeks. At selected time points, 100 µl of the solution was collected, 
analysed by UV-vis spectroscopy, and added back to the sample. The 
collected solutions (100 µl) were analysed on a microplate reader to record 
peak absorbance at either 610 nm (for MB) or 530 nm (for ER). Resulting 
absorbance values were converted into concentration of PS in the medium 
via a linear absorbance-concentration calibration curve (R2 > 0.99) obtained 
by measuring solutions whose PS concentrations covered the range used 
for scaffold PS encapsulation. 
4.2.3 Water Uptake Analysis 
Samples were cut into 1 cm2 squares and weighed individually before 
being incubated in well plates at 37°C in 5ml of distilled water (dH2O) for 24 
hours. Samples were then removed and blotted dry on filter paper to remove 
non-bonded water before being weighed again on an analytical balance. The 
percentage water uptake (WU) of each scaffold was calculated (Equation 
4.1).  
 
WU =
𝑚𝑤 − 𝑚𝑑
𝑚𝑑
× 100 Equation 4.1 – Percentage Water Uptake 
 
where mw and md represent the mass values of hydrated and dry scaffold 
discs respectively. All samples were analysed in triplicate. 
4.2.4 Hydrolytic Degradation 
Samples were cut into 1 cm2 squares and weighed before being 
incubated with 5 ml of PBS solution in sealed Falcon tubes at 37°C for up to 
8 weeks. At selected time points, samples were removed, washed in dH2O 
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three times for 5 minutes each time on a shaker plate and blotted dry before 
being dried in vacuum desiccator for 1 week. All samples were analysed in 
triplicate. The percentage mass loss of the scaffolds was calculated 
(Equation 4.2). 
 
Mass loss =
𝑚𝑡 − 𝑚𝑑
𝑚𝑑
× 100 
Equation 4.2 – Percentage Mass Loss 
 
where mt and md represent the mass values of either the dry partially 
degraded scaffold disc at the selected time point t, or the dry, freshly 
prepared electrospun scaffold disc, respectively. 
4.2.5 Scanning Electron Microscopy 
As described in Section 3.2.6 
4.2.6 Statistical Analysis 
Significant differences in the results were evaluated using an 
unpaired Student's t-test. Data was deemed to be significantly different at p 
< 0.05. All data were collected in triplicate and presented as Mean ± 
Standard Deviation. 
4.3 Results and Discussion 
4.3.1 Wettability 
4.3.1.1 Contact Angle 
The contact angle measurements allow quantification of the overall 
wettability of the scaffold. This is relevant since either PS diffusion or cell 
adhesion (to the surface of biomaterials) can be significantly affected by the 
surface wettability [442,444]. A contact angle of over 90° indicates a low 
interaction between the scaffold and the water (a hydrophobic response)[445]. 
Since fibre and pore size within the fibrous scaffold will affect the contact 
angle[446,447], water contact angle measurements were carried out on both 
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the scaffolds and the pore-free films obtained via casting and drying of the 
same electrospinning solution (Figure 4.1).  
 
 
Figure 4.1 - Water contact angle (WCA) images and measurements on 
dry PS-encapsulated and PS-free (ND) samples in the form of 
electrospun scaffold (top) and film (bottom). Results reported as 
Mean±SD (n=3). (a)-(c): significantly different means (p <0.05, t-test) 
 
Both PLGA7525 and PCL scaffolds proved to display water contact 
angles higher than 90°, whereby a significant increase in contact angle was 
measured on PLGA7525 scaffolds containing either MB or ER when 
compared to the PLGA7525-ND scaffold (p = 0.03 and 0.008 respectively). 
Fibrous scaffolds with a greater surface area have been shown to have an 
increased contact angle to those with a smaller surface area[446], and this 
trend was confirmed in this study via BET analysis and porometry on 
PLGA7525 scaffolds (section 3.3.2.1). PCL-MB electrospun samples 
displayed a significantly decreased water contact angle with respect to those 
of ER-encapsulated and PS-free electrospun samples, so the variation in 
contact angles across the different sample groups did not seem correlated to 
the effect of PS encapsulation on the surface of electrospun structures. In 
order to clarify this point, the effect of the fibre diameter and pore size was 
neglected, and pore-free films were analysed.  
Water contact angles well below 90° were measured in pore-free films 
obtained from respective electrospinning solutions, indicating that all films 
displayed increased compatibility with water in contrast to the case of the 
electrospun scaffold. There was a significant reduction in contact angle in 
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both MB- and ER-loaded PCL films with respect to PS-free (ND) PCL 
controls (p = 0.03 and p = 0.005, respectively), in agreement with previous 
publications[415,448,449], whilst no significant difference was found for either the 
PLGA7525-MB or PLGA7525-ER films (p = 0.06 and 0.6 respectively) with 
respect to the PLGA7525-ND controls. Contact angle values obtained with 
PCL films therefore suggest that PS molecules directly interact with the 
water droplet, leading to increased wettability of the polymer surface with 
respect to the case of electrospun fibrous structures. Electrospun scaffolds 
are non-homogeneous porous materials constructed from solid fibres, such 
that the superficial discontinuities (i.e. air in pores) appear to be responsible 
for the different wetting behaviour of scaffolds with respect to pore-free 
samples. On the other hand, it should be noted that film formation is a 
different process to that of electrospinning, as in film formation the polymer 
solution (with or without PS) is cast and air-dried. 
4.3.1.2 Photosensitiser Release 
The PS release profile from these scaffolds is crucial in terms of the 
intended clinical use of prototype scaffold described previously (section 1.3). 
A gradual release would allow repeated activation of the PS which would 
enable the dental surgeon to reactivate the antimicrobial activity of the 
scaffold should an infection arise requiring more than one aPDT treatment. 
Studies have shown post-operative oral infections are most likely to occur 
within the first 28 days following surgery, so it was decided that this would be 
the maximum time point needed to monitor the PS release as at this time 
point, healing of the oral mucosa should have taken place and the risk of 
infection should therefore be reduced[13,47]. 
Electrospun PCL samples generally presented a faster PS release 
profile compared to equivalent PLGA7525 variants, whilst MB proved to be 
more readily released compared to ER, regardless of the polymer carrier 
employed (Figure 4.2). 
 
 71 
 
  
(A) (B) 
Figure 4.2 - Typical PS release profiles measured via UV-Vis 
spectroscopy of the supernatant collected during incubation (PBS, 
37 °C) of MB- and ER-encapsulated scaffolds at selected time points 
over (A): 6 hours or (B): 672 hours (4 weeks). (-■-): PCL-MB; (-■-): 
PCL-ER; (··▲··): PLGA7525-MB; (··▲··): PLGA7525-ER.  Lines are 
guidelines to the eye. Results reported as Mean±SD (n=3) 
 
Scaffolds of PCL-MB displayed complete release following 96-hour 
incubation, and the cumulative mass of MB measured in the supernatant (m: 
170±9 mg) was found to compare well with the mass of PS encapsulated in 
the electrospun fibres (m: 150±2 mg). The value is slightly higher than 
100%, but this would be expected as the loading efficiency of these scaffolds 
was calculated to be 103±16% (section 3.3.2.1). In comparison, only a 
limited amount of PS was released from both PCL-ER and the PLGA7525 
scaffolds, suggesting that PS is being held within the scaffold due to 
secondary interactions between the PS molecule and the polymer. 
The different PS release profiles recorded from PCL and PLGA7525 
electrospun scaffolds were somewhat surprising, given that the averaged 
pore size was comparable between the two scaffold architectures (section 
3.3.2.1) and that the amorphous morphology of PLGA7525 should allow for 
increased diffusion of the PS out of the electrospun fibres compared to semi-
crystalline PCL. The most likely explanation for the increased release 
capability of PCL with respect to PLGA7525 samples is that the 
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encapsulation of PS in the PCL fibres leads to increased surface 
hydrophilicity, as demonstrated by contact angle data (Figure 4.1), so that 
diffusion of PS molecules is promoted in the PCL samples. The higher and 
faster release of MB with respect to ER can on the other hand be explained 
considering the different solubility in water and molecular weight of the two 
PS. MB (solubility = 35.5 mg·ml-1; M = 319.85 g·mol-1) is more soluble in 
aqueous environment with respect to ER (solubility = 0.7 mg·ml-1; M = 
879.86 g·mol-1), so that an increased diffusion of MB out of the scaffold is 
expected.  
Overall, the burst release observed with these samples is commonly 
seen with fibrous scaffolds used in drug delivery applications [450]. A steady 
PS release would be preferred to allow repeated activation of the PS to treat 
infections which may arise. Altering the monomer ratios in PLGA7525 
polymers could open up relevant avenues to induce polymer crystallisation 
enabling both dimensional stability and weaker PS-polymer interactions 
which would increase the PS-release from these scaffolds[391]. 
4.3.1.3 Water Uptake 
As the hydrolysis of polyester is a second order reaction, the reaction 
rate of hydrolysis will be dependent upon the WU and swelling of the 
polymer with water [451]. Other than hydrolysis, the WU into the scaffold will 
also have an impact as shown here, on the scaffold PS-release capability as 
well as cytocompatibility and regenerative potential in vivo. Following 24-
hour incubation in aqueous medium, a significantly greater WU was 
measured in PCL-ND compared to PLGA7525-ND scaffolds (Figure 4.3), 
and the same trends were observed in respective PS-encapsulated 
samples.  
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Figure 4.3 – Water uptake measured gravimetrically following 
incubation (H2O, 37 °C) of either PS-loaded or electrospun control 
(ND) samples. Grey bars: Polymer-ND scaffolds; Blue bars: Polymer-
MB scaffolds; Red bars: Polymer-ER scaffolds. Results reported as 
Mean±SD (n=3). ‘*’ denotes significantly different means (p <0.05, t-
test) 
 
Although detectable release of PS was measured within the selected 
WU time window (Figure 4.2), the mass percentage loss of PS in the 
electrospun fibre was minimal with respect to that of the control polymer 
fibres, suggesting that the measured WU was mostly ascribed to the effect 
of the scaffold chemical composition (e.g. polymer type) and architecture 
(e.g. fibre diameter) rather than the diffusion of PS out of the material.  
Whilst the averaged fibre diameter and mean flow pore size 
measured in PCL and PLGA7525 sample groups were statistically 
equivalent (section 3.3.2.1), the WU results are in agreement with previous 
contact angle (Figure 4.1) and PS release (Figure 4.2) measurements, 
indicating a higher compatibility with water in PCL with respect to the 
PLGA7525 samples. The WU measured for PS-encapsulated PCL scaffolds 
was greater than the PLGA7525 samples and electrospun controls. These 
trends in WU were found to correlate with the decrease in fibre diameter and 
pore size and the increase in hydrophilicity observed in the water contact 
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angle experiments on the films recorded in both samples PCL-MB and PCL-
ER (Figure 4.1) with respect to sample PCL-ND. 
4.3.2 Degradation 
Degradability of regenerative devices needs to be tailored for the 
intended tissue repair/clinical application, therefore the hydrolytic 
degradability of each fibrous system in this study was investigated[401]. 
Furthermore, it has been experimentally determined that fibroblast 
attachment to polymeric scaffolds is altered by the extent of polymer 
degradation[452]. Previous research performed on porcine palatal wounds 
found that full clinical closure of the small wounds had occurred by 14 days, 
and complete healing of the wound had occurred after 7 weeks[31]. This 
timescale will change depending on the size of the wound and may also 
differ in humans. It was therefore determined that the scaffolds would need 
to maintain integrity for 6-8 weeks in the oral cavity to allow for support of 
neotissue formation to occur. 
Changes in microarchitecture (Figure 4.4 and Figure 4.5), sample 
mass (Figure 4.6) and macroscopic volume (Figure 4.7) were monitored 
following sample incubation in PBS for up to 8 weeks.  
Minimal structural changes were observed for the retrieved PCL 
scaffolds at all selected time points (Figure 4.4), whilst both PLGA7525-ND 
and PLGA7525-MB scaffolds revealed a decrease in pore size between 
fibres after 1 week incubation in PBS (Figure 4.5). 
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Figure 4.4 - Scanning Electron Microscopy (SEM) of electrospun PCL 
scaffolds following 8-week incubation in PBS at 37 °C 
 
Figure 4.5 - Scanning Electron Microscopy (SEM) of electrospun 
PLGA7525 scaffolds following 8-week incubation in PBS at 37 °C 
 
Following 8 weeks incubation, PLGA7525-MB scaffolds were 
disintegrated and a collapsed fibrous architecture was observed, in line with 
the observed macroscopic volume reduction (Figure 4.5 and Figure 4.7). 
Consistent with the greater instability at both macroscopic and microscopic 
scales, electrospun PLGA7525 scaffolds proved to display a higher mass loss 
(14±4 wt.%) than  PCL scaffolds (4±2 wt.%) following 8-weeks incubation 
(Figure 4.6).  
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Figure 4.6 – Mass loss measured on PS-encapsulated or PS-free 
control (ND) samples following hydrolytic degradation (PBS, 37 ⁰C).  
(-■-): PCL-ND; (-■-): PCL-MB; (-■-): PCL-ER; (··◄··): PLGA7525-ND; 
(··◄··): PLGA7525-MB; (··◄··): PLGA7525-ER.  Lines are guidelines to 
the eye. Results reported as Mean±SD (n=3) 
 
Given the increased hydrolytic degradability of PLGA7525 with respect 
to PCL, an increased PS release should be observed in the former with 
respect to the latter scaffolds, following polymer hydrolysis and breakdown of 
the scaffold. This was unexpectedly not the case, possibly due to the 
macroscopic scaffold shrinkage preventing PS release. 
Previously published research has concluded that the pore size 
significantly alters cell adhesion within electrospun scaffold[418,447,453]. As the 
scaffold becomes non-porous in a moist environment (Figure 4.5), cells 
would not be able to infiltrate so the scaffold would not function well as a 
regenerative device. For this reason, the PLGA7525 formulations were 
withdrawn from further studies.  
During scaffold incubation in aqueous medium to monitor 
macroscopic behaviour, mass loss and PS release it was observed that 
none of the PS-encapsulated PCL samples showed a significant change in 
dimensions during the selected incubation time, whilst a drastic macroscopic 
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shrinkage was observed with respective PLGA7525 variants upon contact 
with water (Figure 4.7).  
 
  
(A) (B) 
Figure 4.7 – Macroscopic volume change of (A) PCL scaffolds and 
(B) PLGA7525 scaffolds following 1 week incubation in PBS. The 
yellow grid has 1 cm2 dimensions 
 
PS-encapsulated PLGA7525 samples reduced in macroscopic 
surface area by approximately 50% when compared to the pre-incubated 
scaffolds. Such variation in macroscopic dimensions is likely explained by 
the fact that PLGA7525 fibres display an amorphous polymer morphology 
(section 3.3.2.3); consequently, water molecules can access relatively freely 
throughout the polymer chains, acting as plasticiser and inducing increased 
chain mobility [454]. In contrast, the crystalline regions in PCL fibres present 
limited accessibility to water molecules (section 3.3.2.3), therefore acting as 
physical crosslinks and preventing volumetric change in hydrated scaffold 
dimensions. The plasticising effect of PLGA7525 fibres in aqueous 
environments is dominant in PS-encapsulated samples, given that 
respective fibres proved to display a significantly-decreased diameter with 
respect to the case of electrospun control fibres (51% and 69% reduction 
respectively, section 3.3.2.1). In line with the PS-induced decrease of fibre 
diameter and increased WU, merging of fibres and collapse of the porous 
scaffold architecture are increasingly likely.  
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4.4 Conclusion 
In an aqueous physiological environment, PLGA7525 scaffolds 
displayed significant macroscopic shrinkage upon contact with water and 
collapse of the fibrous structure following 8-week incubation, likely explained 
by the amorphous polymer morphology of PLGA7525 with respect to the 
semi-crystalline state of PCL fibres. This shrinkage resulted in the 
PLGA7525 scaffolds being deemed not suitable for use in the moist 
environment of the mouth, due to reduced porosity which would prevent cell 
infiltration and therefore neotissue formation. No observable shrinkage was 
found for either PCL-ND control samples or the PS-loaded PCL scaffolds. 
Together with results obtained from the hydrolytic degradation study (section 
4.3.2), PCL scaffolds were therefore deemed to be a dimensionally-stable 
polymer carrier for both PS molecules. However, a burst release profile was 
detected for either PS from the PCL scaffolds. 
Further biomaterial optimisation is needed to either slow the PS-
release from the PCL scaffolds or to increase the crystallinity of the 
PLGA7525 scaffolds to prevent shrinkage in aqueous media. Increasing the 
glycolic acid monomer ratio in the PLGA7525 could lead to an increase in 
crystallinity and therefore a more stable polymer carrier. For example, 
previously published work has been performed on electrospun PLGA with a 
lactide to glycolide ratio of 10:90, and minimal shrinkage was observed 
following incubation in aqueous media[229]. 
To summarise, electrospun scaffolds were characterised in terms of 
their behaviour in aqueous medium. The next stage of this study was to 
determine the optimal PS (MB or ER) for loading in the optimised polymer 
carrier based on a comparison of the bactericidal activity and mammalian 
cytotoxicity between these two PS. The lead polymer carrier at this stage, 
PCL, was also used as a model to test the cell survival and bactericidal 
capacity of the PS when loaded into and released from polymer electrospun 
scaffolds.  
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 Selection of Photosensitiser for Antimicrobial 
Photodynamic Therapy 
5.1 Introduction 
The aim of the research presented in this chapter was to determine 
the optimal PS (MB or ER) for encapsulation within polymeric electrospun 
scaffolds to enable aPDT activity in oral applications. 
Initially, a light source was analysed to determine the irradiation 
intensity in comparison with lights currently used in dental applications. This 
was used as a guide for the temporal length of light exposure to be used in 
the mammalian and bacterial cell studies. Solutions of either MB or ER in 
PBS were then analysed for their aPDT capability against two model strains 
of bacteria (Streptococcus mutans (S. mutans) Ingbritt and Escherichia coli 
(E. coli) 11954). These bacteria were chosen as gram-negative and gram-
positive strain models respectively. aPDT is most effective on gram-positive 
strains of bacteria due to the presence of an additional cell wall in gram-
negative strains[455]. 
A comparable experiment was then performed on L929 mouse 
fibroblast cells to provide an early indication of any mammalian cell cytotoxic 
effects induced by the PS when in solution. 
The lead prototype polymer carrier was selected in Chapter 3 and 
Chapter 4 as being PCL, due to the dimensional stability of the respective 
scaffolds in aqueous environments. This PCL electrospun scaffold was used 
as a model scaffold to test the effects of scaffold-induced release of either 
MB or ER on either E. coli bacteria or L929 fibroblasts. 
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5.2 Materials and Methods 
5.2.1 Quantification of Light Intensity 
An easily accessible light source was used as a model for the 
preliminary purpose of this study. For this purpose, a 6000-lumen work light 
(50W, 135 lumen/W, 2800-3200 warm light) was selected. An ILT2400 hand-
held optical meter was used (International Light Technologies NIST 
Traceable Light Measurement Systems) with two laser line filters (532±2 nm 
(ER peak absorbance) and 670±2 nm (MB peak absorbance)) (ThorLabs, 
Inc.) to determine the light intensity in the spectral regions of interest. The 
light was tested both with and without the filters, and with or without a water 
bath which was used to dissipate any heat which may arise from the light 
source in order to protect the samples during testing (section 5.2.5.1, Figure 
5.3). The light meter was held under the light in 9 distinct locations and the 
light intensity (mW/cm2) associated with these were averaged together to 
ensure that the light output in each well under the light was consistent. The 
experiment was repeated three times per parameter.  
5.2.2 General Cell Culture 
5.2.2.1 Cell Culture Materials 
Mouse fibroblast cells (L929) were chosen as a suitable model 
mammalian cell type according to ISO standard testing of cytotoxicity[191,456]. 
PBS, Minimum Essential Media Eagle – alpha modification (α-MEM) 
(supplemented with L-Glutamine, 10 v.% Fetal Bovine Serum (FBS) and 1 
v.% Penicillin-Streptomycin) and Trypsin were all from Lonza 
BioWhittaker®). All media was stored in a 4°C fridge until use and, when 
required, heated in a water bath to 37°C. TritonTM X-100 detergent (Alfa 
Aesar) was diluted in PBS to a working concentration of 10 v.%. Dimethyl 
sulfoxide (DMSO) and all other reagents were from Sigma Aldrich unless 
otherwise stated. 
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5.2.2.2 Cell Culture Passage 
L929 cells were passaged regularly in T175 flasks to maintain 80% 
confluency. When passaging was required, adherent cells were washed 
twice in PBS (5 ml, 37°C) before Trypsin (5 ml, 37°C) was added and the 
flasks incubated (37°C, 5% CO2) for 3 minutes. Following this, flasks were 
tapped gently on the side to detach any cells still adhering to the plastic and 
examined by light microscopy to ensure all cells had detached. Media (5 ml, 
37°C) was then added to deactivate the trypsin enzyme and the resulting 
solution was centrifuged for 5 minutes at 1200 rotations per minute. The 
supernatant was removed, and the pellet of cells was resuspended in fresh 
medium (10 ml, 37°C) and the flask returned to the incubator (37°C, 5% 
CO2). The passage number was monitored throughout all experiments. 
5.2.2.3 Cell Culture Counting 
Cells were passaged and suspended in medium (section 5.2.2.2), 
before an aliquot of 45 µl was taken and put into a 1.5 ml eppendorf tube. 5 
µl of trypan blue was added to the cell suspension and mixed (1:10 dilution), 
before a 10 µl aliquot of the solution was taken and dispensed into a 
haemocytometer. Living cells appeared white and (when present) dead cells 
appeared blue due to penetration of the trypan blue into the cells. All live 
cells in four squares of the haemocytometer were counted and averaged. 
The cell concentration (cells/ml) was then calculated (Equation 5.1).  
 
𝐶𝑒𝑙𝑙 𝐶𝑜𝑛𝑐.  =  
𝑁𝑎𝑣𝑒𝑟𝑎𝑔𝑒
𝑉𝑜𝑙.
 𝑥 𝐷𝐹  Equation 5.1 – Cell Concentration 
 
with ‘Naverage’ representing the average number of living cells per square, 
‘Vol.’ representing the volume of solution in each square (10-4 ml) and ‘DF’ 
(Dilution Factor) representing the dilution of the cell solution with trypan blue. 
To obtain the total number of cells in the cell suspension, the value obtained 
was multiplied by the volume of the initial cell suspension. 
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5.2.2.4 Cell Culture Freezing and Thawing 
Cells were periodically frozen and stored if a constant culture was not 
needed to be maintained. L929 cells were passaged as previously described 
(section 5.2.2.2) but in the final stage, they were resuspended in freezing 
medium rather than the normal α-MEM medium. The freezing medium was 
supplemented with 30 v.% FBS and 10 v.% DMSO. Vials of cells 
resuspended in freezing medium were placed in a Mr. Frosty™ Freezing 
Container (Thermo Fisher Scientific) to control the cooling rate and placed in 
-80ºC freezers.  
When cells were required again, they were thawed by removing from 
the -80ºC freezers and defrosting for ~1 minute in a 37ºC water bath. The 
cell suspension was then resuspended in fresh medium (5 ml, 37°C), 
centrifuged and the supernatant removed to remove traces of the freezing 
medium. The pellet of cells was then resuspended in fresh medium again. 
5.2.3 General Bacterial Culture 
5.2.3.1 Bacterial Culture Materials 
Brain Heart Infusion (BHI) broth and Columbia Blood Agar Base (CB) 
were both from Oxoid. Horse Blood Oxalated was from Thermo Scientific. 
Crystal Violet, Gram’s Iodine and Safranin used for staining were all from 
Pro-Lab Diagnostics. All other reagents were sourced from Sigma Aldrich 
unless otherwise stated. 
5.2.3.2 Broth and Agar Plate Preparation 
Fresh broth and agar plates were made prior to use. BHI and CB agar 
plates were made as per manufacturer’s instructions. Briefly, 37 g of BHI 
was mixed with 1 L of dH2O in a sterile Duran flask and autoclaved. The 
broth was cooled to room temperature overnight prior to use. CB agar plates 
were prepared by mixing 39 g of CB agar base with 1 L of dH2O and 
autoclaving in a sterile Duran flask. The Duran flask was then placed in a 
50ºC water bath to cool the solution for ~1 hour, before 50 ml of oxalated 
horse blood was added and gently mixed to combine. Sterile plates were 
 83 
 
then poured in aseptic conditions and left to solidify at room temperature. 
When set, the plates were inverted and stored in a 4ºC fridge overnight. 
5.2.3.3 Bacterial Strain Characterisation 
Bacterial strains chosen for use in this study were S. mutans Ingbritt 
(gram-positive coccus bacteria) and E. coli 11954 (gram-negative rod-
shaped bacteria). These were chosen as model bacteria to represent a 
gram-negative and gram-positive bacterial strain. 
Each week, a single colony was swabbed onto fresh agar plates and 
incubated overnight at 5% CO2 and 37ºC before being stored in a fridge. 
Each time a fresh agar plate was swabbed, colony morphology and gram-
staining were used to confirm lack of contamination. Gram-staining was 
performed by taking a single colony on a sterile loop and swabbing onto a 
fresh glass slide. The slide was passed briefly through a Bunsen flame to fix 
the sample, before the slide was flooded with Crystal Violet for 1 minute. The 
slides were then washed briefly in water before being flooded with Gram’s 
Iodine for 1 minute. After washing again briefly in water, the slides were 
washed with acetone to decolourise for 2 seconds and washed in water 
again. The slides were finally immersed in Safranin for 30 seconds and 
washed again in tap water, before being visualised by light microscopy with 
immersion oil. Examples of the gram-staining obtained from each bacterial 
strain are shown below (Figure 5.1). Gram-negative bacteria were stained 
pink and gram-positive bacteria were stained purple. 
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(A) (B) 
Figure 5.1 – Examples of Gram-Staining of two bacterial strains used 
in this study. (A) Escherichia coli (E. coli) 11954 (gram-negative); (B) 
Streptococcus mutans (S. mutans) Ingbritt (gram-positive) 
 
Overnight cultures of bacteria were grown by selecting two separate 
colonies on sterile loops and inoculating them into 20 ml BHI in a sterile 
flask. The flasks were incubated in an incubator maintained at 37°C, 5% 
CO2 overnight. 
5.2.3.4 Growth Curve Characterisation 
A growth curve was plotted for each bacterial strain of the variation of 
absorbance at 600 nm (OD600) over time. This was achieved by initially 
growing an overnight culture of bacteria in sterile BHI broth to generate a 
large batch of bacteria. The following day, 25 ml of the overnight solution 
was added to 250 ml fresh sterile BHI, two 1 ml samples were taken and the 
OD600 of each was measured (t = 0). The bacterial suspension was then 
incubated at 37°C and two 1 ml samples were taken every hour for up 6 
hours. The two OD600 readings for each timepoint were averaged, and the 
whole experiment was repeated in triplicate for each bacterial strain. The 
OD600 vs. time curve was plotted and the mid-log phase determined to be 
the linear region of the resulting graph representing the highest rate of 
growth of bacteria (Figure 5.2). 
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Figure 5.2 – OD600 with respect to time of bacterial suspensions. 
Orange: E. coli 11954; Purple: S. mutans Ingbritt; (→): Mid-log 
phase. Results reported as Mean±SD (n=3) 
 
This graph was used to determine that mid-log phase was reached 
after 1.5 hours for E. coli and 3.5 hours for S. mutans. 
Following this, the number of CFU per ml of solution were determined 
for the mid-log phase. 1 ml of overnight culture was added to 9 ml of fresh 
BHI and incubated for the allotted time until mid-log phase was reached (as 
calculated in Figure 5.2). A 10 µl sample was then taken and serially diluted 
in 90 µl of fresh BHI before 10 µl of each dilution was spread on CB agar 
plates in triplicate. The plates were incubated overnight at 37°C and the 
number of colonies counted. Only plates containing 20-100 colonies were 
counted. The whole experiment was repeated twice for each bacterial strain 
and the CFU/ml was calculated (Equation 5.2). 
 
𝐶𝐹𝑈 𝑚𝑙⁄ =  
𝑁𝐶𝐹𝑈 𝑥 𝐷𝐹
𝑉𝑜𝑙.
 Equation 5.2 – Colony Forming Units 
 
with ‘NCFU’ representing the number of colonies on a plate, ‘DF’ representing 
the corresponding dilution from the initial suspension, and ‘Vol.’ being the 
volume of bacterial suspension plated up (0.1 ml). The results were used to 
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generate equations for determining the CFU in a particular suspension of 
bacteria in each study (Equation 5.3 and Equation 5.4). 
 
𝐶𝐹𝑈𝐸.𝐶𝑜𝑙𝑖 =  6.2𝑥10
7 𝑥 𝑂𝐷600 
Equation 5.3 - CFU E. coli 
𝐶𝐹𝑈𝑆.𝑀𝑢𝑡𝑎𝑛𝑠 =  2.7𝑥10
8 𝑥 𝑂𝐷600 
Equation 5.4 – CFU S. mutans 
 
5.2.4 Photosensitiser Uptake Study 
5.2.4.1 Mammalian Cells - Photosensitiser Uptake 
To determine the amount of PS taken up by mammalian cells, L929 
cell lines were passaged, counted and seeded into 96 well plates at a 
density of 5x103 cells/ml and left for 24 hours to allow for cell attachment. 
Confluent monolayers were then exposed to a range of four concentrations 
of either MB or ER solutions in PBS (0.2-200 µg/ml) for 2 hours to allow for 
PS uptake. Control wells contained either the PS solution with no cells or 
fresh PBS with cells. After 2 hours, the solutions were removed, and each 
well was washed in fresh PBS twice to remove any PS which had not been 
taken up by the cells. The PBS solution was then removed and replaced with 
a 10 v.% TritonTM X-100 in PBS solution and well plates were shaken for 5 
minutes and left to incubate for 25 minutes to allow for membrane disruption 
and full release of any incorporated PS. The absorbance of the solution was 
recorded at 610nm for MB and 530nm for ER and the background 
interference (from the absorption values of wells containing only solubilised 
cells) was subtracted. This value was then compared to the absorption of the 
initial PS-loaded solutions (containing no cells) and the percentage uptake 
values were calculated (Equation 5.5).  
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𝑃𝑆 𝑈𝑝𝑡𝑎𝑘𝑒 =  
[𝑃𝑆]𝑐𝑒𝑙𝑙𝑠 
[𝑃𝑆]𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛  
 𝑥 100 Equation 5.5 – Percentage Cell PS 
Uptake 
 
with ‘[PS]cells’ representing the concentration of PS released from cell lysis 
and ‘[PS]solution’ representing the concentration of PS in the initial PS-loaded 
solution. 
5.2.4.2 Bacteria - Photosensitiser Uptake 
To determine the amount of PS taken up by bacterial cells, an 
overnight culture of each bacterial strain was grown. 1 ml of overnight 
culture was placed in 9 ml of fresh BHI and left to incubate to mid-log phase 
(section 5.2.3.4). Following this time, the OD600 of the suspension was 
measured and the suspension diluted in fresh BHI to result in a final 
concentration of 108 CFU/ml. After this, the planktonic bacteria suspension 
was washed once in PBS and then resuspended in a range of four 
concentrations of either MB or ER solutions in PBS (0.2-200 µg/ml), plated 
into 96 well plates and incubated for 2 hours to allow for PS uptake. Control 
wells contained either the PS solution with no bacteria or fresh PBS with 
bacteria. The PS containing solution was then washed off the bacteria and 
the bacteria resuspended in fresh PBS, centrifuged and the supernatant 
removed. This process of washing the bacteria was repeated twice. The 
PBS solution was then replaced with a 10 v.% TritonTM X-100 in PBS 
solution and well plates were shaken for 5 minutes and left to incubate for 25 
minutes to allow for membrane disruption and full release of any 
incorporated PS. The absorbance of the solution was recorded at 610 nm for 
MB and 530 nm for ER and the background interference (from the 
absorption values of wells containing only solubilised bacteria) was 
subtracted. This value was then compared to the absorption of the initial PS-
loaded solutions (containing no bacteria) and the percentage uptake values 
were calculated (Equation 5.6). 
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𝑃𝑆 𝑈𝑝𝑡𝑎𝑘𝑒 =  
[𝑃𝑆]𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎 
[𝑃𝑆]𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛  
 𝑥 100 Equation 5.6 – Percentage 
Bacterial PS Uptake  
 
with ‘[PS]bacteria’ representing the concentration of PS released from bacterial 
lysis and ‘[PS]solution’ representing the concentration of PS in the initial PS-
loaded solution. 
5.2.5 Photosensitiser-Loaded Solution Toxicity 
5.2.5.1 Mammalian Cells - Photosensitiser-Loaded Solution Toxicity 
To determine the cytotoxicity induced by PS-loaded PBS solutions on 
L929 cell lines, confluent cells were passaged, counted and seeded into 96 
well plates at a density of 5x103 cells/ml in 100 µl of medium and left for 24 
hours to allow cell attachment. Confluent monolayers were then exposed to 
a range of either MB or ER solutions in PBS (0.2-200 µg/ml) for 2 hours to 
allow for PS uptake. Control wells contained fresh PBS with cells (negative 
control) and 10 v.% PBS-TritonTM X-100 solution (positive control). The well 
plates were then either exposed to light for 30 or 60 minutes or wrapped in 
foil and left under the light for the same period of time (dark control). A water 
bath was used to dissipate any heat which may alter the samples (Figure 
5.3). 
 
 
 
 89 
 
 
(A) (B) 
Figure 5.3 – Experimental setup for light activation step. Water bath 
was used to dissipate any heat which may arise from the light source 
during exposure time. (A): Light off; (B): Light on. : Location of well 
plate during experiment; : Arrow represents 15 cm 
 
Following this, 100 µl of Cell-TiterGlo® 2.0 solution (Promega) was 
added to each well and the well plate was covered in foil and shaken at 200 
RPM on a shaker for 5 minutes, before being left to equilibrate at room 
temperature for 25 minutes. Well plates were then analysed on a microplate 
reader, with a luminosity reading being recorded for each well. The wells 
were all compared to the average of the negative dark control wells on each 
plate (fresh PBS with cells and no light exposure) to determine the 
percentage of cells which were killed (Equation 5.7). 
 
% 𝐾𝑖𝑙𝑙𝑖𝑛𝑔 =  
𝐿𝑢𝑚𝑡𝑒𝑠𝑡
𝐿𝑢𝑚𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 𝑥 100 Equation 5.7 – Percentage Killing 
 
with ‘Lumtest’ representing the luminosity of the test well and ‘Lumcontrol’ 
representing the luminosity of the control well. 
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5.2.5.2 Bacteria - Photosensitiser-Loaded Solutions Antimicrobial 
Photodynamic Therapy Activity 
To determine the aPDT capability of PS-PBS solutions on bacterial 
cells, an overnight culture of bacteria in BHI broth was grown for each 
bacterial strain. 1 ml of overnight culture was placed in 9 ml of fresh BHI and 
left to incubate to mid-log phase as determined for each bacterial strain 
(section 5.2.3.4). The OD600 of the suspension was then measured and the 
suspension diluted in fresh BHI to an OD equivalent to 108 CFU/ml.  The 
bacteria were washed once in 1 ml of PBS and then resuspended in a range 
of concentrations of either MB or ER solutions in PBS (1 ml at 0.2-200 
µg/ml) and 100 µl of each plated into 96 well plates and incubated for 2 
hours to allow for maximum PS uptake. Control wells contained bacteria 
suspended in fresh PBS (negative control) and bacteria suspended in 10 
v.% PBS-TritonTM X-100 solution (positive control). The well plates were then 
either exposed to light for 30 or 60 minutes or wrapped in foil and left under 
the light for the same period of time (dark control). Following this, 100 µl of 
Bact-TiterGlo® solution (Promega) was added to each well and the well 
plate was covered in foil and shaken at 200 RPM on a shaker for 1 minute 
before being left to equilibrate at room temperature for 4 minutes. Well 
plates were then analysed on a microplate reader, with a luminosity reading 
being recorded for each well. The wells were all compared to the average of 
the negative dark control wells on each plate (fresh PBS with bacteria and 
no light exposure) to determine the percentage of bacteria which were killed 
(Equation 5.7). 
5.2.6 Photosensitiser-Encapsulated PCL Scaffold Toxicity 
5.2.6.1 Mammalian Cells - Photosensitiser-Encapsulated PCL Scaffold 
Extract Toxicity 
Room temperature scaffolds were cut into squares with a mass of ~20 
mg before being disinfected for 15 minutes on each side using an ultraviolet 
light source. These were then placed in triplicate in Falcon tubes with 5 ml of 
PBS and incubated at 37°C for 0, 2 or 24 hours to allow for PS release to 
generate ‘extract solutions’.  
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L929 cells were passaged, counted and seeded into 96-well plates at 
a density of 5x103 cells per well in 100 µl of medium and left for 24 hours to 
allow for cell attachment. After this time, media was removed from the wells 
and they were each washed with fresh PBS to remove residual media 
contaminants, before the extract solution was added and left for 2 hours. 
Control wells contained fresh PBS with cells (negative control) and 10 v.% 
PBS-TritonTM X-100 solution (positive control). The well plates were then 
either exposed to light for 30 or 60 minutes or wrapped in foil and left under 
the light for the same period of time (dark control). 
Following this, 100 µl of Cell-TiterGlo® 2.0 solution was added to 
each well and the well plate was covered in foil and shaken at 200 RPM on a 
shaker for 5 minutes, before being left to equilibrate at room temperature for 
25 minutes. Well plates were then analysed on a microplate reader, with a 
luminosity reading being recorded for each well. The wells were all 
compared to the average of the negative dark control wells on each plate 
(cells in PBS with no light activation) to determine the percentage of cells 
which were killed (Equation 5.7).  
5.2.6.2 Bacteria - Photosensitiser-Encapsulated PCL Scaffolds 
Antibacterial Photodynamic Therapy Activity  
Due to this experiment being performed during an external placement 
at the University of Massachusetts Amherst, a different but comparable 
bacterial strain was used, and different reagents were used. All reagents 
were purchased from Sigma Aldrich unless otherwise stated. 
An overnight culture of bacteria was prepared. Briefly, 5 ml of Luria-
Bertani (LB) media and 5 µl Carbenicillin (Carb) antibiotic were added to an 
autoclaved test tube in aseptic conditions. A pipette tip was flame sterilised 
and used to collect a single colony from an agar plate containing the K12 
MG1655 E. coli bacterial strain, which was then added to the test tube. This 
was then flame sterilised, sealed and incubated on a stirrer plate at 250 
rotations per minute overnight at 37°C. 
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When ready to use, a sample of the culture solution was diluted in a 
cuvette with additional LB media to obtain an absorbance reading at 600 nm 
between 0.5 and 1 against an LB media background. An absorbance 
reading of 1 was taken to be equivalent to 1.6x108 CFU/ml according to the 
McFarland 0.5 standard to calculate the number of bacterial cells in the 
overnight culture solution[457]. Approximately 2.5x107 CFU was used in each 
experiment. 
Room temperature scaffolds were cut into round discs with a diameter 
of 1.27 cm (weight ~20mg) before being disinfected for 15 minutes on each 
side using an ultraviolet light source. These were then placed in a 6-well 
plate with 5ml of M9 minimal salts medium per well. Glass slides were used 
for the control wells, which contained either M9 minimal salts medium 
(negative control) or ethanol (positive control) with the same quantity of 
bacteria in each well. The well plates containing M9 medium and scaffolds 
were incubated at 37°C for 0, 2 or 24 hours to allow for PS release. After this 
time, overnight bacterial culture solution and 5 µl of Carb was added. The 
plates were then irradiated (at 1 cm distance) with the light source (3500 
lumen Husky LED portable work light) for either 30 or 60 minutes. During 
each experiment, a duplicate plate was wrapped in foil and placed in the 
same incubator as a ‘dark’ control to measure the level of toxicity of the PS 
and scaffold when not activated by the light source. The temperature of the 
incubator was monitored to ensure that there was no significant increase of 
temperature for the duration of the experiment.  
The E. coli K12 MG1655 bacteria used were engineered to fluoresce 
with a maximum excitation wavelength of 488nm and a maximum emission 
wavelength of 510nm thus eliminating the need to stain the bacteria with a 
‘live’ green fluorescent protein (GFP) stain. PI (propidium iodide), was used 
to monitor the number of dead cells in each experiment. Following light 
exposure, the bacterial solution was removed and 2 ml of PI solution (12.5 µl 
per ml of deionised water) was added to each well. This was left to incubate 
at room temperature for 15 minutes to allow bacterial staining to occur. After 
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this, each sample was removed, rinsed in deionised water to remove excess 
stain and blotted gently on Kimwipes to remove excess water.  
The samples were then placed onto a glass slide and imaged directly 
under a Zeiss epifluorescence microscope using GFP (488 nm) and PI (535 
nm) wavelength filters and ZenPro software. Images were taken at 20x 
magnification in three randomly chosen areas across the scaffold. ImageJ 
was used with the multi-point tool to count the live or dead cells on each 
image. The average log reduction in live bacteria was calculated according 
to (Equation 5.8). 
 
𝐿𝑜𝑔 𝑅𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =  log10
𝑛𝑑𝑒𝑎𝑑 + 𝑛𝑙𝑖𝑣𝑒
𝑛𝑑𝑒𝑎𝑑
 Equation 5.8 – Log Reduction of 
Live Bacteria 
 
where ‘ndead’ and ‘nlive’ are the number of dead (red) and live (green) 
bacteria, respectively, measured in the epifluorescence microscope image.  
5.2.7 Statistical Analysis 
Significant differences in the results were evaluated using an 
unpaired Student's t-test. Data was deemed to be significantly different at p 
< 0.05. All data were collected in triplicate and presented as Mean ± 
Standard Deviation. 
5.3 Results and Discussion 
5.3.1 Quantification of Light Intensity 
The average light intensity of the model work light was calculated 
either with no filter (the full spectrum of light intensity) or filters to detect the 
light output intensity in correspondence of the maximum absorption areas for 
MB (670 nm) or ER (530 nm) (Table 5.1). 
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Experimental 
Conditions 
Light Intensity  
(mW/cm2) 
Energy Density  
(J/cm2) 
No Water Water 30 mins 60 mins 
No Filter 103±15  119±9 215±16         430±32         
670nm Filter (MB) 3±0.4  3±1 6±1         11±2 
532nm Filter (ER) 3±1   3±1  5±1 11±2 
Table 5.1 – Summary of average light intensity tested in various 
experimental conditions. No water refers to readings taken without 
the presence of the water bath. The energy density values are 
calculated from light intensity values with water bath. Results 
reported as Mean±SD (n=3) 
 
The water bath which was used to protect the samples from any light-
induced heat was found to have no significant impact on the intensity 
readings at either 670 nm or 530 nm (p = 0.4 and 0.4 respectively). No 
significant difference was found between the light intensity at the 
wavelengths of interest for MB and ER (p = 0.7). This is important as it 
enabled a direct comparison of the two PS to be performed using this light 
system. 
A handheld portable device with a non-thermal diode laser currently 
available on the market (PeriowaveTM, Ondine Biopharma, Vancouver, 
Canada) has been specifically designed for use with MB in oral applications 
with a wavelength range of 650-670 nm[458]. This product has been reported 
to have a maximum output of between 150-200 mW and following a 60 
second light exposure, an energy density of 21 J/cm2[458–460]. 
In this preliminary study, light exposure times of 30 minutes and 60 
minutes were selected based on previously published studies using a similar 
white light source[333,353,461]. It is important to note that research has shown 
that repeated smaller doses of light exposure (also known as light 
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fractionation) led to greater aPDT effect than an equivalent single dose of 
light[462–465]. This is likely to be due to the absence of photobleaching effect 
on the PS. The phenomenon of light fractionation confirms that the overall 
light energy density is not the only factor to consider in PDT and this should 
be considered in the future development of this medical device. 
5.3.2 Photosensitiser Uptake 
An experiment was designed to determine the PS uptake based on a 
previously published protocol[466]. Four solution concentrations ranging from 
0.2-200 µg/ml of either MB or ER in PBS were tested on L929 mammalian 
cells and two bacterial strains, one gram-positive (S. mutans) and one gram-
negative (E. coli).  
Due to the low absorbance readings of the amount of PS taken up at 
the lowest two concentrations (0.2 µg/ml and 2 µg/ml), there was no 
significant difference between the absorbance measurement and the ‘cell 
only’ controls for either PS, meaning that the result was undetectable using 
this experimental procedure. These results are therefore not shown here, 
and only the results for the two highest PS concentrations are compared 
(Figure 5.4). 
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(A) 
 
 
 
 
(B) (C) 
Figure 5.4 – PS Uptake by either cells or bacteria during a 2 hour 
incubation in PS-loaded solutions. : MB-loaded PBS solutions; : 
ER-loaded PBS solutions.  (A) L929 mammalian cells, (B) S. mutans 
Ingbritt gram-positive bacteria, (C) E. coli 11954 gram-negative 
bacteria. Results reported as Mean±SD (n=3). ‘*’ denotes significantly 
different means (p <0.05, t-test) 
 
The overall uptake values are comparable to those found in the 
previously published literature[466].There was a significantly greater uptake of 
MB compared to the uptake of ER at either concentration for both the E. coli 
(p = 2x10-5 and 0.0004 respectively) and the S. mutans (p = 3x10-6 and 
4x10-5) bacterial strains and the L929 mammalian cells (p = 0.01 and 6x10-5 
respectively). This is likely to be due to cationic charge of the MB enhancing 
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uptake by interacting more strongly with the external wall or outer membrane 
of the cell or microorganism[466]. Studies have also shown that microbial 
efflux pumps play a role by enhancing uptake of cationic PS such as MB 
which was not found with anionic PS[467]. 
For the cationic MB, gram-positive S. mutans bacteria took up 
significantly more PS than Gram-negative E. coli over the 2-hour incubation 
period for both the 20 µg/ml and 200 µg/ml concentrations (p = 4x10-5 and 
0.003 respectively). It is expected that this is due to the need to penetrate 
the outer membrane which acts as a barrier to uptake of PS in gram-
negative bacteria. 
These results would suggest that at comparable concentrations, more 
MB will be moved intracellularly than ER and therefore it could be more 
active as a PS for aPDT. 
5.3.3 In vitro testing with Photosensitiser-Loaded Solutions 
5.3.3.1 Mammalian Cell Photosensitiser-Loaded Solution Testing 
Testing was performed by incubating a confluent mammalian 
fibroblast cell line (L929) in either MB-loaded or ER-loaded PBS solutions at 
four concentrations (0.2 µg/ml to 200 µg/ml) for 2 hours to allow for PS 
uptake. The viability of the cells was determined using an ATP detection 
assay, ‘Cell-Titre Glo® 2.0’. ATP was used as an indicator of metabolically 
active (living) cells. Briefly, the assay involved the full lysis of cells to release 
any intracellular ATP. The ATP was then reacted with luciferin and the Ultra-
GloTM rLuciferase enzyme to generate oxyluciferin which was luminescent. 
The RLU (relative light units) measured correlates to cell survival: the 
greater RLU reading, the greater the number of living cells present in the 
sample[197]. The negative dark control with cells in fresh PBS and no light 
activation was assumed to be representative of the RLU for 100% cell 
survival. The average RLU reading of these control samples was used to 
calculate the percentage killing of the other test samples, based on a 
percentage reduction in RLU.  
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In each experiment, PBS was selected as a negative control and a 
solution of PBS containing 10 v.% TritonTM X-100 detergent to lyophilise all 
the cells was selected as a positive control (Figure 5.5). 
 
  
(A) (B) 
  
(C) (D) 
Figure 5.5 - L929 Solution Toxicity. (A) 30 min ‘dark’ control; (B) 30 
min light exposure. (C) 60 min ‘dark’ control; (D) 60 min light 
exposure. : MB-loaded PBS solutions; : ER-loaded PBS 
solutions; : fresh PBS negative control; : PBS-TritonTM X-100 
solution positive control. Results reported as Mean±SD (n=3). ‘*’ 
denotes significantly different means (p <0.05, t-test) 
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The cell killing produced by the positive control of PBS containing 10 
v.% TritonTM X-100 was found to indicate cell killing of 98±0.4% over all 
experiments, and cell killing in PBS alone was -0.2±0.6%, providing 
evidence that the cells could be killed, but that without treatment the cells 
were able to survive. 
An important consideration in the use of PS is the ‘dark toxicity’ of the 
PS, which describes the toxicity induced by the PS without light 
activation[389,468]. This is primarily controlled by the concentration of the PS 
within the PS-loaded solution. Upon optimisation of the PS polymer carrier, 
an ideal release profile is sought which will provide a controlled release of 
the PS. This steady release should avoid high, potentially toxic 
concentrations of PS accumulating at any point in time. To determine the 
concentration suitable for a non-toxic release profile of PS, testing of PS-
loaded PBS solutions was performed on monolayers of mammalian cells 
and bacteria to identify the PS concentration causing minimal ‘dark toxicity’ 
(i.e.30% cell death). 
For 100 µl of a PS concentration of 200 µg/ml and 20 µg/ml with no 
light activation, MB killed significantly more L929 cells than ER after 60 
minute incubation times (p = 1x10-11 and p = 0.01 respectively) (Figure 
5.5C). However, both PS killed >85% of the cells at either of these 
concentrations, which indicates that these concentrations would be too toxic 
for use in a tissue regenerating scaffold product. The initial loading of PS 
into the scaffold and the consequent release profile will need to be tuned to 
avoid these concentrations being reached. 
At 2 µg/ml, the average dark toxicity for the 60 minute timepoint was 
14±11%, and the maximum dark toxicity for ER was 20±3%, with no 
significant difference between the two PS (p = 0.1) (Figure 5.5C). At the 
lowest concentration of 0.2 µg/ml, the average dark toxicity was <1% for 
either PS (-2±10% and 1±3% for MB or ER respectively) and again, there 
was no significant difference between the two PS (p = 0.4) (Figure 5.5C). 
Therefore, either 2 or 0.2 µg/ml were tolerated by the cells and could 
therefore be encapsulated in the electrospun scaffold. 
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It is worth noting that although comparisons can be made between 
the concentrations of PS in PBS, the molarity of these solutions is different 
as the molecular weight of MB (319.85 g·mol-1) is approximately 2.6 times 
less than that of ER (835.90 g·mol-1). Conversions of these mass 
concentrations into molarity concentrations is summarised below for clarity 
(Table 5.2). 
 
Concentration of PS 
in PBS (µg/ml) 
Molarity of MB 
(mol/L) 
Molarity of ER 
(mol/L) 
0.2 6.3 x10-7 2.4x10-7 
2 6.3 x10-6 2.4x10-6 
20 6.3 x10-5 2.4x10-5 
200 6.3 x10-4 2.4x10-4 
Table 5.2 – Conversion of concentration of photosensitiser in 
solution into molarity 
 
 Therefore, at comparable mass concentrations, a smaller number of 
molecules of ER would be available, which may be the cause of the 
increased toxicity found with the MB-loaded solutions of PBS in comparison 
to the ER-loaded solutions.  
Although the target for the aPDT effect (the toxicity associated with 
the combination of PS and light) will be oral pathogenic bacteria, it was 
important to also determine the extent of mammalian cell toxicity induced 
upon light activation of these PS solutions in the presence of monolayers of 
cells to determine whether normal tissue would be damaged at a PS dose 
which would be toxic to bacteria. 
Following 30 minute light exposure, MB killed significantly more L929 
cells at each concentration (200, 20, 2 and 0.2 µg/ml) than ER (p = 1.0x10-6, 
5.3x10-7, 2.9x10-4 and 0.03 respectively) (Figure 5.5B). The same trend was 
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observed for the 60 minute light exposure (p = 4.6x10-6, 3.1x10-5, 6.5x10-8 
and 0.002 respectively) (Figure 5.5D). This could be due to the significantly 
greater uptake of MB over ER (Figure 5.4), and may have implications for 
the cytotoxicity of the scaffold in vivo. However, it is important to note that 
this experiment is not fully reflective of the clinical application of the scaffold. 
The results here are an indication as to what could happen should all the PS 
be taken up by mammalian cells. If bacterial cells were present and the 
desired concentration was slowly released over a suitable period of time, 
these unacceptable levels of toxicity could be avoided. 
For further assurance that this test would be more ‘extreme’ than the 
clinical scenario, it was decided to test two other commonly used PS in a 
comparable experimental set-up to compare to the cytotoxicity found with 
MB. These were Toluidine Blue O (TB)[52,329,350,367,469] and New Methylene 
Blue (NMB)[470–472] (Figure 5.6). 
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(A) (B) 
 
 
(C) (D) 
Figure 5.6 - L929 Solution Toxicity Comparison with three 
photosensitisers. (A) 30 min ‘dark’ control; (B) 30 min light exposure. 
(C) 60 min ‘dark’ control; (D) 60 min light exposure. : MB-loaded 
PBS solutions; : TB-loaded PBS solutions; : NMB-loaded PBS 
solutions. Results reported as Mean±SD (n=3). ‘*’ denotes 
significantly different means (p <0.05, t-test) 
 
In all cases, the mammalian cell killing for TB or NMB was either not 
significantly different or was significantly greater than that of MB. This 
experiment supports the hypothesis that the mammalian cell killing is greater 
in this system than would be expected in a clinical setting, as it has 
previously been published that all three of these PS have limited mammalian 
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cell cytotoxicity[473–476]. In a clinical setting, the cells are unlikely to be 
incubated in this high concentration of PS for a prolonged period of time due 
to the turnover of saliva in the oral cavity. 
5.3.3.2 Antimicrobial Photodynamic Therapy Capability of
 Photosensitiser-Loaded Solutions 
A comparable experiment to the mammalian cell toxicity 
determination (section 5.2.5.1) was performed with planktonic bacteria to 
determine the bactericidal capacity of each PS solution. The use of an ATP 
bioluminescence assay for determining the antimicrobial activity of a 
compound has been used in previously published literature[477]. The initial 
‘dark toxicity’ of the solutions towards each bacterial strain was first 
determined experimentally before quantifying the toxicity of the same 
solutions following application of light (Figure 5.7 and Figure 5.8). 
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(A) (B) 
 
 
 
(C) (D) 
Figure 5.7 – Bactericidal toxicity of S. mutans following incubation in 
PBS solutions containing PS. (A) 30 min ‘dark’ control; (B) 30 min 
light exposure. (C) 60 min ‘dark’ control; (D) 60 min light exposure. 
: MB-loaded PBS solutions; : ER-loaded PBS solutions; : fresh 
PBS negative control; : PBS-TritonTM X-100 solution positive 
control. Results reported as Mean±SD (n=3). ‘*’ denotes significantly 
different means (p <0.05, t-test) 
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(A) (B) 
  
(C) (D) 
Figure 5.8 – Bactericidal toxicity of E. coli following incubation in 
PBS solutions containing PS. (A) 30 min ‘dark’ control; (B) 30 min 
light exposure. (C) 60 min ‘dark’ control; (D) 60 min light exposure. 
: MB-loaded PBS solutions; : ER-loaded PBS solutions; : fresh 
PBS negative control; : PBS-TritonTM X-100 solution positive 
control. Results reported as Mean±SD (n=3). ‘*’ denotes significantly 
different means (p <0.05, t-test) 
 
As with the mammalian cell data (section 5.3.3.1), it was first 
confirmed that the control samples demonstrated that both the S. mutans 
and E. coli bacteria survived in PBS alone (log reductions of 0.01±0.9 and -
0.01±0.7 respectively) and were killed in the TritonTM X-100 solution (log 
reductions of 1.4±0.6 and 1.3±0.4 respectively). 
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Following this, the ‘dark toxicity’ of the solutions was evaluated across 
both 30- and 60-minute exposure times. For the ‘on-demand’ aPDT 
capability of the scaffold to be achieved, a low dark toxicity would be 
expected (<0.5 log reduction), which would increase significantly upon light 
activation. It was found that at the two highest concentrations (200 and 20 
µg/ml), MB-loaded solutions (log reductions of 1.9±0.3 and 0.5±0.1 
respectively) proved more bactericidal against E. coli than corresponding 
ER-loaded solutions (log reduction of 0.7±0.03 and 0.3±0.05 respectively) (p 
= 2.2x10-8 and 0.0002). At the lower concentrations of (2 and 0.2 µg/ml), the 
dark toxicity was minimal with the highest observed log reduction in bacteria 
being for ER at 2 µg/ml (0.1±0.09). 
For S. mutans bacteria, the same trend was observed. The two 
highest concentrations (200 and 20 µg/ml) of MB had log reductions of 
1.6±0.4 and 0.5±0.1 respectively, which was significantly greater than the log 
reductions for ER of 0.6±0.1 and -0.02±0.1 respectively (p = 2x10-6 and 
3x10-9). At the lower two concentrations of MB (2 and 0.2 µg/ml) the toxicity 
was 0.5±0.4 and 0.2±0.3 respectively, and for ER this was -0.05±0.2 and 
0.1±0.3 respectively.  
For E. coli after 30 minutes light activation, a log reduction of >1 was 
achieved by the two highest concentrations of MB (1.8±0.4 and 1.0±0.2 
respectively) but not for the two lower concentrations of MB tested (0.8±0.2 
and 0.2±0.5 respectively). After 60 minutes light activation, again, the two 
highest concentrations displayed a >1 log reduction in live bacteria (1.9±0.3 
and 1.1±0.05 respectively) but not for the lower concentrations (0.9±0.1 and 
0.5±0.3 respectively). 
For E. coli tested with the ER solutions, the minimum threshold 
required was not met by any of the concentrations (200, 20, 2 or 0.2 µg/ml) 
tested following 30 minutes light exposure (0.9±0.2, 0.5±0.3, -0.1±0.1 and -
0.1±0.03 respectively). After 60 minutes light exposure, only the 200 µg/ml 
solution showed a >1 log reduction of live bacteria (1.3±0.3) with all other 
concentrations being below this threshold. We conclude that against E. coli 
bacteria, MB was shown to be more effective at comparable concentrations.  
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A similar trend was found in the results from the S. mutans 
experiments. After 30 minutes light exposure, a 1.6±0.1 log reduction in live 
bacteria was recorded for the 200 µg/ml concentration of MB-loaded PBS 
solution, but less than 1 log reduction (0.6±0.1, 0.7±0.1 and 0.3±0.2 
respectively) was recorded for the other concentrations. For each of the 
tested concentrations for ER, a log reduction below 1 (0.8±0.1, 0.2±0.1, 
0.1±0.1 and -0.1±0.2 respectively) was measured. After 60 minutes light 
exposure, again, the greatest concentration of MB caused a 1.7±0.2 log 
reduction in bacterial numbers, but all other concentrations recorded less 
than 1 log reduction of bacteria (0.7±0.04, 0.8±0.3 and 0.5±0.3). For ER, no 
concentration tested met or exceeded 1 log of bactericidal activity following 
60 minutes of light exposure (0.9±0.1, 0.3±0.03, 0.1±0.2 and 0.1±0.3 at 0.2-
200 µg/ml respectively). This again highlights that MB was more effective at 
killing bacteria than ER. Cationic PS such as MB have been shown to be 
more effective than anionic PS such as ER due to the charge interactions 
with the bacterial cell wall[281,478]. 
Contrasting the log reductions for the two bacterial strains, it was 
interesting to find that for MB, there was no significant difference between 
the killing of gram-negative E. coli and gram-positive S. mutans for all 
concentrations tested, except that of 20 µg/ml where significantly more E. 
coli was killed than S. mutans (p = 0.001 and 5x10-8 after 30 and 60 minute 
light exposures respectively). For ER at the same concentration, again 
significantly more E. coli was killed than S. mutans (p = 0.04 and 0.02 after 
30- and 60-minute light exposures respectively). This would be a particular 
advantage in the oral cavity, where gram-negative bacteria in biofilms are 
the main target as these are most difficult to destroy[58,479]. 
5.3.4 In vitro testing with Photosensitiser-Encapsulated PCL 
Scaffolds 
The next stage of this study was to test the effects of the PS released 
from the polymer carrier on the bacteria and cells. The PCL scaffolds were 
selected over PLGA7525 scaffolds as a model PS-carrier at this stage due 
to their dimensional stability in an aqueous environment (section 4.3.2). 
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5.3.4.1 In vitro Testing of Photosensitiser-Encapsulated PCL Scaffolds 
on Mammalian Cells 
As these scaffolds are designed for use as regenerative devices, it 
was important to determine initially whether the scaffolds were toxic to 
mammalian cells. Samples containing approximately 20 mg of PCL-ND, 
PCL-MB (containing approximately 4.4x10-7 moles equivalent to 0.14 mg of 
MB) and PCL-ER (containing approximately 4.4x10-7 moles equivalent to 
0.38 mg of ER) scaffolds were irradiated under UV light for 30 minutes and 
then incubated in 5 ml of PBS for either 1 minute (0 hours), 2 hours or 24 
hours to allow for PS release. These times were chosen as they may be 
clinically relevant, as the oral surgeon could decide to activate the PS 
immediately in high risk patients, or wait 2 hours to allow for release from the 
scaffold, or request the patient return a day after surgery for a ‘check-up’ 
where they then may decide to light activate the PS. These ‘extract’ 
solutions were then added to monolayers of confluent L929 cells and 
incubated for 2 hours to allow for PS uptake. As in the solutions testing 
(section 5.2.5.1), the dark toxicity was determined first (Figure 5.9). 
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(A) (B) 
  
(C) (D) 
Figure 5.9 – L929 monolayer cytotoxicity following application of PCL 
scaffold PBS extract solution. (A) 30 min ‘dark’ control; (B) 30 min 
light exposure. (C) 60 min ‘dark’ control; (D) 60 min light exposure. 
: PCL-ND control scaffold extract solutions; : PCL-MB scaffold 
extract solutions; : PCL-ER scaffold extract solutions; : fresh 
PBS negative control; : PBS-TritonTM X-100 solution positive 
control. Results reported as Mean±SD (n=3). ‘*’ denotes significantly 
different means (p <0.05, t-test) 
 
This experiment highlighted that the PCL-ND scaffolds were non-toxic 
as cell killing was below 6% in all experiments. In some cases, the PCL-ND 
scaffolds appeared to aid proliferation of cells with a negative value being 
observed, particularly in the 60-minute timepoint experiments. 
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The dark toxicity of scaffold extract solutions across both 30- and 60-
minute exposure times was above 30% for 0-, 2- and 24-hour incubation 
times of MB scaffolds (31±15, 47±16 and 53±14% respectively). The toxicity 
of the 0-hour incubation time for ER scaffolds was low (-0.9±6%) but 
increased to >30% after 2- or 24-hours incubation (35±18 and 60±21% 
respectively). 
There was a significant increase in cell killing for all PS-included 
samples upon light activation, apart from the PCL-ER samples following 60-
minute light activation where there was no significant difference. This 
confirms that the combination of light and PS causes killing of mammalian 
cells. 
There was an increase in the percentage of cells killed between the 0- 
and 2-hour incubation times for MB after 30 minutes light exposure (p = 
0.005) but not after 60 minutes light exposure (p = 0.05). There was also no 
significant increase in killing between 2- and 24-hour incubation times for 
either 30- or 60-minute light exposure times (p = 0.6 and 0.7 respectively). 
This is likely to be due to the cell killing being close to maximal after this 
point and therefore an increase in PS release does not significantly impact 
the cell killing. This correlates with the PS-release data (section 4.3.1.2) as 
~100% of MB was found to be released during the first 2 hours incubation in 
PBS. 
For ER, there was a significant increase between 0- and 2-hour 
incubation times for both 30- and 60-minutes light exposure (p = 4x10-8 and 
9x10-6 respectively). However, there was no significant difference between 
the 2- and 24-hour incubation time for the two different light exposure times 
(p = 0.7 and 0.7 respectively). 
Again, these results indicate an unacceptably high mammalian cell 
toxicity for either PS used in the tissue regenerating scaffolds, which 
exemplifies the importance of slowing the release from the scaffold and 
potentially reducing the amount of PS loaded into the electrospun scaffold 
during production.  
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5.3.4.2 In vitro Testing of Photosensitiser-encapsulated PCL Scaffolds 
with Bacteria 
The antibacterial activity of the PS-encapsulated PCL scaffolds was 
determined during an external placement to the University of Massachusetts 
Amherst in the Chemical Engineering department under the supervision of 
Prof. Jessica Schiffman. Due to the time-constraints of this placement, only 
one bacterial strain was able to be tested. The aPDT effect has been shown 
in previously published data to be more effective against Gram-positive 
bacteria[480]; consequently, only E. coli was used in these studies to test the 
effect of aPDT scaffolds on a model Gram-negative bacteria. 
This experiment was performed by directly imaging the bacteria 
populating the scaffold with fluorescence microscopy (Table 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
 
 Dark Light 
Bacteria in fresh M9 
salts solution 
(Negative Control) 
  
Bacteria in Ethanol 
(Positive Control) 
  
PCL-ND 
  
PCL-MB 
  
PCL-ER 
  
Table 5.3 – A set of live/dead images showing an example set of the data 
from testing E. coli bacteria on PCL-PS scaffolds following 60 minute light 
exposure 
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Initially, the scaffolds were incubated in medium for 2 hours to allow 
for PS release. Following this time E. coli bacteria were added to the 
scaffolds (section 5.2.6.2). These scaffolds were then light activated for 30 
or 60 minutes and live/dead images were collected for each scaffold and the 
log reduction calculated based on these results (Figure 5.10). 
 
 
  
(A) (B) 
  
(C) (D) 
Figure 5.10 – Log reductions of E. coli bacteria on PCL scaffolds. (A) 
30 min ‘dark’ control; (B) 30 min light exposure. (C) 60 min ‘dark’ 
control; (D) 60 min light exposure. : PCL-ND control scaffolds; : 
PCL-MB scaffolds; : PCL-ER scaffolds; : Fresh M9 medium 
negative control; : Ethanol positive control. Results reported as 
Mean±SD (n=3) 
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A key observation from these results was that there was minimal 
killing observed for the control scaffolds with no PS inclusion. This implies 
that the PS is responsible for the bacterial death, and that the scaffolds 
themselves are not inherently bactericidal. 
To verify that the selected PS molecules were not toxic prior to light 
activation, an identical set of foil-covered scaffold samples were analysed in 
each experiment to calculate the ‘dark toxicity’ of the scaffolds. In all 
experiments, the dark toxicity of the PS-encapsulated scaffolds was below 
0.05 log reductions. These results should be compared to the light activated 
PS-free electrospun scaffold controls (, Figure 5.10) which confirms that 
the PS and the light combination is needed to deactivate the bacteria. 
A key observation seen across all PS-containing scaffold 
formulations, was that the longer the light exposure, the more bacteria were 
killed, e.g. for PCL-MB scaffolds following 30- or 60-minute light exposure, 
the log reductions were 0.5 and 0.9 respectively. This finding is in agreement 
with previous reports that the greater the dose of light, the more toxic 
reactive species are generated and the more active the PS is[353]. 
Following this initial study, samples were incubated in medium for 1 
minute (0 hours) and 24 hours prior to bacterial addition. This was to 
determine whether the greater PS concentration available increased the 
bacterial killing. 
It can clearly be seen from these results that the MB-encapsulated 
scaffolds with the same PS concentration were found to kill significantly 
more E. coli than ER-encapsulated scaffolds across all incubation times and 
with both light exposure times. This observation is in agreement with the 
increased release of MB from the scaffold with respect to ER (section 
4.3.1.2) resulting in an expected increase in cellular MB uptake. The 
increased aPDT effect of MB-encapsulated fibres may also due to the fact 
that MB is cationic, which would result in greater interaction with the Gram-
negative E. coli cell membranes and therefore more damage to the outer 
membrane[313].  
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5.4 Conclusion 
These experiments were conducted to identify an optimal PS dose for 
loading of and releasing from a polymer scaffold for use in oral applications. 
They were used to quantify the aPDT capability of the scaffold and provide 
an indication of how either MB or ER would behave in vivo. However, it is 
important to note that in a clinical setting, results would vary as the 
mammalian cells would not be present in monolayers and bacteria will be 
mainly growing as biofilms rather than in planktonic form. Additionally, the 
cell types would effectively be present as a mixed population rather than 
each in isolation. However, the experiments here were a suitable model for 
comparing the effects of MB or ER on bacteria and mammalian cells in order 
to determine the most suitable PS for continued analysis. 
In this study, MB was shown to be more readily taken up by both 
bacterial and mammalian cells than ER (Figure 5.4). This is likely to be due 
to MB being cationic and ER being anionic. Cationic PS have previously 
been found to be more readily taken up by bacteria due to the increased 
interaction between PS and bacterial cell wall, which has the advantage of 
limiting the amount of damage to surrounding mammalian tissue[481]. 
When testing solutions of PS on monolayers of mammalian cells and 
planktonic bacteria, the dark toxicity of MB and ER were similar. When light 
activated, at lower concentrations of PS, an increase in cell or bacterial 
killing was observed which indicates that both the light and PS combination 
is needed in aPDT. This would also suggest that both PS act in a drug- and 
light- dose dependent manner. This study provides evidence that MB is 
more effective against both gram-positive and gram-negative bacteria than 
ER at comparable concentrations, which is potentially advantageous for the 
desired application of this biomaterial. 
As this study aims to conclude with the production of a clinically 
relevant medical device, it is important to consider regulation and approval of 
each PS for use in clinical applications. MB is currently clinically approved 
for aPDT in dentistry, which will aid the regulatory hurdles needed to take 
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the product to market[281]. In contrast, ER was de-listed in the US in 1990 for 
use in either externally applied drugs or cosmetic products due to findings of 
carcinogenicity in rat models[482]. 
A discussion on the light source is also important for clinical 
translation. Blue light has the advantages of being inherently antimicrobial, 
but red light is a greater tissue penetration range[281]. As this scaffold will be 
used for tissue regeneration, light may be required to penetrate new tissue 
which has formed on the surface of the scaffold to activate PS taken up by 
bacteria which may be populating the scaffold below this. Therefore, the red 
light required to activate MB may be advantageous for the product. 
Aside from the PS comparison, a conclusion to be drawn from the 
results presented here was that PCL control scaffolds were confirmed to be 
non-toxic to both mammalian cells and bacterial cells. This is important as 
the scaffold will be required to support neotissue formation and this would be 
limited if the scaffold was inherently cytotoxic. 
To conclude, of the two PS tested in this study with light activation, 
MB was shown to be more effective at killing bacteria than ER in all studies. 
Combined with the unusual secondary interactions found with the ER-loaded 
scaffolds (section 3.3.1.2), it was decided at this point in the project to 
discontinue the use of ER and focus on optimising the biomaterial properties 
of MB-loaded polymeric electrospun scaffolds. Although these studies 
provide evidence that the MB from the PCL scaffolds is toxic to cells, further 
studies will be performed to elucidate the selectivity achieved relative to the 
concentration of PS introduced into the scaffold system. 
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 Optimisation of Polymer Carrier with Methylene Blue for 
Use as a Regenerative Electrospun Scaffold in Oral 
Environments 
6.1 Introduction 
This chapter was aimed to describe the work conducted to characterise 
and optimise a polymer carrier for use as a regenerative scaffold. Chapter 3 
and Chapter 4 of this thesis discussed the use of PCL and PLGA7525 as the 
polymer carrier, with either MB or ER PS. From these chapters, it was 
concluded that PLGA7525 was not suitable for the intended application as the 
resulting scaffold shrunk upon incubation in aqueous media. PCL proved to be 
a stable polymer carrier over the 8-week incubation period, but the PS was 
released in a ‘burst’ within the first 2 hours which resulted in toxic levels of PS 
being reached, which would prevent neotissue formation. 
Chapter 5 then compared MB and ER with both mammalian and 
bacterial cell types to determine the optimal PS for use in the final prototype 
scaffold.  From this study, MB was taken up more readily into the bacteria and 
was found to be more toxic to the tested bacterial cells at comparable 
concentrations in comparison to ER. Also in Chapter 5, PCL scaffolds were 
used as a model carrier as an additional test for comparison of the activity of 
the PS. This study confirmed that MB was being released too quickly from the 
scaffold as toxic concentrations for mammalian cells were reached almost 
immediately upon incubation. 
Therefore, this chapter presents evidence aimed at characterising a 
new polymer carrier that will maintain integrity over approximately 8 weeks in 
oral environments and not show signs of macroscopic shrinkage or fibrous 
microstructure collapse upon incubation in aqueous media. The scaffold 
should also be capable of controlled release of MB over approximately 4 
weeks to allow for long-lasting activation of antimicrobial PDT when required 
but prevent toxic levels of MB from being reached for the mammalian cells 
populating the scaffold. There are many examples in the literature of the use 
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of coaxial electrospinning[483], hybrid electrospinning[484] or chemically-bonding 
drugs into the scaffold[485] in order to achieve controlled release profiles.  
Due to limitations in access to equipment and the desire to keep the 
processing of the polymer system as simple as possible for regulatory 
purposes, it was decided to try a different monomer ratio of PLGA initially. It 
has previously been published that the lactic acid component of the PLGA is 
responsible for the amorphousness (and consequent water-induced 
shrinkage) of the PLGA copolymer[421,486,487]. PGA is also known to be a semi-
crystalline polymer and so increasing the percentage of this monomer in the 
polymer ratio should lead to increased crystallinity in the copolymer[488]. With 
respect to the previous PLGA formulation, it was therefore decided to use a 
polymer with a higher glycolide and lower lactide monomer ratio, i.e. 
PLGA1090 with 10% poly(lactic acid) and 90% poly(glycolic acid). 
6.2 Materials and Methods 
6.2.1 Materials 
Poly(rac-lactide-co-glycolide) (PLGA1090) (Mn: 63,000 g·mol-1, 10:90 
molar ratio of lactic and glycolic acid units) was purchased from Purac 
Biomaterials (PURASORB PLG 1017). All other materials are as listed 
previously (section 3.2.1). 
6.2.2 Electrospinning Solution Preparation 
As described previously (section 3.2.2). Where polymers were blended, 
each polymer was weighed out as a mass percentage of either 80:20, 50:50 
or 20:80 of PCL to PLGA1090. The total concentration of polymer in HFIP 
remained unchanged from previous electrospinning solutions at 6 wt.%. 
For reduced concentration electrospinning solutions, 1.1mM or 0.2mM 
concentrations of MB were added to each polymer solution. These were 
referred to as 50% and 10% respectively. 
6.2.3 Viscosity Measurements 
As described previously (section 3.2.3). 
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6.2.4 Electrospinning 
As described previously (section 3.2.5). 
6.2.5 Scanning Electron Microscopy 
As described previously (section 3.2.6). 
6.2.6 Loading Efficiency  
As described previously (section 3.2.7). 
6.2.7 Scaffold Colour Measurements 
As described previously (section 3.2.10). 
6.2.8 Differential Scanning Calorimetry 
As described previously (section 3.2.11). 
6.2.9 Tensile Testing 
As described previously (section 3.2.12). 
6.2.10 Water Uptake Analysis 
As described previously (section 4.2.3). 
6.2.11 pH Testing 
The pH of the aqueous supernatant was recorded at regular time points 
over the course of the experiment using a Mettler Toledo ‘FiveEasyTM FE20’ 
pH meter with a VWR pH electrode (DJ 113). Prior to use, the pH meter was 
calibrated using Buffer reference standards (Sigma Aldrich) at pH 4, 7 and 10. 
Between each sample, the pH electrode was rinsed thoroughly in dH2O to 
remove traces of the previous testing solution. The probe was placed into 
each testing solution, stirred, and left until a stable reading was reached. 
6.2.12 Hydrolytic Degradation 
6.2.12.1 Hydrolytic Degradation Trial with Controlled pH in Tris 
Buffer 
A 1M Tris buffer was made by dissolving Tris base (Sigma Aldrich, MW: 
121.14 g/mol) in dH2O before adjusting the pH to 7.4 using concentrated 
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hydrochloric acid (HCl, Sigma Aldrich). Prior to use, this was diluted 1:100 to 
reach a 10mM Tris-HCl solution. 
Samples were cut into 1 cm2 squares and weighed before being 
incubated with 5 ml of Tris buffer solution in sealed falcon tubes at 37°C for 1 
week. Following this time, the pH of the solutions was recorded to determine if 
there had been a significant decrease. 
6.2.12.2 Modified Hydrolytic Degradation 
As described previously (section 4.2.4) but with additional monitoring of 
the pH. pH was monitored at least every 3 days during the 8-week 
experiment, and if necessary, fresh PBS solution was added until the pH ~7.4 
was achieved.  
6.2.13 Modified Release Kinetics 
As described previously (4.2.2) but with additional monitoring of the pH. 
pH was monitored at least every 3 days during the 8-week experiment, and if 
necessary, fresh PBS solution was added until the pH ~7.4 was achieved.  
6.2.14 Statistical Analysis 
Significant differences in the results were evaluated using an unpaired 
Student's t-test. Data was deemed to be significantly different at p < 0.05. All 
data were collected in triplicate and presented as Mean ± Standard Deviation. 
6.3 Results and Discussion 
A new polymer carrier, PLGA1090, with comparable molecular weight to 
the previously tested polymers (PCL and PLGA7525) was obtained as fibre a 
building block to evaluate the potential structure-property relationships of the 
scaffolds. Electrospun polymer constructs were first analysed in terms of 
fibrous architecture and then with regards to the scaffold behaviour in 
aqueous medium. 
6.3.1 PLGA1090 Characterisation 
6.3.1.1 PLGA1090 Polymer Solution Characteristics 
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To allow direct comparison of results, an initial screen of three different 
PLGA1090 polymer concentrations (6, 9 and 12 wt.%) was first performed to 
determine which concentration would yield measurements most similar to the 
two previous polymer carriers used in this study (Figure 6.1).  
 
 
Figure 6.1 – Viscosity of PS-free (ND) electrospinning polymer 
solutions at different concentrations in HFIP. (): PLGA1090-ND-6 
wt.%; (): PLGA1090-ND-9 wt.%; (■): PCL-ND-6 wt.%; (●): 
PLGA7525-ND-12 wt.%. Lines are guidelines to the eye 
 
Each PLGA1090 solution concentration tested was found to display the 
same shear-thinning as observed with PCL and PLGA7525 (section 3.3.1). 
PLGA1090 was found yield solutions with increased viscosity with respect to 
PLGA7525 solutions at the same concentration. At 12 wt.%, the PLGA1090 
solution was too viscous to handle and a viscosity reading could not be taken, 
as was the situation with the PCL solutions at 12 wt.% concentration. The 
most similar viscosity with respect to the PLGA7525 12 wt.% and PCL 6 wt.% 
solutions was measured with 6 wt.% PLGA1090 solutions. Therefore, this 
polymer concentration was chosen to be carried forward into the remainder of 
the study. 
As discussed in Chapter 5, MB was found to be the most effective PS 
to use in this study with respect to aPDT capability, so the viscosity a 6 wt.% 
PLGA1090 solution doped with 2.2 mM MB was determined (Figure 6.2). 
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Figure 6.2 – Viscosity of electrospinning polymer solutions at 
different concentrations in HFIP at 6 wt.% polymer concentration with 
or without 2.2mM MB. (): PLGA1090-ND; (): PLGA1090-MB. Lines 
are guidelines to the eye 
 
In previously tested PCL and PLGA7525 polymer, there was a 
decrease in viscosity following inclusion of MB, but this was not statistically 
significant. In contrast, the viscosity of the PLGA1090-MB solution was 
significantly reduced in comparison to the PLGA1090-ND solution control (p = 
0.004, Figure 6.2). The observed decrease in solution viscosity could suggest 
that there is an additional interaction between the polymer chains of 
PLGA1090 and MB in solution, which may have an impact on the material 
properties and microarchitecture of the electrospun scaffolds. This was found 
(more severely) with the PLGA7525 and ER interaction, which resulted in a 
significant decrease in fibre diameter (section 3.3.2.1) and an increase in 
scaffold degrability (section 4.3.2). 
6.3.1.2 PLGA1090 Electrospun Scaffold Characteristics 
The polymer solutions were electrospun and resulting electrospun 
scaffolds analysed using SEM (Figure 6.3). 
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Figure 6.3 – Microstructural analysis of MB-encapsulated scaffolds 
and electrospun ‘ND’ controls. SEM images taken at 1000x 
magnification and Specific Surface Area (SSA) measurements 
obtained via BET analysis 
 
Both PLGA1090-ND and PLGA1090-MB solutions produced bead-free 
fibrous scaffolds. Macroscopically, the PLGA7525-MB scaffolds, the 
PLGA1090-MB scaffolds were blue coloured as opposed to the purple 
coloured PCL-MB scaffold as discussed previously (section 3.3.2.2). This 
would suggest that the MB molecules are present in monomeric form.  
To ensure that all the PS had been transferred from the electrospinning 
solution into the resultant scaffolds, the loading efficiency of the scaffolds was 
calculated. This was calculated to be 97±6%, which confirms that the PS 
loading efficiency is equal to that of the previously characterised polymer 
carriers at approximately 100% efficiency. 
The fibre diameters were measured from the SEM images (Figure 6.4). 
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Figure 6.4 – Average Fibre Diameter determined from SEM images 
for each PLGA1090 electrospun scaffold. Grey bars: Control 
scaffolds; Blue bars: MB-included scaffolds. Results reported as 
Mean±SD (n=3). ‘*’ denotes significantly different means (p <0.05, t-
test) 
 
There was found to be a significant reduction between the PLGA1090-
ND and the PLGA1090-MB scaffolds in fibre diameter of 48% (p = 2.5 x10-27). 
This is comparable to the reductions of the fibre diameter in PCL-MB and 
PLGA7525-MB fibres previously observed results (54% and 51% respectively, 
section 3.3.2.1).  
Following the scaffold characterisation, it was important to ensure that 
the crystallinity of the polymer had been increased as the presence of 
crystallites is expected to enhance macroscopic stability of the scaffolds in 
aqueous environments[489]. Therefore, DSC analysis was carried out (Figure 
6.5).  
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Figure 6.5 – Differential Scanning Calorimetry heat flow plots. (―): 
Unprocessed PLGA1090 polymer; (―): PLGA1090-ND scaffolds; (―): 
PLGA1090-MB scaffolds 
 
The DSC plot highlights both a glass transition (Tg) (related to the 
amorphous regions of the polymer) and a melting transition (related to the 
crystalline regions of the polymer) for both the polymer and respective 
electrospun scaffolds (Table 6.1).  
 
 Tm (ºC) ΔHm (J/g) Tg (ºC) 
PLGA1090 
Raw 198.8 49.3 42.1 
ND 200.0 76.4 44.1 
MB 199.2 67.9 44.7 
Table 6.1 – DSC Thermal Analysis Values for PLGA1090 samples of 
either ‘Raw’ polymer pellets, PS-free (ND) control scaffold samples or 
MB-incorporated scaffold samples 
 
This indicates that the semi-crystalline structure is maintained following 
electrospinning. PCL scaffolds were found to be predominately crystalline and 
the PLGA7525 was found to be predominately amorphous as discussed 
previously (section 3.3.2.3). As this new polymer possess both a Tg and a Tm 
in the heat flow plot generated during DSC analysis, this would suggest that 
 126 
 
the new polymer may be a ‘mid-way’ point in crystallinity between the two 
previously tested polymers. 
The inclusion of MB with PLGA1090 reduced the Tg from 44.1ºC for the 
control (ND) scaffold to 41.7ºC. This effect of a small molecule included in 
PLGA fibrous polymers reducing the Tg has been previously published[490] and 
is thought to be due to the molecule inclusion increasing mobility of polymer 
chains, thus lowering the temperature required[491].  
As it is known that the crystallinity of a scaffold affects the mechanical 
properties of a scaffold[492–494], tensile testing was performed on samples of 
each of these scaffold types (Figure 6.6 and Figure 6.7). 
 
 
Figure 6.6 – Stress-strain curve of PS-encapsulated PLGA1090 
polymer scaffolds. (―): PLGA1090-ND; (―): PLGA1090-MB 
 
The stress-strain curve of the PLGA1090-ND and PLGA1090-MB was 
used to quantify the elastic modulus (E), percentage strain (ε) and toughness 
(UT) (Figure 6.7). 
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(A) 
  
(B) (C) 
Figure 6.7 – Mechanical properties measured in PLGA1090 samples. 
(A) Elastic Modulus (E); (B) Strain at Break (ε) and (C) Ultimate 
Toughness (UT). Grey bars: control polymer scaffolds; Blue bars: MB-
loaded scaffolds. Results reported as Mean±SD (n=3). ‘*’ denotes 
significantly different means (p <0.05, t-test) 
 
The elastic modulus of the control PLGA1090 samples was 9.5±3.6 
MPa, this was significantly greater than the PCL sample controls at 1.4±0.3 
MPa (p = 0.01). The PLGA1090-MB scaffolds had a significantly decreased 
elastic modulus in comparison to the PLGA7525-ND control scaffolds 
(18.7±1.9 MPa, p = 0.004). This could be related to the crystallinity of the 
scaffolds, as this polymer type was found to be at a mid-way point between 
the two polymers in terms of crystallinity as well as elastic modulus. 
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There was no significant difference between the PLGA1090-ND and 
the PCL-ND or PLGA7525-ND controls in relation to the calculated strain at 
failure (p = 0.9 and 0.9 respectively). The PLGA1090 and PCL controls had 
comparable ultimate toughness values (p = 0.7), but significantly lower values 
than the PLGA7525 control (p = 0.03). 
The inclusion of MB in the scaffold did not significantly change the 
elastic modulus or the toughness of the electrospun scaffold (p = 0.1 and 1.0 
respectively). However, the elongation at break was significantly decreased (p 
= 0.004). This reflects the same result as with the PLGA7525-MB scaffolds in 
comparison to the control samples. 
6.3.1.3 PLGA1090 Electrospun Scaffold Interactions in Aqueous Medium 
It was discussed previously in this thesis that the crystallinity of the 
scaffolds impacts on the interaction of the scaffold with water molecules and 
WU of the scaffolds (section 3.3.2.3 and section 4.3.1). To confirm this point 
with the polymer system, the wet-state behaviour of the new PLGA1090 
scaffolds was quantified. 
The WU for all samples was found to be over 100% for both the control 
and the PS-included samples (Figure 6.8).  
 
 
Figure 6.8 – Water uptake measured gravimetrically following 
incubation (H2O, 37 ⁰C) of either PS-loaded or electrospun control 
PLGA1090 samples. Grey bars: Pol-ND scaffolds; Blue bars: Pol-MB 
scaffolds. Results reported as Mean±SD (n=3) 
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Although an increase in the mean WU was observed for the 
PLGA1090-MB scaffolds, this was not a statistically significantly different 
result (p = 0.1). This was also found with the PCL polymer scaffolds, in which 
there was a non-significant increase between the PCL-ND and PCL-MB WU 
measurements (p = 0.1).  
Importantly, no macroscopic shrinkage occurred during this experiment. 
This was a crucial result as the PLGA7525 polymer scaffolds were found to 
significantly shrink over this time period, which highlights the impact of 
glycolide/lactide monomer ratio on the interaction of resulting copolymers with 
water. 
The scaffolds were next incubated in PBS at 37ºC for up to 8 weeks to 
ensure that the scaffold maintained the fibrous morphology over this time 
(Figure 6.10 and Figure 6.10). 
 
 
Figure 6.9 – Mass loss measured on samples following hydrolytic 
degradation in PBS (PBS, 37 ⁰C).  (-⚫-): PLGA1090-ND; (-⚫-): 
PLGA1090-MB. Lines are guidelines to the eye. Results reported 
as Mean±SD (n=3) 
 
 
 
 130 
 
 
Figure 6.10 – Scanning Electron Microscopy (SEM) of 
electrospun PLGA1090 scaffolds. W1 and W2 refer to 1 week and 
2 weeks incubation time points 
 
After 1 week incubation both the PLGA1090-ND and PLGA1090-MB 
scaffolds had lost integrity and could not be handled as a complete scaffold 
but only as fragments (Figure 6.10). The SEM micrographs of the fragments 
at week 2 confirm the loss of structure during this time (Figure 6.10). The 
PLGA1090-ND scaffold were fibrous but compact during this time, but the 
PLGA1090-MB scaffolds had a collapsed structure which would not be 
suitable for use in this medical device. Although the more crystalline, 
PLGA1090 polymer scaffolds were observed to degrade more quickly than the 
PLGA7525 scaffolds (section 6.3.1.3), this finding is likely due to the 
decreased lactide content of the polymer, as the glycolide component is more 
hydrophilic and will therefore increase the degradation when a greater ratio is 
present in the copolymer[495]. 
As the polymer degraded rapidly, acidic monomer residues were 
expected to be released into the 5ml of PBS. The accumulation of these could 
cause an autocatalytic effect on the degradation of the polymer and result in a 
rapid degradation profile which would not be found in vivo[496–498]. When 
implanted in the oral cavity, the turnover of the aqueous medium (saliva) is 
likely to carry some of these acidic monomers away from the scaffold. It was 
therefore decided to determine the pH of the solutions to ensure that the 
‘buffering’ ability of the PBS was sufficiently minimising the acidic effect of the 
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monomers being released. This was done by incubating each of the polymer 
scaffolds with incorporated MB in 5ml of PBS and measuring the pH value of 
the solution at the 4-week time point (Table 6.2). 
 
Scaffold Type Average 
PCL-MB 7.3±0.005 
PLGA7525-MB 6.7±0.02 
PLGA1090-MB 3.0±0.008 
Table 6.2 – pH Values of the PBS supernatant containing the 
Pol-MB scaffold following 4-weeks incubation at 37ºC. Results 
reported as Mean±SD (n=3) 
 
The results show that although the PCL and PLGA7525 scaffolds 
maintain a pH of ~7, the scaffolds containing the rapidly degrading PLGA1090 
had a large reduction in pH. It was therefore decided to use a higher buffer 
capacity with these samples to determine whether a control of the pH could be 
achieved.  
Samples of PCL-MB and PLGA1090-MB were incubated in 5 ml of 10 
mM Tris-buffer for 1 week and the pH values were recorded after this time to 
determine whether this buffer could minimise the pH change. The PCL-MB 
scaffold solution was found to have a pH of 7.4 but the PLGA1090-MB 
scaffold supernatant had a pH of 3.8. This trial highlighted the that the higher 
buffer capacity was still not able to control the pH reduction.  
Although a simple solution would be to start with a larger volume of 
PBS, this would result in low absorbance values being reached for the MB 
release study. The MB release and the hydrolytic degradation are known to be 
linked, so although this methodology would work for the mass loss study, it 
would not be appropriate for the release kinetics. An additional trial was 
conducted by performing the mass loss in 5 ml of PBS but then monitoring the 
pH every other day and adding further PBS upon a drop in pH to sustain a pH 
of ~7. This technique was found to be successful as it could be used to 
achieve a controlled pH but with an initial monitoring of the sample in 5 ml of 
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PBS. After an initial study, a full 8-week hydrolytic degradation study was 
performed on all PLGA1090 scaffolds with pH monitoring. The pH of the 
solution in this study did not reduce below pH 6.5 at any time point (Figure 
6.11 and Figure 6.12). 
 
 
Figure 6.11 - Mass loss measured on samples following hydrolytic 
degradation in PBS with controlled pH (PBS, 37 ⁰C, pH ~7.4).  (⚫): 
PLGA1090-ND; (⚫): PLGA1090-MB. Lines are guidelines to the eye. 
Results reported as Mean±SD (n=3) 
 
 
 
Figure 6.12 - Scanning Electron Microscopy (SEM) of electrospun 
PLGA1090 scaffolds. W1 and W2 refer to 1 week and 2 weeks 
incubation time points 
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This study showed that the scaffolds were more stable in the non-acidic 
environment, but that the PLGA1090-MB samples had still lost integrity at 
week 2 so were unsuitable for the intended use. 
Besides the wet-state scaffold integrity, one of the two primary reasons 
for the choice of polymer carrier was to manufacture a scaffold capable of 
gradually releasing the PS over several weeks. The scaffolds were incubated 
initially in 5 ml of PBS for 24 hours and extracts were taken and analysed at 
regular timepoints. This was to ensure that the absorbance readings from the 
PS release were large enough to detect accurately. Following this, the pH was 
regularly monitored and additional PBS was added to ensure that the solution 
remained at pH ~7 at all times (to reflect the hydrolytic degradation study) 
(Figure 6.13). 
 
 
Figure 6.13 – Typical PS release profile measured via UV-Vis 
spectroscopy of the supernatant collected during incubation with 
controlled pH (PBS, 37 ºC, pH ~7.4) from PLGA1090-MB scaffolds at 
selected time points over 672 hours (4 weeks). Line is guideline to the 
eye. Results reported as Mean±SD (n=3) 
 
The release profile suggests that the polymer is suitable to deliver 
sustained release of PS over this time frame. Although the scaffolds lost 
integrity and became fragments after two weeks incubation, it is likely that the 
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PS release continues to increase over this time due to fragments of the 
scaffold being broken down.  
6.3.2 Blended PCL and PLGA1090 Scaffold Characterisation 
From the initial study, it was found that PLGA1090 polymer scaffolds 
had the advantage of gradually releasing the PS over the timeframe, but the 
sample lost integrity over 2 weeks, which would restrict scaffold functionality 
with time. The PCL polymer carrier characterised in Chapter 3 and Chapter 4 
had the advantages of being stable in aqueous environments and displaying 
controlled degradation over the 8 week time-frame required by the medical 
device. However, PCL scaffolds proved to release the PS in a burst release. 
The desired polymer carrier therefore needed specific qualities of each of 
these two polymers. One way of possibly achieving the desirable properties of 
two different polymers is to combine them. 
There are four main techniques to combine two polymers when 
electrospinning: blend, emulsion, co-axial and hybrid electrospinning[499,500]. 
Blend electrospinning is arguably the simplest method as it involves mixing 
two electrospinning solutions together and then using the same apparatus as 
with a single solution to produce a scaffold. Emulsion electrospinning involves 
similar apparatus but requires the use of two immiscible solvents such as an 
organic and an inorganic solvent. The solutions are vortexed together prior to 
electrospinning to produce an emulsion. Co-axial electrospinning involves a 
different experimental set up by attaching an additional syringe to a dual 
needle, with one solution being at the ‘core’ of the needle tip and one being 
around the outside as the ‘shell’. Finally, hybrid electrospinning involves the 
use of two separate electrospinning solutions being used in two different 
syringes separately but aimed at the same grounded collector[501]. 
As blend electrospinning requires no change of solvent or experimental 
setup, this was the most logical first choice to try. A previous study had used 
blend electrospinning of these two polymers demonstrating that resulting 
electrospun materials displayed increase stability in water and decreased 
degrability as well as controlled drug release and improved mechanical 
properties such as Young’s modulus and tensile strength[434].  It was therefore 
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decided to combine the two polymer types in formulation to determine whether 
this would improve the PS-release capability and wet-state electrospun 
architecture of resulting PS-encapsulated scaffolds.  
6.3.2.1 Polymer Blend Solution Characteristics 
The polymer solutions were mixed in three different ratios of 
PCL:PLGA1090 at various wt.%, i.e. 80:20, 50:50 and 20:80. From this point 
onwards, these scaffolds are referred to as 0000-ND or 0000-MB, where 0000 
represents the four digits of the polymer ratio, and ND and MB represent ‘No 
Dye’ or ‘Methylene Blue’ incorporated samples as previously reported. 
Initially, a screening of the viscosity of each polymer formulation was 
performed to ensure that electrospinning was still possible (Figure 6.14). 
 
 
Figure 6.14 – Viscosity of electrospinning PCL and PLGA1090 polymer 
blend solutions at different concentrations in HFIP. (♦):8020-ND; 
(♦):8020-MB; ():5050-ND; ():5050-MB; (►):2080-ND; (►): 2080-MB. 
Lines are guidelines to the eye 
 
As expected, the same shear-thinning behaviour of the polymer 
solutions was observed, as found with each of the polymers in isolation 
(section 3.3.1 and section 6.3.1.1). There was a small decrease in MB-
incorporated scaffolds viscosity for all polymer blends with respect to the 
related PS-free control scaffolds. However, the decrease from MB-doped to 
 136 
 
PS-free scaffold viscosity was not significant for the 8020 and the 2080 blends 
(p = 0.05 and 0.05), but statistically significant for the 5050 sample (p = 
0.006).  
6.3.2.2 Polymer Blend Scaffold Characteristics 
The PLGA1090 polymer solutions were electrospun into scaffolds for 
further analysis (Figure 6.15). 
 
 
Figure 6.15 – Microstructural analysis of PS-encapsulated PCL and 
PLGA1090 electrospun polymer blend scaffolds and controls. SEM 
images taken at 1000x magnification 
 
The electrospinning polymer blend solutions each produced smooth 
bead-free fibres. Upon blending purple PCL-MB and blue PLGA1090-MB 
polymer solutions, a gradient in colouration of the resulting scaffolds was 
observed. This was quantified as per LAB colour space measurements (Table 
3.3). 
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  L A B 
PCL-MB 68.55 24.6 -20.24 
8020-MB 68.45 17.51 -19.69 
5050-MB 69.73 11.41 -18.24 
2080-MB 68.93 -12.32 -28.55 
PLGA1090-MB 67.64 -7.22 -30.85 
Table 6.3 – LAB colour space results for PS-loaded scaffolds. 
Colours of associated rows of the table represent the colour of the 
scaffold as per the LAB result 
  
When MB was electrospun with pure PCL, the resulting scaffolds were 
purple in colour (section 3.3.2.2). When MB was electrospun with pure 
PLGA7525 or pure PLGA1090, the resulting scaffolds were blue in colour 
(section 3.3.2.2 and section 6.3.1.2). When PCL-MB and PLGA1090-MB were 
mixed and the solutions electrospun, the resulting scaffolds displayed a 
gradient in colour from a purple to a blue/purple to a blue colour. These 
results were taken as a visual indicator that the electrospinning solutions had 
been successfully mixed and the resulting scaffolds were a blend of the two 
polymer types. 
The loading efficiency of each of these polymer blends was calculated 
again to ensure that full transfer of MB from solution to electrospun scaffold 
had been achieved. For the 8020-MB, 5050-MB and 2080-MB scaffolds, the 
loading efficiency was calculated at 100±1%, 104±7% and 103±1% 
respectively, indicating successful fibre PS-encapsulation. 
The SEM images were analysed to determine the fibre diameters of 
each scaffold (Figure 6.16). 
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Figure 6.16 – Average Fibre Diameter determined from SEM images for 
each PCL and PLGA1090 polymer blend electrospun scaffold. Grey bars: 
Control scaffolds; Blue bars: MB-included scaffolds. Results reported as 
Mean±SD (n=3). ‘*’ denotes significantly different means (p <0.05, t-test) 
 
Each of the 8020, 5050 and 2080 scaffolds showed a significant 
decrease between the control and MB-incorporated scaffolds (p = 9.8x10-46, 
1.8x10-10 and 2.7x10-13 respectively). The average reduction in fibre diameters 
(68%, 44% and 53% respectively), which was comparable to those found with 
the previous scaffold formulations from the polymers in isolation. 
  As discussed previously (section 6.3.1.2), DSC analysis of the polymer 
is important to ensure that the semi-crystalline structure of the polymer 
scaffold has been maintained upon electrospinning. Therefore, the DSC 
profiles of the polymer scaffolds were analysed (Figure 6.17). 
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(A) 
  
(B) (C) 
Figure 6.17 - Differential Scanning Calorimetry heat flow plots of 
PCL:PLGA1090 blended polymer scaffolds. (A) 80:20, (B) 50:50, (C) 
20:80 polymer blends. (―): Polymer-ND scaffolds; (―): Polymer-MB 
scaffolds 
 
The melting transition temperatures at 56.7-60.7 ºC are due to the 
presence of the PCL polymer (section 3.3.2.3), and the melting transition 
temperatures at 199.6-201.8 ºC are due to the presence of the PLGA1090 
polymer (section 6.3.1.2). A summary of the thermal properties of the blends 
in comparison to the pure polymers is given to allow for direct comparison 
(Table 6.4 and Table 6.5). 
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 PCL 8020 5050 2080 PLGA1090 
Tm (PCL) (ºC) 57.5 56.7 56.9 54.5 - 
ΔHm (PCL) (J/g) 118.2 33.4 21.8 10.1 - 
Tm (PLGA1090) (ºC) - 199.6 201.8 197.4 200.0 
ΔHm (PLGA1090) (J/g) - 37.1 43.9 58.4 76.4 
Tg (PLGA1090) (ºC) - - - - 44.1 
Table 6.4 – DSC Thermal Analysis Values for pure and blended scaffolds 
for PS-free (ND) control samples 
 
 PCL 8020 5050 2080 PLGA1090 
Tm (PCL) (ºC) 56.4 57.1 60.7 57.0 - 
ΔHm (PCL) (J/g) 89.0 71.6 59.1 16.3 - 
Tm (PLGA1090) (ºC) - - 200.0 200.9 199.2 
ΔHm (PLGA1090) (J/g) - - 20.3 47.2 67.9 
Tg (PLGA1090) (ºC) - - - - 44.7 
Table 6.5 – DSC Thermal Analysis Values for pure and blended scaffolds 
with MB inclusion 
 
Each of these DSC plots indicates the presence of only melting 
transition temperatures, and no glass transition temperatures were found to 
be present. This would suggest that the polymers in each scaffold type exist in 
a predominantly crystalline form.  
Previously published reports on the thermal properties of polymer 
blends conclude that fully miscible blends display one transition temperature, 
but if polymers were not fully miscible then the transition temperatures of each 
individual polymer were present[502–504]. Two melting transition peaks are 
present for all samples except for that of the 8020-MB polymer blend, which 
exclusively displayed a Tm in the region which would be expected for the 
melting temperature of PCL (57.1 ºC). This was initially thought to suggest 
that the polymer forms are miscible in this sample, as the melting peak has 
also shifted towards that of the PLGA1090 polymer which would occur if the 
different polymer types within the blend which have interacted[505]. However, 
when analysing the full data set obtained from running the DSC analysis on 
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the 8020MB sample, it can be seen that both melting points are observed in 
the first cycle which was used to remove the thermal history of the polymers 
(Figure 6.18). 
 
 
Figure 6.18 - Differential Scanning Calorimetry heat flow plots of the 
first cycle from PCL:PLGA1090 blended polymer scaffolds at 80:20 
ratio and MB (―) 
 
It is only when the thermal history has been removed that the 
PLGA1090 peak does not appear on the heat flow plot. Therefore, the 
presence of two melting peaks in each of these samples would suggest that 
the polymers are immiscible. A surfactant could be used to increase miscibility 
if this causes adverse properties for the scaffolds[502]. 
In previous studies, the mechanical properties of blended scaffolds 
have been reported to change in comparison to the pure polymers from either 
constituent scaffold[502,506,507]. The tensile properties of the blended scaffolds 
in this study were analysed either without PS or with PS inclusion (Figure 
6.19 and Figure 6.20). 
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Figure 6.19 - Stress-strain curve of PS-encapsulated PCL and 
PLGA1090 polymer blend scaffolds. (―): 8020-ND; (―): 8020-MB; (---): 
5050-ND; (---): 5050-MB; (…): 2080-ND; (…): 2080-MB 
  
The PS-included and PS-free control stress-strain graphs of each 
polymer scaffold type was used to quantify the mechanical behaviour of the 
blended polymer scaffolds (Figure 6.20). 
 
 
 
 
 
 
 
 143 
 
 
(A) 
  
(B) (C) 
Figure 6.20 – Mechanical properties measured in PCL and PLGA1090 
polymer blend samples. (A) Elastic Modulus (E); (B) Strain at Break (ε) 
and (C) Ultimate Toughness (UT). Grey bars: control polymer scaffolds; 
Blue bars: MB-loaded scaffolds. Results reported as Mean±SD (n=3). 
‘*’ denotes significantly different means (p <0.05, t-test) 
 
Comparing the elastic modulus of the control samples without PS 
inclusion of the polymer blends, there was a significant increase with an 
increased ratio of PLGA1090 to PCL (from 8020-ND to 5050-ND, p = 0.0001 
and from 5050-ND to 2080-ND, p = 4x10-5). This has been observed 
previously in the literature[434,506,508,509]. This incremental increase in 
mechanical properties with increasing ratio suggests that the two polymers 
have been successfully combined[434]. 
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Studying the effect of MB-incorporation on the elastic modulus, there 
was found to be a significant increase between the control and the MB-
incorporated samples in each 8020-MB, 5050-MB and 2080-MB polymer 
blend ratio (p = 0.0001, 0.0004 and 0.0001 respectively). This decrease in 
flexibility is also reflected in the elongation at break values, which reduces 
significantly for each of the PS-included scaffolds in comparison to the control 
samples (p = 0.002, 0.00004 and 3x10-7 respectively). 
The toughness of the polymer scaffolds significantly decreased for the 
8020 and the 2080 ratio blends (0.03 and 0.0007 respectively), but no 
significant difference was found for the 5050 ratio of polymer electrospinning 
solutions (p = 0.9). 
6.3.2.3 Polymer Blend Scaffold Interactions in Aqueous Medium 
The main purpose of blending the polymers in these scaffolds was to 
control the degradation of the polymer scaffolds when incubated in aqueous 
medium whilst enabling sustained release of MB from the PLGA1090 polymer 
fibres. Initially, this was tested through the ability of the scaffold to take up 
water over 24 hours (Figure 6.21). 
 
 
Figure 6.21 – Water uptake measured gravimetrically following 
incubation (H2O, 37 ⁰C) of either PS-loaded or electrospun control PCL 
and PLGA1090 polymer blend samples. Grey bars: ND scaffolds; Blue 
bars: MB scaffolds. Results reported as Mean±SD (n=3). ‘*’ denotes 
significantly different means (p <0.05, t-test) 
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As with the PLGA1090 and PCL scaffolds, there was not found to be 
any shrinkage over the 24-hour incubation period for any of the polymer 
blended scaffolds.  
There was a significant increase in WU for each of the polymer 
scaffolds with MB incorporation when compared to the control samples (p = 
0.003, 0.00009, 0.04). The WU values for each of the MB-encapsulated 
samples was greater than 200% which would be advantageous for both MB 
release and in allowing exchange for the nutrients of cells populating the 
scaffold. 
As with the PLGA1090 scaffolds, it was determined to be more 
clinically applicable to regularly change the aqueous media to ensure that the 
autocatalytic hydrolytic effect would be minimised, and to more closely 
replicate the biological environment. Therefore, degradability experimental 
analysis was performed with this modification (Figure 6.22 and Figure 6.23). 
 
 
Figure 6.22 – Mass loss measured on PCL and PLGA1090 polymer 
blend samples following hydrolytic degradation in PBS with controlled 
pH (PBS, 37 ⁰C, pH ~7.4).  (■):8020-ND; (■):8020-MB; (⚫):5050-ND; 
(⚫):5050-MB; (▲):2080-ND; (▲):2080-MB.  Lines are guidelines to the 
eye. Results reported as Mean±SD (n=3) 
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(B) 
Figure 6.23 – Scanning Electron Microscopy (SEM) of electrospun 
PLGA1090 scaffolds. W1, W2, W6 and W8 refers to 1, 2, 6 and 8 week 
incubation time points respectively. N/A samples had degraded so were 
unable to be analysed 
 
The 8020 scaffolds which contain a higher ratio of PCL showed the 
least mass loss over the 8-week period. Both the control and MB-incorporated 
2080 electrospun scaffolds which had a higher ratio of PLGA1090 showed the 
fastest degradation profiles, with both the 2080-MB scaffolds losing integrity 
after 2 weeks incubation. From the SEM image at the 6-week timepoint, it can 
be observed that a loss of fibrous structure has occurred. As discussed 
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previously (section 3.3.2.1) for the PLGA7525 scaffolds, a narrowing of pore 
size could result in cells being unable to penetrate the scaffold and this would 
limit the scaffold performance as a neotissue-encouraging regenerative 
device.  
The final property to analyse was the PS release profiles of the blended 
scaffolds types. The scaffolds were analysed in the same way as with the 
PLGA1090MB scaffolds (section 6.3.1.3) (Figure 6.24).  
 
  
(A) (B) 
Figure 6.24 – Typical PS release profiles measured via UV-Vis 
spectroscopy of the supernatant collected during incubation with 
controlled pH (PBS, 37 ºC, pH ~7.4) from MB-incorporated scaffolds at 
selected time points over (A) 6 hours or (B) 672 hours (4 weeks). 
(■):8020-MB; (⚫):5050-MB; (▲):2080-MB.  Lines are guidelines to the 
eye. Results reported as Mean±SD (n=3) 
 
The 8020-MB scaffold, which degraded the least over the 8-week 
window, also had the highest concentration of PCL and therefore had the 
greatest ‘burst’ release of MB. This appears to be consistent with the result 
from the DSC (Figure 6.17) which suggested that the 8020-MB scaffolds are 
predominately crystalline and therefore the MB was unable to penetrate the 
polymer chains and is therefore more freely available upon scaffold incubation 
in PBS. Both 5050-MB and 2080-MB scaffolds had the ability to gradually 
release the PS into the aqueous media over 4 weeks. However, the 2080-MB 
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sample had lost integrity over the course of the experiment, and only the 
fragments remained after 2 weeks incubation. 5050-MB gradually released 
the PS but also maintained integrity for the duration of the 8-week mass loss 
experiment which would suggest that it would be suitable for use as a 
regenerative scaffold in the desired application. 
6.3.2.4 5050 Polymer Blend Scaffold with Reduced Methylene Blue 
Concentrations 
The next stage of this study involved testing the lead prototype polymer 
carrier for MB (a 50:50 blend of PCL and PLGA1090 with a total polymer 
concentration of 6 wt.%) with both mammalian cells and bacteria. Prior to in 
vitro analysis, new scaffolds were electrospun with a lower concentration of 
MB in the electrospinning solution to provide a comparison in cytotoxic and 
bactericidal properties. The selected concentrations were either the full ‘100%’ 
concentration (100%-MB, 2.2 mM), 50% of the initial MB concentration (50%-
MB, 1.1 mM) or 10% of the initial MB concentration (10%-MB, 0.2 mM). These 
solutions were made as previously described and electrospun into scaffold 
samples. As this concentration change was relatively small, it was not 
expected to cause any changes to the biomaterial properties of the scaffolds. 
To confirm this, the new range of scaffold samples were analysed via SEM to 
calculate the average fibre diameter of the scaffolds (Figure 6.25). 
 
 
Figure 6.25 – Microstructural analysis of MB-encapsulated 
electrospun polymer blend (5050) scaffolds from electrospinning 
solutions with various concentrations of MB. 0.2mM: 10% MB; 
1.1mM: 50% MB; 2.2mM: 100% MB. SEM images taken at 1000x 
magnification 
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SEM images were analysed with ImageJ as previously described 
(section 3.3.2.1) to determine the average fibre diameter. This was then 
compared to the average fibre diameter of the 100%-MB 5050 polymer blend 
scaffolds to determine whether the reduction in MB has led to a different 
scaffold morphology (Figure 6.26). 
 
 
Figure 6.26 - Average Fibre Diameter determined from SEM images for 
each MB concentration of 5050 polymer blend electrospun scaffold. 
Results reported as Mean±SD (n=3). ‘*’ denotes significantly different 
means (p <0.05, t-test) 
 
This data confirms that there is a comparable significant decrease in 
average fibre diameter between the ND control and each of the 10%, 50% 
and 100% MB-included 5050 blend scaffolds (p = 7x10-12, 4x10-5 and 2x10-10 
respectively). There was no significant difference between the 100%-MB 
scaffolds and either the 10%-MB or 50%-MB scaffolds (p = 0.12 and 0.9 
respectively). This data suggests that a decrease in MB within this range of 
MB concentrations (2.2 mM – 0.2 mM) does not significantly change the 
physical characteristics of the scaffold. 
 To ensure that the crystallinity of the polymer had not changed with a 
reduction of MB, DSC analysis was performed on the 10%-MB scaffolds as 
 150 
 
this scaffold has the greatest reduction in MB so would represent the largest 
change if there was to be one (Figure 6.27). 
 
 
Figure 6.27 - Differential Scanning Calorimetry heat flow plots of 5050 
PCL:PLGA1090 blended polymer scaffolds with a reduced MB 
concentration. (―): 10%-MB 5050 scaffolds 
 
These DSC plots are similar to that of 5050-MB with a 2.2 mM 
concentration, with both melting transition temperatures for the presence of 
PCL and PLGA1090 polymers present (Table 6.6).  
 
 10%-MB 5050 100%-MB 5050 
Tm (PCL) (ºC) 57.8 60.7 
ΔHm (PCL) (J/g) 32.4 59.1 
Tm (PLGA1090) (ºC) 201.2 200.0 
ΔHm (PLGA1090) (J/g) 30.0 20.3 
Table 6.6 – Comparison of DSC Thermal Analysis Values for 5050 
polymer blended scaffolds with MB inclusion at a higher and lower 
concentration 
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As the fibre diameter of these scaffolds were found to be comparable, 
and there was no apparent change in the crystallinity of the scaffold caused 
by reducing the MB concentration, it was therefore decided that there was no 
significant change in the characteristics of the 5050-MB scaffold. Further 
characterisation was therefore not needed, and all properties were assumed 
to follow the same trends as the characterised 100%-MB 5050 polymer 
scaffolds characterised previously in this chapter. 
6.4 Conclusion 
Initially, a 10% lactide and 90% glycolide copolymer (PLGA1090) was 
explored for suitability as a polymer carrier for MB which could maintain 
integrity over an 8-week period in aqueous medium. After initial 
characterisation, a 6 wt.% polymer concentration electrospinning solution was 
electrospun into bead-free fibrous scaffolds either with or without 2.2 mM 
concentration of MB. The MB containing scaffolds had a 48% reduction in 
average fibre diameter to the control samples. DSC analysis confirmed the 
presence of both a glass transition temperature and a melting point peak in 
PLGA1090 polymer scaffolds, which suggests the polymer arrangement is of 
increased crystallinity in comparison to the PLGA7525 polymer carrier which 
shrunk macroscopically in solution.  
The mechanical properties of the MB-containing and control PLGA1090 
scaffold samples were comparable in all properties except elongation at 
break, which was significantly lower for the PLGA1090-MB scaffold. The WU 
analysis was comparable to that of the PCL polymer scaffolds, and 
importantly, there was no shrinkage of the PLGA1090 scaffolds in solution. 
Despite a desirable gradual release of MB over a 4-week timeframe, the 
polymer scaffolds lost integrity after 2 weeks incubation and were therefore 
deemed unsuitable for use in this application. 
To obtain the desirable degradation profile of PCL and gradual PS 
release of PLGA1090, blending of these two electrospinning solutions was 
performed in ratios of 80:20, 50:50 and 20:80. 
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The resulting electrospinning solutions were characterised in terms of 
their viscosity, before being electrospun and confirming the presence of bead-
free fibres. Again, a reduction in fibre diameter was confirmed for the MB-
containing scaffolds in comparison to the control scaffolds. 
Miscibility of the polymer solutions was suggested visually with a colour 
gradient of the scaffolds from purple (PCL) to blue (PLGA1090) scaffolds, but 
the polymers were shown to be immiscible through DSC analysis. Mechanical 
characterisation highlighted an increase in elastic modulus and a decrease in 
elongation at break for the MB-containing scaffolds for all polymer blend 
ratios. 
Upon degradation studies, 2080-MB ratio blend was found to degrade 
too quickly and lost fibrous structure after 6 weeks in solution. Both the 8020-
MB and 5050-MB formulations proved promising in terms of their stability in 
the aqueous environments over 8 weeks. 
The MB release profile for 8020-MB scaffolds was similar to that of the 
PCL scaffolds, in that the MB was released quickly upon scaffold incubation in 
PBS. However, the 5050-MB scaffolds demonstrated the ability to gradually 
release MB. In combination with the desirable degradation profile, this was 
identified as the lead prototype to move on into the next and final stages of 
this study. 
Finally, to allow for comparison in the in vitro studies with the lead 
prototype, two lower concentration 5050-MB scaffolds were electrospun. 
These were confirmed via SEM and DSC analysis to have comparable 
characteristics to the 5050-MB original concentration scaffolds. 
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 In vitro Testing of Prototype Scaffolds 
7.1 Introduction 
The aim of the work presented in this chapter was to determine a lead 
prototype regenerative medical device using in vitro testing techniques. A 
range of three scaffolds were electrospun using a 50:50 polymer blend of PCL 
and PLGA1090 which were characterised in Chapter 6. These were ‘5050-ND’ 
(a control scaffold with no MB-encapsulation) and then three different 
concentrations of MB. The original concentration of MB was 2.2 m\M, and 
these scaffolds are referred to as 100%-MB. The two lower dose scaffolds 
contained 1.1 mM and 0.2 mM, referred to as 50%-MB and 10%-MB 
respectively. 
In vitro methods for determining cytotoxicity are categorised into two 
main groups; extract and contact assays[456]. Both of these methods are 
described in ‘ISO 10993 Biological evaluation of medical devices - Part 5: 
Tests for in vitro cytotoxicity’ (2018), which is the international standard used 
to determine whether medical devices are cytotoxic against mammalian 
cells[192,510]. Any medical device will need to have been shown to comply to 
these standards prior to commercialisation.  
The tests initially determine whether an extract solution taken from the 
sample causes a cytotoxic response. In ISO 10993, it is stated that a 
reduction in cell viability of up to 30% is commonly used as an acceptable 
value for cell tolerance[192]. Therefore, this threshold was used in this chapter. 
Additionally, direct visualisation of cells in contact with the medical device was 
used to determine whether the cell morphology would be altered. A summary 
of the grading system used in the ISO 10993 report was used, and is given 
below for reference (Table 7.1). 
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Grade Reactivity Conditions 
0 None No limited cell growth 
1 Slight Slight growth inhibition 
<20% cells round and loosely attached 
2 Mild <50% growth inhibition 
<50% cells round and loosely attached 
3 Moderate <50% growth inhibition 
<70% cells round and loosely attached 
4 Severe Nearly complete or complete destruction of cells 
Table 7.1 – ISO 10993 morphological grading of cells [192] 
 
 After the determination of the lead scaffold prototype with an 
acceptable level of cytotoxicity, experiments were performed with model 
bacteria strains to determine the extent to which this scaffold formulation 
could be used to kill bacteria following aPDT principles. This was initially 
performed using a comparable extract testing experiment, which involved 
producing extract solutions from the scaffold and using a luminosity assay to 
determine the log reduction in metabolically active bacteria[511,512]. Following 
this, another commonly used microbiology test was used to determine the 
growth limiting effect of the treatment[366,368,513,514]. This involved exposing a 
bacterial suspension to PDT using the extract solutions, and then diluting and 
plating the resulting bacteria onto agar plates. After allowing for bacterial 
growth (typically over incubation at 37°C, 5% CO2 for 24 hours), the reduction 
in CFU as a result of PDT was compared to non-treated bacterial 
samples[63,515–517]. 
Finally, antibacterial tests based upon ISO 20645 standards (‘Textile 
Fabrics Determination of Antibacterial Activity - Agar Diffusion Plate Test’) 
were used to determine the bactericidal effect of the scaffolds in direct contact 
with the model bacteria[294]. UV-treated scaffolds were placed on agar plates, 
light-activated and then incubated overnight. A ‘zone of inhibition’ (ZOI) was 
measured as the diameter of the area of no growth around the sample 
(Figure 7.1).  
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Figure 7.1 – Experimental setup schematic for ‘Zone of Inhibition’ 
microbiological testing 
7.2 Materials and Methods 
7.2.1 Mammalian Cell Toxicity Testing 
L929 cells were cultured as previously described (section 5.2.2). 
7.2.1.1 Mammalian Cell Extract Testing – Luminosity Assay 
As previously described (section 5.2.6.1) but with new scaffolds 
(section 6.3.2.4). 
7.2.1.2 Mammalian Cell Contact Testing – Scanning Electron 
Microscopy Morphology  
SEM was used to visualise the morphology of L929 cells in contact with 
the scaffolds. Scaffolds were cut into 20 mg squares and placed in 48 well 
plates. These scaffolds were exposed to UV light for 15 minutes in the tissue 
culture hoods on each side for disinfection purposes, before 0.5 ml of sterile 
cell culture medium was added and the samples placed in an incubator (37°C, 
5% CO2) for 1 hour to allow for the scaffolds become moist. Confluent L929 
cells were passaged, counted and seeded onto the centre of each scaffold 
sample in 0.5 ml of media to result in a final seeding density on each scaffold 
of 5x103 cells/ml. The samples were then either exposed to light for 30 or 60 
minutes or kept in the dark for the same period of time. Following this, 
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samples were incubated for either 24 hours or 7 days (with media changed for 
fresh media every other day). At the selected time, samples were removed 
from cell culture medium, washed twice in fresh PBS and placed in formalin 
for 24 hours. The scaffolds were then removed and dehydrated in a series of 
ethanol concentrations (Table 7.2). 
 
 Ethanol Concentration in 
Distilled Water (v.%) 
Time  
(minutes) 
 
 25 5  
 50 5  
 70 5  
 80 10  
 95 10  
 100 10  
 100 10  
Table 7.2 – Series of Solutions and Incubation Times for Dehydrating 
Cells on Scaffold Samples prior to Scanning Electron Microscopy 
 
Following dehydration, samples were each placed in 24-well plates and 
left at 4 °C for 48 hours to dry. Dry samples were attached to metal stubs 
using carbon double-sided stickers and sputter coated with gold (x2) before 
being visualised using a 6-sample multi-stub holder on a Hitachi Scanning 
Electron Microscope at 1000x and 4000x magnification. 
7.2.2 Antibacterial Photodynamic Therapy Activity Testing 
7.2.2.1 Bacteria Extract Testing – Luminosity Assay 
Overnight E. coli or S. mutans cultures were produced by inoculating a 
single colony of bacteria in 20 ml of BHI overnight. The following day, 1 ml of 
this broth was added to 9 ml of fresh BHI and the solution incubated until mid-
log phase (section 5.2.3.4). Bacteria numbers were then estimated using 
OD600 (section 5.2.3.4) and the concentration altered to reach a final 
concentration of 108 CFU/ml. Bacteria were then washed once in PBS before 
 157 
 
being resuspended in each of the same extract solutions as previously used in 
the mammalian cell testing (section 7.2.1.1). Controls of Triton X-100TM (10 
v.%) and fresh PBS were used with each well plate. 100 µl of each solution 
was then plated in triplicate into opaque walled 96-well plates and either 
exposed to light for 30 or 60 minutes or kept wrapped in foil as a dark control.  
Following the allotted light exposure time, 100 µl of Bact-TiterGlo® 
solution was added to each well, the plate was shaken for 1 minute and then 
left at room temperature for 4 minutes. A multiplate reader was then used to 
analyse the luminosity reading from each well, and the percentage bacterial 
killing was calculated (Equation 5.7). 
7.2.2.2 Bacteria Extract Testing – Colony Counting 
Overnight bacterial cultures were produced by inoculating a single 
colony of bacteria in 20 ml of BHI overnight. The following day, 1 ml of this 
broth was added to 9 ml of fresh BHI and the solution incubated until mid-log 
phase (section 5.2.3.4). Bacterial numbers were then estimated using OD600 
(section 5.2.3.4) and the concentration altered to reach a final concentration of 
5x108 CFU/ml. Bacteria were washed once in PBS before being resuspended 
in 10% extract solutions. They were then immediately exposed to light for 30 
or 60 minutes or kept in the dark as described previously (section 7.2.2.1). 
Following this treatment, the solutions were serially diluted and 100 µl spread 
on fresh agar plates. The plates were then incubated at 37 °C for 24 hours. 
The following day, manual counting of colonies was performed and the 
number of CFU for each solution was calculated and compared to the initial 
inoculation. The experiment was performed in triplicate to allow for statistical 
significance to be calculated  
7.2.2.3 Bacteria Contact Testing - Zone of Inhibition 
Fresh agar plates were made as described previously (section 5.2.3) a 
day prior to testing. Overnight cultures were produced by inoculating a single 
colony of bacteria in 20 ml of BHI overnight. Three replicate samples of each 
scaffold type were cut into discs using a biopsy punch (diameter of 10 mm) 
and disinfected for 15 minutes on each side under UV light. 
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The following day, 1 ml of overnight bacterial culture was added to 9 ml 
of fresh BHI and the solution incubated until mid-log phase (section 5.2.3.4). 
Lawns of bacteria were spread by using a sterile swab dipped in bacterial 
broth and streaking across a fresh agar plate. Sterile tweezers were used to 
place disinfected scaffold discs onto the agar plate inoculated with bacteria in 
triplicate. The plates were then incubated for 1 hour to allow for MB release, 
before being exposed to light for 30 or 60 minutes (or wrapped in foil as the 
dark control). Agar plates were then incubated at 37 °C overnight to allow for 
bacterial growth. The following day, images were taken of each plate. Zones 
of inhibition were calculated using the straight-line tool on ImageJ® to count 
the number of pixels in a known section of the image to produce a scale, and 
then to measure the zone size for each image. 
7.2.3 Statistical Analysis 
Significant differences in the results were evaluated using an unpaired 
Student's t-test. Data was deemed to be significantly different at p < 0.05. All 
data were collected in triplicate and presented as Mean ± Standard Deviation. 
7.3 Results and Discussion 
7.3.1 Mammalian Cell Cytotoxicity Testing 
7.3.1.1 Mammalian Cell Extract Testing 
Initially, the scaffolds were examined in a similar way to the testing 
performed with extract solutions described previously (section 5.3.4.1). In this 
chapter, the experimental setup was used to distinguish between two PS (MB 
or ER). Here, it was used initially as a ‘worst case scenario’ testing method 
(i.e. it was expected to have a more severe effect on the cells than in vivo). 
Initially the extract solutions were generated by incubating 20 mg of 
scaffold in PBS for 0, 2 and 24 hours. From the data in collected in Chapter 6, 
these solutions were expected to contain the concentrations of MB given in 
Table 7.3. 
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Collection 
Time (hours) 
Expected MB Concentration (µg/ml) 
10%-MB 50%-MB 100%-MB 
0 0.4±0.1 2.1±0.7 4.3±1.4 
2 0.9±0.3 4.4±1.6 8.8±3.2 
24 1.5±0.3 7.6±1.5 15.2±2.9 
Table 7.3 – Expected concentrations of MB in extract solutions 
collected following 0, 2 or 24 hour incubations times 
 
These solutions were applied to the monolayers of L929 cells and 
incubated for 2 hours prior to light activation (Figure 7.2). 
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(A) (B) 
  
(C) (D) 
Figure 7.2 - L929 extract solution toxicity. (A) 30 min ‘dark’ control; (B) 
30 min light exposure. (C) 60 min ‘dark’ control; (D) 60 min light 
exposure. Solutions extracted from various 5050 polymeric 
electrospun scaffolds. : MB-free (ND) controls; : 100%-MB; : 50%-
MB; : 10%-MB; : fresh PBS negative control; : PBS-TritonTM X-100 
solution positive control; (--): 30% reduction in cell viability. Results 
below this line are accepted as ‘non-cytotoxic’ in line with ISO 10993. 
Results reported as Mean±SD (n=3) 
 
A value of <30% cytotoxicity was selected as an acceptable level of cell 
tolerance in line with ISO 10993 standards[192]. In all experiments, the control 
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without MB-encapsulation resulted in minimal cell killing (2.7±4.9%) confirming 
that the scaffolds were non-cytotoxic. 
In the non-light activated control experiments, none of the scaffolds 
tested were cytotoxic for the 0-hour extract solution. These extract solutions 
all had MB concentrations of <4.3 µg/ml. This is in agreement with 
comparable toxicity study described previously (section 5.3.3.1) where all MB 
solutions with a concentration of the most similar concentration tests (2 µg/ml) 
in ‘dark control’ samples also resulted in <30% cytotoxicity. For 2- and 24-hour 
extract solutions, 100%-MB scaffolds proved to be cytotoxic following both 30 
minute (34.5±4.4% and 34.9±5.1% respectively) and 60 minute (49.7±7.7% 
and 47.6±5.8% respectively) ‘dark’ control time points. These extract solutions 
contained 8.8±3.2 µg/ml and 15.2±2.9 µg/ml respectively. The corresponding 
50%-MB scaffold sample solutions for 2 and 24 hour extract times 
(concentrations of 4.4±1.6 µg/ml and 7.6±1.5 µg/ml respectively) were shown 
to induce <30% cell viability after 30 minutes light activation (24.8±3.5% and 
23.2±4.1% respectively) whilst >30% cell viability reduction was recorded after 
60 minute light activation (36.8±5.0% and 31.6±5.8% respectively). This would 
suggest that the concentration for the ‘dark’ cytotoxicity threshold is 
approximately 4-8 µg/ml. Each of the 10%-MB scaffolds extract solutions had 
a concentration of <1.5 µg/ml and were found to be non-cytotoxic without light 
activation (<4.2%). 
Upon light activation for either 30 or 60 minutes, all MB-incorporated 
scaffolds resulted in a >70% cell killing value for both the 2 and 24-hour 
extract scaffold solutions. This would indicate that all scaffolds are too 
cytotoxic for use with mammalian cells in agreement with the results described 
previously (section 5.2.5.1) as all MB-loaded PBS solutions of 2 µg/ml 
following 30 or 60 minutes of light activation resulted in >30% cytotoxicity. 
However, upon a review of the literature it was determined that other 
experimental setups test cytotoxicity with <10 minutes pre-incubation time in a 
particular PS solution prior to light activation[474,518,519]. In the experiments 
used to generate the results in Figure 7.2, pre-incubation of 2 hours was used 
prior to light exposure. A pre-incubation time of <2 hours can be justified in 
oral applications as the high turnover of saliva in the oral cavity is likely to 
 162 
 
prevent localised accumulation of MB over time. Therefore, the full experiment 
was repeated with <10 minutes pre-incubation time (Figure 7.3). 
 
  
(A) (B) 
  
(C) (D) 
Figure 7.3 - L929 Extract Solution Toxicity with no pre-incubation prior 
to light activation. L929 Extract Solution Toxicity. (A) 30 min ‘dark’ 
control; (B) 30 min light exposure. (C) 60 min ‘dark’ control; (D) 60 min 
light exposure. Solutions extracted from various 5050 polymeric 
electrospun scaffolds. : MB-free (ND) controls; : 100%-MB; : 50%-
MB; : 10%-MB; : fresh PBS negative control; : PBS-TritonTM X-100 
solution positive control; (--): 30% reduction in cell viability. Results 
below this line are accepted as ‘non-cytotoxic’ in line with ISO 10993. 
Results reported as Mean±SD (n=3) 
  
 163 
 
In this optimised experiment, all samples with or without MB-
encapsulation were non-cytotoxic (<30% reduction in cell viability) in the 
absence of light activation. Therefore, the new ‘dark’ cytotoxicity threshold for 
this experiment was >15.2±2.9 µg/ml. 
Upon light activation for 30 minutes none of the scaffolds tested as 
‘cytotoxic’ for the 0-hour extract solutions. However, for the 2- and 24-hour 
extract solutions, both 50%-MB (56.2±3.1% and 56.0±1.9% respectively) and 
100%-MB scaffolds (62.7±1.5% and 65.7±1.3% respectively) exceeded the 
30% cell killing threshold. Alternatively, 10%-MB scaffold extract solutions 
obtained with an extraction time of 0, 2 or 24 hours were found to be non-
cytotoxic (-2.0±1.3%, 8.0±3.1% and 18.7±1.0% respectively) following 30 
minutes of light activation. Therefore, MB concentrations of >4.4±1.6 µg/ml 
were cytotoxic following 30 minutes light exposure, but <2.1±0.7 µg/ml were 
below the cytotoxicity threshold. Therefore, the MB concentration released 
from the scaffold would need to stay below ~4 µg/ml to be non-cytotoxic. 
After 60 minutes light activation, the 100%-MB scaffolds were cytotoxic 
for each of the scaffold extract solutions (48.4±4.5%, 70.9±1.0% and 
73.1±1.6% respectively). The 50%-MB scaffolds were non-cytotoxic for the 0-
hour extract solutions but exceeded 30% cell killing for the 2- and 24-hour 
extract solutions (66.8±0.9% and 66.3±0.3% respectively). The 0- and 2-hour 
solutions from the 10%-MB scaffolds were non-cytotoxic (-6.4±0.6% and 
24.2±1.2%), but the 24-hour extract solutions were marginally above the 30% 
killing threshold (34.9±2%). The concentration of the extract solution collected 
here (1.5±0.3 µg/ml) is likely to at the threshold of cytotoxicity following 60 
minutes light exposure. Despite this fact, the 10%-MB was the most optimal 
scaffold out of the range of scaffolds tested. 
7.3.1.2 Mammalian Cell Contact Testing 
Morphological examination of cells cultured in contact with the scaffolds 
was conducted. Cells were added to UV-treated scaffold samples, allowed to 
attach for 2 hours, before being exposed to 30 or 60 minutes of light activation 
(or kept in the dark as controls). The scaffolds were incubated to allow for cell 
proliferation for either 24 hours or 7 days. Samples were then fixed in 
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formalin, dehydrated with ethanol treatments and visualised using SEM 
(Figure 7.4 and Figure 7.5) [520].
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Figure 7.4 - L929 Cell Morphology following 30 or 60 minutes light activation (or kept in the dark as a control) and then 24 hours 
incubation on electrospun scaffolds. Scanning electron micrographs taken at 1000x or 4000x magnification 
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Figure 7.5 - L929 Cell Morphology following 30 or 60 minutes light activation (or kept in the dark as a control) and then 7 days 
incubation on electrospun scaffolds. Scanning electron micrographs taken at 1000x or 4000x magnification 
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 The ISO 10993 grading system given in Table 7.1 was used to analyse 
the images shown in Figure 7.4 and Figure 7.5. The cells populating the 
control samples with no MB-incorporation displayed good proliferation, with 
evidence of ECM deposition. After 24 hours, cells appeared to have spread 
between fibres, and following 7-day incubation, cells with or without light 
activation appeared to have formed a full ‘sheet’ across the fibres. These 
samples were valued at Grade 0 as there was no visual limitation to cell 
growth (Table 7.1). 
In the scaffold samples with MB-incorporation, the 100%-MB scaffolds 
appeared to be cytotoxic, as cells had not attached to the scaffold. These 
samples were marked as ‘Grade 4 (i.e. Severe ‘reactivity’), with near complete 
destruction of cells being seen. One cell was visualised in 24-hour samples for 
the 30-minute dark control, but it was spherical and did not appear to be 
attached. This sample was valued as being ‘Grade 3 - Moderate’ reactivity. 
The results in this study support the results described previously (section 
7.3.1.1) which suggested that the 100%-MB scaffolds were too cytotoxic to 
support neotissue formation. 
After 24 hours, cells appeared to have attached to the 50%-MB 
scaffolds in either dark or light activation conditions, but they presented a 
rounded appearance in most places, and there had been obvious growth 
inhibition in comparison to the ‘ND’ control samples. These were scored as 
‘Grade 3 – Moderate’ reactivity. There was no major difference seen between 
the light activated and the dark control samples. After 7 days, the samples for 
the 50%-MB scaffolds had increased to ‘Grade 4 – Severe’ reactivity, as no 
cells could be seen on the scaffolds suggesting that the MB within the scaffold 
had killed the L929 cells. Along with the results described previously (section 
7.3.1.1), these scaffolds were also determined to be too cytotoxic to support 
tissue growth in a regenerative scaffold. 
 Finally, the dark controls of the 10%-MB scaffolds for the 24-hour 
incubation time were graded as ‘Grade 3 – Moderate’ reactivity, as the cells 
populating the scaffold appeared rounded. Interestingly, upon light activation, 
the cells appeared less rounded. Here the scaffolds were graded as ‘Grade 2 
– Mild’ reactivity. This effect has been found in previous studies, with Ayuk et 
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al. reporting that light exposure can increase viability and proliferation of 
cells[521]. In ‘stressed’ cell states this response was enhanced, which could be 
occurring in these test samples as well due to the ‘stress’ induced by the MB 
exposure[521]. Jin et al. also found a similar increase in proliferation with the 
growth of human dermal fibroblasts on electrospun fibres when exposed to 
light[522]. 
After 7 days of incubation, the cells populating the 10%-MB scaffolds 
appeared to have deposited a layer of ECM. As <20% of cells were round and 
loosely attached, these samples were graded as ‘Grade 1 – Slight’ reactivity 
when compared to the control samples. This would again support the 
conclusion from previously described results (section 7.3.1.1), and these 
scaffolds were therefore concluded to be suitable to support neotissue 
formation in a regenerative device from these preliminary cytotoxicity assays. 
7.3.2 Antibacterial Photodynamic Therapy Activity of Lead 
Prototype 
7.3.2.1 Bacteria Extract Testing 
As the scaffold was required to display both tissue regenerating and 
antimicrobial functionality, only the 10%-MB scaffold was tested with E. coli 
and S. mutans bacteria as it was the only MB-encapsulated scaffold with 
acceptable levels of cytotoxicity towards L929 cells following light activation 
for either 30 or 60 minutes. Initial screening was performed using the extract 
solutions collected from the experiment described previously (section 7.3.1.1) 
with a luminosity assay to detect ATP activity from each bacterial strain. As 
the protocol with no incubation time was deemed most similar to the clinical 
situation in the mammalian cell assay, this was also used to quantify bacterial 
killing so that comparative data could be collected (Figure 7.6 and Figure 
7.7). 
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(A) (B) 
  
(C) (D) 
Figure 7.6 – S. mutans Extract Solution Toxicity with no pre-incubation 
time prior to light activation. (A) 30 min ‘dark’ control; (B) 30 min light 
exposure. (C) 60 min ‘dark’ control; (D) 60 min light exposure. 
Solutions extracted from various 5050 polymeric electrospun 
scaffolds. : MB-free (ND) controls; : 10%-MB; : fresh PBS 
negative control; : PBS-TritonTM X-100 solution positive control. 
Results reported as Mean±SD (n=3). ‘*’ denotes significantly different 
means (p <0.05, t-test) 
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(A) (B) 
  
(C) (D) 
Figure 7.7 – E. coli Extract Solution Toxicity with no pre-incubation 
time prior to light activation. (A) 30 min ‘dark’ control; (B) 30 min light 
exposure. (C) 60 min ‘dark’ control; (D) 60 min light exposure. 
Solutions extracted from various 5050 polymeric electrospun 
scaffolds. : MB-free (ND) controls; : 10%-MB; : fresh PBS 
negative control; : PBS-TritonTM X-100 solution positive control. 
Results reported as Mean±SD (n=3). ‘*’ denotes significantly different 
means (p <0.05, t-test) 
 
When bacteria were exposed to extract solutions collected at 0-, 2- and 
24-hour time points, there was no significant reduction in live bacteria for 
either S. mutans or E. coli bacterial strains in comparison to the ND control 
scaffolds without light activation (‘dark’ controls). The only exception to this 
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was the 2-hour extract solutions after 60 minutes incubation which did 
produce a small but significant reduction in the bacterial count for either 
bacteria (p = 0.01 and 0.01 for S. mutans or E. coli respectively). This 
confirms that without light activation, the PS exposure will not kill bacteria 
which is crucial for the ‘on-demand’ aspect of the scaffold to be achieved. 
Upon 30 minutes of light activation with the S. mutans bacteria, the 2- 
and 24-hour extract solutions significantly reduced the bacterial viability (p = 
0.01 and 0.005 respectively). After 60 minutes of light activation, all three 
extract solutions reduced the bacterial viability (p = 0.03, 0.001, 0.0002 
respectively). The viability of E. coli bacteria was significantly reduced for all 
extract solutions at either 30 minute (p = 0.008, 5x10-9 and 0.004 respectively) 
or 60 minutes light activation (p = 0.0002, 4x10-9 and 4x10-7 respectively). 
These results indicate that the combination of light and MB led to a reduction 
in the viability of bacteria. However, the log reductions in living bacteria for 
either bacterial strain were low, with the maximum reduction for S. mutans 
bacteria being 0.3±0.2, and the maximum reduction for E. coli being 0.9±0.1 
log reductions.  
As the ATP assay described previously was used to determine 
metabolic activity of the bacteria (section 5.3.3), a comparable experiment 
was performed but the extract solutions containing bacteria were swabbed 
onto agar plates and incubated overnight to determine whether the bacteria 
could reproduce (Figure 7.8). 
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Figure 7.8 – Example set of plates grown overnight of E. coli 
suspended in extract solutions from 10% MB scaffolds. D: Dark 
controls; L: Light controls; PBS: Positive control; 0hr, 2hr, 24hr: Time 
of incubation prior to extract solution collection. All plates presented 
are 10-6 dilution from the original inoculation to allow for direct visual 
comparison 
 
Following incubation, the counting of bacterial colonies was used to 
determine the reduction in CFU obtained after treatments (Figure 7.9 and 
Figure 7.10). 
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(A) (B) 
  
(C) (D) 
Figure 7.9 – S. mutans Extract Solution Toxicity with Agar Plate 
Testing for 10%-MB Scaffolds. (A) 30 min ‘dark’ control; (B) 30 min 
light exposure. (C) 60 min ‘dark’ control; (D) 60 min light exposure. 
Solutions extracted from various 5050 polymeric electrospun 
scaffolds. Results reported as Mean±SD (n=3). ‘*’ denotes significantly 
different means (p <0.05, t-test) 
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(A) (B) 
  
(C) (D) 
Figure 7.10 – E. coli Extract Solution Toxicity with Agar Plate Testing 
for 10%-MB Scaffolds. (A) 30 min ‘dark’ control; (B) 30 min light 
exposure. (C) 60 min ‘dark’ control; (D) 60 min light exposure. 
Solutions extracted from various 5050 polymeric electrospun 
scaffolds. Results reported as Mean±SD (n=3). ‘*’ denotes significantly 
different means (p <0.05, t-test) 
 
This data shows significantly higher rates of killing than that from the 
ATP detection study (Figure 7.6 and Figure 7.7). The ATP assay detects how 
metabolically active the bacteria are and uses this as an estimate of their 
survival. The method based on bacterial CFU counting involved plating up the 
bacteria and allowing time for reproduction and so directly detects if the 
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bacteria can replicate. This is a more traditional and commonly used method 
in microbiological studies[523]. The results presented here therefore suggest 
that the bacteria are metabolically active immediately after treatment with 
extract solutions and light but are unable to reproduce given the opportunity.  
The dark controls for the 30-minute experiments did not result in a 
significant reduction in CFU with S. mutans bacteria, but the 60-minute dark 
controls did result in a significant reduction in CFU for both the 2- and 24-hour 
extract solutions (p = 0.002 and 0.001). The increased exposure time of the 
bacteria to the MB was likely to be the cause of this.  
Following 30 minutes of light activation, the S. mutans CFU count was 
significantly reduced for both 2 hour and 24-hour extract solutions (p = 0.02 
and 0.007 respectively) with average log reductions of 1.7±0.4 and 2.6±0.4 
respectively. After 60 minutes of light exposure, there was a significant 
reduction in CFU/ml for each of the 0-, 2- and 24-hour extract solutions (p = 
6x10-6, 0.002 and 0.002 respectively) with average log reductions of 2.3±0.08, 
2.7±0.3 and 4.0±0.4 respectively. These results indicate that after 2 hours 
post-implantation, the scaffolds should be capable of killing a significant 
amount of gram-positive bacteria. 
There was found to be a small significant reduction in the colonies 
counted for the dark control of the 30-minute E coli samples for the 24-hour 
extract solutions (p = 0.03) but no significant decreases were found with the 
60-minute dark control samples. Upon 30 minutes of light activation, both the 
2- and 24-hour extract solutions were found to significantly reduce the CFU (p 
= 0.02 and 0.002 respectively) with average log reductions calculated to be 
2.0±0.6 and 2.3±0.3 respectively. After 60 minutes light exposure, these 
reductions for the 2- and 24-hour extract solutions were also observed (p = 
0.006 and 5x10-5) with average log reductions of 2.0±0.4 and 2.6±0.2. 
There were not found to be a significant difference in the log reduction 
of each bacteria at comparable time points and extract solution treatments for 
most of the test conditions. However, this study indicated that after 60 minutes 
of light activation of both the 0 hour and the 24 hour scaffold extract solutions, 
significantly more S. mutans was killed in comparison to E. coli bacteria (p = 
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5x10-6 and 0.02 respectively) with an average difference of 2.2±0.2 and 
1.4±0.3 log reductions respectively. Additionally, the extract solutions for 2- 
and 24-hour time points killed both bacteria after 30- and 60-minutes light 
activation, however, the 0-hour extract solutions only killed S. mutans bacteria 
after 60 minutes of light activation. As discussed previously (section 5.2.5.2), 
gram-positive bacteria (such as S. mutans) has been previously found to be 
more susceptible to aPDT than gram-negative bacteria strains (such as E. 
coli) which has been confirmed with these results. 
7.3.2.2 Bacteria Contact Testing 
Finally, ZOI screening was used to assess the bactericidal capacity of 
the scaffolds when in direct contact with bacteria (as opposed to testing the 
extract solutions on planktonic bacteria)[524,525]. The full range of scaffolds (ND 
control, 10%-MB, 50%-MB and 100%-MB) was tested to allow for the non-
cytotoxic lead prototype (10%-MB) to be compared relatively to the scaffolds 
with increased doses of MB. ZOI determination was based on previously 
published protocols for electrospun scaffolds[416]. Images were taken of plates 
in order to accurately calculate the ZOI area which was measured as the 
diameter of the sphere of inhibited growth (as described in Figure 7.1) 
(Figure 7.11).  
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(A) (B) 
Figure 7.11 – Zone of Inhibition Plates for (A) S. mutans or (B) E. coli. 
(…): Example zone of inhibition measured; (1): ND (MB-free) control 
scaffold; (2): 10%-MB; (3): 50%-MB; (4): 100%-MB; (30D) 30 min ‘dark’ 
control; (30L): 30 min light exposure; (60D): 60 min ‘dark’ control; 
(60L): 60 min light exposure 
 
ZOI were measured on the images taken (where present) using ImageJ 
and the results collated (Figure 7.12 and Figure 7.13). 
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(A) (B) 
  
(C) (D) 
Figure 7.12 – S. mutans Zone of Inhibition Testing. (A) 30 min ‘dark’ 
control; (B) 30 min light exposure. (C) 60 min ‘dark’ control; (D) 60 min 
light exposure. Results reported as Mean±SD (n=3). ‘*’ denotes 
significantly different means (p <0.05, t-test) 
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(A) (B) 
  
(C) (D) 
Figure 7.13 – E. coli Zone of Inhibition Testing. (A) 30 min ‘dark’ 
control; (B) 30 min light exposure. (C) 60 min ‘dark’ control; (D) 60 min 
light exposure. Results reported as Mean±SD (n=3). ‘*’ denotes 
significantly different means (p <0.05, t-test) 
 
For both the S. mutans and the E. coli bacteria, both in dark controls and 
with light activation, there was no detectable ZOI for the ND control scaffolds 
without MB-incorporation. This would indicate that MB is responsible for the 
bactericidal capacity of the scaffold. These results agree with the results 
presented previously in this thesis (section 5.2.6.2, section 7.2.2.1 and section 
7.2.2.2) as well as with the literature[524]. 
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In all samples with MB-incorporation which were light activated 
(regardless of the concentration of MB, the time of light activation or the 
bacterial strain), ZOI were found to be present. Each of these zones had a 
defined perimeter, however, a ‘blue haze’ can be seen outside the ZOI 
(Figure 7.11). This could suggest that the MB has been released further than 
the boundary of the inhibition zone, but the concentration of MB is not enough 
to kill bacteria outside of the zone for the light exposure times used. 
The size of the zone is known to be indicative of the level of antibacterial 
activity[301]. The 10%-MB scaffolds showed a small ZOI when tested with S. 
mutans bacteria in the dark controls at 30 and 60-minute timepoints (10.5±0.7 
and 10.7±0.2 mm). This significantly increased upon light activation for either 
30 (13.1±0.6 mm, p = 0.01) or 60 minutes (14.8±0.7 mm, p = 0.008). There 
was no detectable ZOI for the 10%-MB scaffolds in the dark against E. coli 
bacteria at either the 30- or 60-minute time points. Following 30 or 60 minutes 
of light activation, a ZOI was apparent (11.7±0.3 and 15.6±2.1 respectively). 
These results indicate that the lead prototype scaffolds have limited 
bactericidal capability in the dark but are able of killing bacteria upon light 
activation. Again, this conclusion supports the results previously discussed in 
this thesis (section 7.2.2.1 and section 7.2.2.2) and suggests that the scaffold 
can be activated ‘on-demand’ to trigger the bactericidal activity of the MB. 
For the S. mutans bacteria experiments, following 30 minutes light 
exposure there was a significant increase in the ZOI between the 10%-MB 
lead prototype and the increased MB concentrations in both the 50%-MB and 
100%-MB samples (p = 0.003 and 0.001 respectively). After 60 minutes light 
exposure, there was no significant difference between 10%-MB and 50%-MB 
zones of inhibition (p = 0.05) but there was still a significant difference 
between the lead prototype and the 100%-MB scaffolds (p = 0.007). 
Therefore, the lower concentration of MB in 10%-MB is incapable of killing as 
much bacteria as the 50%-MB scaffolds after only 30 minutes light exposure, 
but a greater dose of light is capable of eradicating the concentration effect 
and the killing effects become comparable following 60 minutes light 
exposure. 
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Interestingly, in the E. coli experiments, no significant difference was 
found between the three MB-incorporated scaffolds for either 30 minutes light 
activation (p = 0.55 and 0.23 respectively) or 60 minutes light activation (p = 
0.23 and 0.16 respectively). This suggests that the amount of MB released 
from any of the scaffolds is enough to kill the bacteria, and an increase in MB 
release does not correlate to a greater bactericidal effect. This is 
advantageous as the results previously discussed (Figure 7.4 and Figure 7.5) 
confirm that a lower concentration of MB is less toxic to mammalian cells. 
Therefore the 10%-MB scaffolds can be used in the lead prototype which 
would have an acceptable level of cytotoxicity to mammalian cells but would 
capable of killing as much bacteria as the 100%-MB scaffolds.  
7.4 Conclusion 
In vitro tests were performed on a range of control and MB-encapsulated 
electrospun scaffolds to determine the level of cytotoxicity on L929 cell lines of 
the scaffolds both with and without MB-inclusion. Initial testing was performed 
using an extract solution collected from incubated scaffolds at 0-, 2- or 24-
hour timepoints in PBS. These tests confirmed that all ND control scaffolds 
were non-cytotoxic in the dark or light conditions, which confirms that the ND-
polymeric scaffold and the light source are non-cytotoxic without the inclusion 
of MB. Initial toxicity testing involving pre-incubation of the cells with the 
scaffolds for 2 hours prior to light activation of either 30 or 60 minutes 
produced >30% cell death with any of the MB-encapsulated scaffolds. Upon 
an adaptation of experimental procedure to align with other experiments which 
did not involve a pre-incubation time, the cell death was reduced to <30% for 
all scaffolds in the dark controls. The 50%-MB and 100%-MB scaffolds were 
found to be above the threshold for cytotoxicity. However, the 10%-MB 
scaffold killed <30% after 30 minutes light activation and <35% following 60 
minutes of light activation. Although this result was over the 30% threshold in 
the latter case, this scaffold formulation was the least cytotoxic to mammalian 
cells out of the three MB-included scaffolds.  
In the L929 contact assays, 10%-MB scaffolds demonstrated the ability 
to support cell growth with ‘mild’ reactivity after 24 hours incubation and ‘slight’ 
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reactivity after 7-day incubation in comparison to the ND control samples. 
Considering these results, it was decided to move these scaffolds on into 
further tests to determine whether they could kill bacteria when combined with 
light. 
The initial testing with the same scaffold extract solutions used in the 
L929 cytotoxicity assay did show a significant decrease in bacterial metabolic 
activity when compared to the ND control scaffolds, but the log reduction in 
metabolic activity was <1 log for either bacterial strain, indicating a non-
bactericidal effect. 
Other than bacterial metabolic activity, an alternative analysis was 
developed to directly count bacterial CFU and determine whether the bacteria 
were able to reproduce after treatment with the extract solutions and light 
activation. This experiment confirmed that a >1.5 log reduction was being 
achieved by the extract solutions. Together with the previous experiments 
based on the ATP assay, this data therefore suggests that although the 
bacteria have only had a small, but significant reduction in metabolic activity 
immediately after treatment, they are unable to replicate. 
Other than extract assays, ZOI analysis was performed to compare the 
bactericidal capacity of the scaffolds when in direct contact with the bacteria. 
This confirmed that the combination of both light and MB were needed to kill 
the bacteria, as the ND controls and the ‘dark’ controls had significantly 
smaller ZOI or no zone was present. This provides further confirmation of the 
‘on-demand’ antibacterial capacity of the scaffolds. With increased MB 
concentration in the 50%-MB and 100%-MB scaffolds, significantly more S. 
mutans bacteria were killed in comparison to the 10%-MB scaffold, but no 
significant difference was found against the E. coli bacteria. As the 10%-MB 
scaffolds were the only scaffolds with an acceptable level of mammalian cell 
cytotoxicity, these were selected as the most acceptable prototype.  
To conclude, electrospun scaffolds manufactured from a blend of 50% 
PCL and 50% PLGA1090 with 0.2 mM concentration of MB (10%-MB 
scaffolds) were shown to successfully support L929 cell growth and result in a 
>1.5 log reduction in live bacteria after 30 or 60 minutes of light activation. 
These scaffolds therefore present a promising strategy towards the 
 183 
 
regeneration of oral soft tissue whilst treating bacterial infections without the 
need to prescribe antibiotics. A general discussion of the results presented in 
this thesis and the next stages to be considered in the development and 
commercialisation of this medical device are presented in the following 
chapter. 
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 Discussion 
8.1 General Discussion 
8.1.1 Project Rationale 
AMR remains a prominent healthcare concern with significant medical 
and financial burdens expected in the future[526,527]. There is a currently unmet 
need to treat oral infections through antibiotic-free techniques to minimise the 
spread of AMR[528,529]. 
Advancements are continuously being made in the field of regenerative 
medicine, such as the use of 3D bioprinting to manufacture scaffolds 
populated with cells[530]. Despite this, we are currently still unable to generate 
synthetic functional replacement tissue and organs for transplantation into the 
body. Throughout the duration of this project, a number of interesting research 
articles aiming to meet this clinical need have been published which 
emphasises the importance of regenerative medicine, particularly in the field 
of dentistry[531,532]. The most recent research articles aimed at regenerating 
oral mucosa focus on the use of cell sheet technologies[533,534]. However, 
despite reports of successful research using in vitro systems, commercialised 
medical products relying on cell-based techniques are likely to be subject to a 
lengthy regulatory process and great expense for both the patient and the 
healthcare economy. Therefore, an acellular scaffold (such as the prototype 
proposed in this thesis) would be preferable. 
The aim of this project was to determine the feasibility of designing and 
manufacturing a commercially relevant prototype scaffold which is capable of 
being activated on-demand to selectively kill bacteria through aPDT 
technology whilst supporting oral soft tissue regeneration. 
8.1.2 Key Findings 
Following a review of the preliminary research on this product concept 
and of commonly used FDA-approved polyesters and PS, a series of 
formulations for the prototype polymer scaffold were initially selected. 
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Throughout this research project, these formulations have been systematically 
characterised and optimised for use in the desired application (Figure 8.1). 
 
 
Figure 8.1 – A collection of the formulations discussed in each chapter 
of this thesis. : successful formulations following that stage of 
development; : final formulation (lead prototype). Abbreviations were 
explained in the relevant chapter. 
 
8.1.2.1 Initial Choice of Polymers for Scaffolds 
The aim of Chapter 3 was the initial manufacture and characterisation 
of the biomaterial properties of scaffolds electrospun from two FDA-approved 
polymers (PCL and PLGA7525) along with two FDA-approved PS (MB and 
ER). After an initial screening of polymer concentrations (section 3.3.1.1), a 
range of scaffolds were successfully electrospun containing ~100% of the 
expected mass of PS (section 3.3.2.1). A significant reduction in fibre 
diameter (and consequently the pore size) upon inclusion of either PS was 
found, which was likely to be due to the charge repulsion in the polymer jet 
during electrospinning (section 3.3.2.1). 
Chapter 4 contains a range of characterisation methods aimed at 
describing the interactions between this range of scaffolds and aqueous 
environments. The scaffolds proved to be hydrophilic as demonstrated by WU 
(section 4.3.1.3) and contact angle (section 4.3.1.1) analyses. This 
hydrophilicity was further enhanced with PS encapsulation. In vitro PS release 
profiles indicated that PLGA7525-PS scaffolds released a minimal amount of 
PS over the 4-week timeframe (section 4.3.1.2). However, during the 8-week 
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hydrolytic degradation study, PLGA7525 scaffolds shrunk macroscopically in 
solution and collapsed microscopically, resulting in a lack of porosity of the 
structure which would prevent cell integration in vivo (section 4.3.2).  
PCL-ER scaffolds only released ~20% of ER included within the 
scaffold, which was in contrast to the PCL-MB scaffolds which displayed a 
typical burst release profile with 100% of MB being released during the first 24 
hours of incubation (section 4.3.1.2). Neither of these profiles were ideal, as a 
gradual release of the PS was desired to be achieved over the first 4 weeks 
post-implantation in a clinical setting to allow for repeated photoinduced 
activation of the PS if required. The hydrolytic degradation study indicated that 
PCL scaffolds displayed minimal microstructure alteration and minimal mass 
loss (section 4.3.2).  
Therefore, PLGA7525-MB and PLGA7525-ER scaffolds were 
withdrawn from further analysis and PCL-MB and PCL-ER scaffolds were 
taken forward into the next stage of the project. 
8.1.2.2 Selection of Photosensitiser for Antimicrobial Photodynamic 
Therapy 
The aim of Chapter 5 was to determine which PS was most suitable for 
the desired antimicrobial effect out of two FDA-approved PS; MB and ER. 
Initially, MB uptake was found to be greater than ER uptake into L929 
mammalian cells and S. mutans and E. coli bacterial cells (section 5.3.2). This 
is likely to be a contributing factor to the increased toxicity of MB-loaded 
solutions against both mammalian and bacterial cells in comparison to ER-
loaded solutions (section 5.3.3). However, solutions of PS were compared 
with regards to mass concentrations (mg/ml) rather than molarity 
concentrations, so although the results of these studies suggested that MB 
was more effective than ER, the molarity concentrations compared were 
approximately 3 times greater for the MB than ER. It is worth noting that many 
published research papers have compared the effectiveness of PS based on 
mass concentrations rather than molarity concentrations so both data sets are 
valuable to allow for comparisons to be made between this research and 
previous studies[365,535,536].  
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Finally, the toxicity of two selected prototypes (PCL-MB and PCL-ER) was 
determined for both mammalian and bacterial cell types (section 5.3.4). PCL-
MB scaffolds were found to be more effective at deactivating E. coli bacteria 
populating the scaffolds in vitro than the corresponding PCL-ER scaffold 
variant with the same molarity of PS. These results, along with a review of the 
literature confirming the advantages of the use of MB in dental aPDT, lead to 
MB being chosen as the optimal PS to be used in the intended aPDT system. 
8.1.2.3 Optimisation of Polymers of Polymer Building Blocks for 
Electrospun Scaffolds 
The data presented in Chapter 6 were the result of a series of 
experiments performed to determine whether biomaterial properties could be 
improved through altering the polymer used to manufacture the scaffolds with 
MB. Due to the amorphous nature of PLGA7525 resulting in scaffold 
shrinkage upon contact with water (sections 3.3.2.3 and 4.3.2), a new 
monomer ratio of PLGA (PLGA1090) was selected for analysis (section 6.3.1). 
These new scaffolds were found to have a greater degree of crystallinity 
(section 6.3.1.2) which contributed to the demonstrated optimised properties 
such as no detectable shrinkage in aqueous media and desirable release 
profiles with MB-encapsulation. However, they did degrade too quickly for the 
intended purpose (following 1-2 weeks incubated in PBS) (section 6.3.1.3). 
A combination of the desirable properties of PCL (resistance to 
hydrolytic degradation) and PLGA1090 (sustained MB release) were needed. 
Therefore, the remainder of Chapter 6 was used to characterise blends of 
these two polymers in three ratios (80:20, 50:50 and 20:80) with MB-
encapsulation (section 6.3.2.1). Characterisation of these scaffolds concluded 
that the 50:50 blend had the optimised properties from both of these systems 
(section 6.3.2.3). 
Finally, in preparation for the final ‘in vitro testing’, the 50:50 polymer 
blend was electrospun with three different concentrations of MB (10%-MB, 
50%-MB and 100%-MB) (section 6.3.2.4). No significant changes to the fibre 
diameter and crystallinity of the scaffolds were found upon the reduction in MB 
within this range. 
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8.1.2.4 In vitro Testing of Optimised Prototype Scaffold 
Chapter 7 used a series of experimental tests on the optimised scaffold 
with a range of three MB concentrations in order to determine whether 
selective aPDT effect could be achieved i.e. toxicity to bacteria but 
mammalian cell tolerance. 
Both extract (section 7.3.1.1) and contact assays (section 7.3.1.2) were 
performed with L929 mouse fibroblasts. 50:50 10%-MB scaffolds proved to be 
non-toxic to cells in each of these tests in accordance with ISO 10993 
standards. Therefore, this formulation was also tested with model gram-
negative and gram-positive bacteria (i.e. E. coli and S. mutans) to determine 
the selectivity achievable between mouse fibroblast and bacterial cells 
(section 7.3.2). In both extract and contact in vitro assays, 50:50 10%-MB 
scaffolds demonstrated the ability to deactivate both bacterial strains in the 
light activated samples with minimal toxicity being found in the ‘dark’ control 
samples. Therefore, it was concluded that this scaffold had the required aPDT 
selectivity for the lead prototype at the conclusion of this project. 
8.2 Commercialisation Discussion 
This research has been conducted as the result of an iCASE 
collaboration between the University of Leeds and an industry sponsor, 
Neotherix Ltd. Therefore, one of the objectives of the research was to 
determine the potential commercial feasibility of this prototype in dental 
markets. For the remainder of this thesis, the prototype medical device will be 
referred to as ‘PhotoTherixTM’. 
8.2.1 Technology Readiness Levels 
Technology Readiness Level (TRL) descriptions were developed by 
NASA in 1995 as a way to describe and monitor the progression of new 
technologies within the organisation[537]. The TRL scale has now been 
adopted for the research and development of a wide range of technological 
advancements. Typically, a scale from TRL 1 (foundation level research) 
through to the final TRL 10 stage (the technology is being used commercially) 
is adopted (Table 8.1)[538]. 
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1 2 3 4 5 6 7 8 9 10 
Science Technology Commercialisation Market 
Research 
Idea 
Proof of 
Market 
Proof of 
Concept 
Proof of 
Validation 
Market 
Validation 
Proof of 
Concept 
Pathway 
Develop 
Product 
Market 
Launch 
Monitor 
Basic 
science 
Search for 
novelty and 
compare to 
market 
leaders 
Evidence of 
inventive 
concept 
Prove 
advantage 
compared 
to market 
leaders 
Develop 
strategy, 
protect IP, 
engage 
partners 
Meet 
industry 
standards 
Perform IP 
sale, 
license or 
spin-out 
Industry 
partner 
develops 
product for 
launch 
Launch 
product 
Monitor 
impact and 
finance 
Table 8.1 – Technology Readiness Level (TRL) description[538] 
 
 
 
1
8
9
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At the beginning of this project, a design concept for the technology 
had been hypothesised (TRL 1) and a preliminary market search had been 
performed (TRL 2) in the form of an external report produced by BITECIC 
Ltd[246]. Proof of concept research had been performed for PhotoTherixTM 
with regards to a skin application. The research performed as part of the 
research project presented in this thesis was aimed to progress the 
technology from TRL 2 to TRL 3 for specific use in oral applications. 
This project has concluded with a prototype PhotoTherixTM medical 
device being proposed. Through a range of in vitro experimental techniques, 
the scaffold demonstrated the ability to be stable in an aqueous environment 
for up to 8 weeks, to gradually release PS over 4 weeks and to selectively 
deactivate bacteria but sustain fibroblast cell growth following light activation. 
These had been determined as the minimum criteria required to 
demonstrate that the prototype had the potential to be an effective clinically 
used product. Therefore, the technology has been progressed to the ‘Proof 
of Concept’ TRL 3 stage.  
Regulatory considerations have been implemented during the project 
to ‘future proof’ the prototype. For example, FDA-approved polyesters and 
PS were chosen to simplify the approval process. Also, awareness of the 
regulatory approval processes (i.e. test procedures of the ISO standard) 
were implemented during the design of the experiments in Chapter 7. The 
aim of this was to de-risk the technological design and determine whether 
this product concept could overcome the ‘valley of death’ following proof of 
feasibility stage towards a proof of commercial concept study[539]. If a product 
works perfectly in the laboratory but the design is too complex to be 
approved by the regulatory bodies in a cost-effective fashion, the research is 
unlikely to result in innovation and a patient/end-user benefit or attract the 
investment funding necessary for commercial development. 
The next steps on the TRL scale would be to develop the research 
further into TRL 4, which would require PhotoTherixTM to be compared to 
market leaders to ensure that the device has benefits with respect to the 
current commercially available products in either effectiveness or cost in 
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order to identify potential unique selling points. This could involve activities 
such as consulting clinicians and the use of animal models to indicate safety 
and efficacy in vivo. For this next stage of development, additional 
investment would be needed, so potential funding sources should also be 
considered. 
 
8.2.2 Regulation and Classification 
The Medical Device Directive (MDD) was introduced in 1993 to help 
regulate new medical devices in the EU to provide a way of ensuring that 
commercially available products were safe for use[540]. Notified bodies such 
as the British Standards Institute (BSI) in the UK were nominated to help 
enforce these directives on behalf of the competent authority, which in the 
UK is the Medicines & Healthcare Products Regulatory Agency (MHRA)[541]. 
As such, they assess new devices based on their safety for CE marking 
purposes. Part of this process involves classifying medical devices by 
examining their end use duration, and what risk this would pose to a patient 
if failure of the device were to occur[542]. If approval is sought in one 
geographical area, this can often aid the process of applying for approval in 
another. An increased risk to health and length of exposure results in 
increased rigorousness in the testing protocols (Table 8.2). 
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EU Medical 
Devices 
FDA Medical 
Devices 
Risk Level Example 
Class I Class I Low Hospital beds 
Class IIa Class II Medium Hearing aids 
Class IIb 
Class III 
Higher Infusion pumps 
Class III Highest Prosthetic joints 
Active Implantable Medical 
Devices (AIMD) 
Very high 
Spinal cord 
stimulators 
Table 8.2 – Medical device classifications[542] 
 
In May 2017, a new set of directives were announced by the EU for 
medical device regulation, known as the Medical Device Regulations 
(MDR)[543]. The main differences between the MDD and the new MDR 
include more stringent checks being required for most devices, cosmetic and 
‘non-medical’ devices such as coloured contact lenses are now included in 
the regulations, and a new Unique Device Identification (UDI) has been 
introduced which will be required on all devices[543]. When announcing the 
new MDR, a 3 year ‘transition period’ was stated in which both the MDD and 
MDR are active[544]. However, this transition period finishes in May 2020, so 
with regards to the future commercialisation of PhotoTherixTM, approval from 
the MDR will be of more importance than the MDD.  
It is worth noting that due to the uncertainty surrounding the UK 
leaving the EU at the time of writing this thesis, it may be that these 
classification systems leading to approval will be different for the UK and the 
EU. However, for selling PhotoTherixTM in international markets, adhering to 
these systems will be required anyway. 
Although flow charts are widely available online to predict which 
classification applies to a new medical device, official advice from relevant 
notified bodies should be sought out during prototype development. Due to 
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the large size of the market in the US for dental products, it is likely that 
PhotoTherixTM will be aimed for sale in both the EU and the US. Therefore, it 
would be useful for the device to adhere to both regulatory systems for 
approval by the EU and the FDA[542].  
In the US, many companies aim for their devices to be approved 
through the 510(k) process, which is a 90-day review procedure in which a 
company will submit documentation to explain that the new device is 
comparable to a currently approved device and would therefore not be 
required to go through the lengthy and expensive procedure of seeking 
additional approval[542]. Unfortunately, as there is no device like 
PhotoTherixTM on the market currently, it is unlikely that a 510(k) approval 
will be possible. Therefore, in the US, pre-market approval from the FDA 
would need to be sought out. 
It is important to note that PhotoTherixTM is a borderline product, as it 
is not clear whether it would be classified as a medical device or a medicinal 
product. As PhotoTherixTM is designed to be fully resorbed by the body, it 
would be classified as a Class III medical device. However, this relies on the 
assumption that the primary function of PhotoTherixTM is as a regenerative 
scaffold, with an additional functionality of the bactericidal effect. If 
PhotoTherixTM were to be primarily a delivery device for the PS, it would be 
more likely to be classified as a medicinal product. In order to be approved 
as medicinal product a different set of directives are relevant, which require 
even more stringent testing. This would be more costly in both time and 
expense to continue the development of this concept into a commercial 
product so this should be avoided if possible. Due to the difficulty in 
distinguishing the classification of borderline products, official advice would 
need to be gained from the relevant authorities. 
8.2.3 Use in Dental Surgery 
The prototype of PhotoTherixTM has been designed to be used by a 
dental practitioner in oral surgeries to help regeneration of oral soft tissue 
whilst treating localised oral infections. Questions remain as to how the 
device should be implanted, and in which types of surgical dental 
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procedures it would be most useful. Literature searches and informal 
discussions with dental practitioners in the department of Oral Biology at the 
University of Leeds led to the following suggested uses for the scaffold. 
8.2.3.1 Gingival Recession treatment 
Gingival recession is the erosion of the gingiva resulting in the 
exposure of the tooth root surface to the oral environment[545]. It can be 
caused by many factors such as abrasion from aggressive brushing of the 
teeth, periodontal disease and surgery[545]. Gingival recession often results in 
aesthetic and functional issues (e.g. root hypersensitivity)[546]. Traditionally, 
autologous tissue harvested from elsewhere in the oral cavity (e.g. the 
palate) can be used during root covering surgeries. Currently, bioresorbable 
porcine collagen membranes such as Geistlich Mucograft® (Geistlich 
Pharma Inc.) are commonly used to prevent the need for two surgical sites 
and to decrease operation times[547]. The use of PhotoTherixTM in place of 
the porcine collagen could be advantageous due to some patients being 
exempt from treatment with porcine tissue because of ethical or moral 
reasons. An additional benefit would be the extra protection from infection 
provided by the antimicrobial functionality of PhotoTherixTM. However, oral 
tissue staining resulting from the use of MB may be a potential disadvantage 
and should be explored with customers (both end-user clinicians and 
patients). 
8.2.3.2 Split Thickness Tissue Grafting 
Split thickness grafts are used to treat large defects to the oral 
mucosa[548]. They involve the extraction of a sublayer of autologous oral 
tissue, and the combination of this split-thickness tissue with a membrane to 
form a new layer of oral mucosa e.g. around implants or for patients with 
dental bone loss[549]. Briefly, this surgery involves the withdrawal of the 
tissues surrounding the tooth and the debridement of bone tissue in the 
cavity[549]. Bone stock is then taken (commonly from the third molar) and 
packed into the cavity with some blood to increase healing[549]. The gap is 
then sealed over with a biodegradable scaffold to hold it all in place[549]. 
PhotoTherixTM would be a good alternative to current membranes, as the 
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site would be easily accessible for light activation and the antimicrobial 
aspect would be an additional advantage. 
8.2.3.3 Closure of Extraction Socket 
PhotoTherixTM could also be used as a periodontal ligament membrane 
to close an extraction socket (socket seal technique)[20]. Currently, an 
antimicrobial membrane is used in root extraction surgery for 1 week to seal 
over the site around the tooth which is then removed, prior to implantology 
surgery being performed[550]. Currently, cement loaded with zinc oxide-
eugenol is a common choice to cover this site[551]. Although this works well 
as an antimicrobial, patients can be sensitive to the use of eugenol so this 
treatment cannot be used in certain patient populations[551]. An alternative 
scaffold is ‘CoE-Pak’ (GC America Inc.) which is eugenol free[552]. The use of 
PhotoTherixTM would allow for universal treatment and the on-demand 
antimicrobial aspect of the scaffold would be advantageous. This use of this 
product would allow for repeated light activation within the week in which the 
scaffold is in situ. However, this proposed use would not require the scaffold 
to function as a tissue regenerating device. In fact, this would be a 
disadvantage as the scaffold would need to be removed. 
8.2.3.4 Surgical Technique 
As described above, some suggested uses of the scaffold would involve 
the incorporation of an autograft or additional membrane along with the 
scaffold. This would require implanting the scaffold either underneath or on 
top of the autograft.  
If the scaffold were to be placed on top of the membrane, PhotoTherixTM 
would be easily accessible for the dental practitioner to light activate. 
However, the scaffold may not fully integrate with the tissue if placed on top. 
If ‘sandwiched’ between the autograft and the wound bed, PhotoTherixTM 
would be in a good position for tissue integration, but it may have limited 
accessibility for the light source. The light required to activate MB is 610-665 
nm which is in the ‘red’ region of the visible light spectrum. Red light has 
been found to have greater tissue penetration (of up to 1-2 mm[553]) 
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compared to other wavelengths within the visible light spectrum due to its 
shorter wavelength[336]. 
A final consideration for this product would be the fixation of the product 
during placement in the oral cavity. Two possible methods include sutures or 
mucoadhesion. Sutures are the current most commonly used method for 
securing grafts in the oral cavity[228]. Single button[554] or cross[178] resorbable 
sutures can be used. 
However, many interesting research articles have been published which 
explore a variety of new methods to generate mucoadhesive compounds[555–
557]. Despite further research being required before these techniques 
become the ‘gold standard’, with scientific advancements these could be 
used in combination with this product during oral surgery. 
8.2.4 Competitor Analysis 
Successful products are currently available on the market either for 
oral soft tissue regeneration (e.g. mucoderm® (Botiss Dental)) or the 
treatment of oral infections through aPDT (e.g. PeriowaveTM with advanced 
formulation syringes (Ondine Biomedical)). For PhotoTherixTM to be a 
commercially viable option, there would need to be a unique selling point 
(USP) for there to be an advantage of purchasing and using this product 
over the currently used products. This could include being a more cost-
effective option, proving to be more clinically effective or proving to have a 
unique additional feature. At the time of the publication of this thesis, there is 
no other medical device commercially available (to the best of the author’s 
knowledge) which combines a synthetic polymer scaffold for the 
regeneration of oral soft tissue with the release of PS designed for use with 
aPDT technology. This could prove to be the additional unique feature which 
gives a commercial advantage to this product as it would be the ‘first to 
market’. Further to this, electrospinning is a relatively cheap technique which 
has the potential to generate large sheets of product. As only a small 
amount of product would be required per operation, the device could also be 
sold at a competitive price in comparison to the other products available. For 
example, online prices for mucoderm® are reported as between £105-£189 
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per matrix (www.straumann.co.uk) depending on the size of requested 
(although costs are likely to vary depending on order quantity and source). 
8.2.5 Patentability 
Patents are legal documents which allow a monopoly of the rights of a 
specific invention to be obtained for up to 20 years[558]. Obtaining a patent is 
seen by many as key in order to protect intellectual property and allow 
commercialisation of a new product as without doing so, larger companies 
could launch an identical product at a more competitive price. It has been 
reported that SMEs (Small and Medium Enterprises), such as Neotherix Ltd., 
are more likely to exploit their patent portfolio for monetary gains than larger 
firms[559]. This is because larger firms have a greater abundance of financial 
resources, so they can afford to strategically patent a host of inventions to 
hide their main product or to prevent competition. This contrasts SMEs who 
are unlikely to patent an invention unless they intend to exploit the 
intellectual property rights through licensing to a larger company or 
developing the invention into a viable product. 
In 2010, a patent was filed for the research concept of PhotoTherixTM, 
jointly between the University of Leeds, the University of Bradford and 
Neotherix Ltd. Unfortunately, the increasing annual payments required to 
sustain the enforcement of the patent were not maintained and the patent 
was abandoned. This could be a potential disadvantage when applying for 
future investment into the technology to develop it further, as investment 
may rely on the security associated with a patent. 
However, the existence of the expired patent may be enough to deter 
other market leaders from competing commercially. Another factor to 
consider is that the device could still be commercialised if a full set of data 
were to be obtained as the ‘first to market’ advantage. If the device were to 
be established as the leading product prior to a similar product being 
commercialised, it could deter competitors in the same market. 
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 Future Work 
9.1 Choice of Light Source and Exposure Time 
In this study, a broad spectrum ‘security light’ was used as a model 
system for PS activation due to dental lasers being too expensive to 
purchase at this stage in the study. Laser light of a higher intensity is likely to 
result in a greater activation of the PS and therefore a higher rate of bacterial 
cell death[560–562].  
As discussed previously (section 5.3.1), the PeriowaveTM handheld laser 
light source is a commercial product designed to activate PS such as MB in 
oral applications. One interesting future study would be to use this device 
with the proposed prototype in order to determine whether the light exposure 
time could be reduced to a clinically relevant timescale (30- or 60-seconds) 
whilst still killing enough bacteria. The reduced light exposure time may also 
reduce the mammalian cytotoxicity, so selectivity should be reassessed 
following these experiments with a different light source. 
Another interesting future study would be to look into the effects of light 
fractionation[320], e.g. by exposing the scaffolds to a 30 second light exposure 
from PeriowaveTM or three 10 second light exposure time points to see 
whether his changes the level of bacterial death. 
9.2 Photosensitiser Release Profile Accuracy 
The oral cavity is a notoriously difficult environment for which to 
predict accurate drug release profiles due to the variation in pH, saliva and 
the range of bacterial strains possible between patients[563]. Research has 
been performed aimed at measuring the average volume of the saliva in the 
oral cavity[564] but this does not account for the vast differences in 
composition, particularly in the case of infected oral cavities[565]. As with the 
majority of the published literature, a simplified in vitro PS release 
experiment using PBS has been used in this thesis to model drug release in 
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the oral cavity (section 4.2.2). However, future experiments should focus on 
a more accurate prediction of the drug release behaviour specifically in the 
oral mucosa. This could be done either through in vivo studies or the use of 
an ex vivo diffusion model, such as the Franz diffusion cell system with 
rabbit oral mucosa tissue[566]. 
9.3 Mammalian Cell Cytotoxicity 
The scaffold system has currently only been tested on L929 cells as 
these are most frequently used in the regulatory approval process[191]. 
However, future experiments should be designed with primary cells which 
are taken from the oral mucosa of patients. 
An external placement was performed at the University of Sheffield 
under the supervision of Dr Helen Colley and Dr Craig Murdoch to determine 
the mammalian cell cytotoxicity using an in vitro infected oral mucosal 
disease model which they have developed[39,567]. General details of the 
placement are given in the Appendix A. Unfortunately, the time given for the 
project was not sufficient to yield results due to the optimisation needed to 
the oral mucosal model prior to the application of the prototype scaffolds. 
However, the model does provide a potential future direction for this project 
and could be used to test the system whilst utilising the first of the ‘3Rs’ 
(Replace, Reduce, Refine) in animal testing[568]. The use of this system prior 
to animal testing should prevent unnecessary animal testing being 
performed if the results suggest that further optimisation is required. 
However, if this model can be used to further demonstrate that the system is 
non-cytotoxic, progression should then be made to test the scaffold in an in 
vivo animal model study. From this point onwards, clinical trials could be 
designed to validate the safety of the product for use in clinical applications. 
9.4 Antimicrobial Photodynamic Therapy Capability Against 
Oral Bacteria  
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This initial prototype has only been tested on model strains of 
planktonic bacteria during this study. Prior to commercialisation, there is a 
need to confirm that the product is also effective against biofilms of 
anaerobic oral bacteria commonly found in oral infections. These could 
include P. gingivalis which is known to be involved in the progression of 
periodontal diseases[287]. However, there are already a vast amount of 
studies published on the use of aPDT with MB to deactivate biofilms, so this 
study will be to confirm the model system is effective at delivery of the PS as 
opposed to the efficacy of the PS itself[279,569,570]. 
9.5 Sterilisation Methods 
It is vital that any regenerative medical device to be made 
commercially available can be proven to be sterile. In this thesis, disinfection 
was achieved via UV-treatment of the scaffolds. This proved to be effective 
for the purpose of the in vitro studies, evidenced by the cell growth observed 
via SEM (section 7.3.1.2). However, although UV-treatment is known for 
disinfection[571], it is not approved as a sterilisation method in industrial 
applications. Alternative suitable sterilisation techniques commonly used in 
the medical device industry include heat treatment, gamma irradiation, 
electron beam irradiation, plasma treatment or ethylene oxide chemical 
treatment. Dai et al published a comprehensive review on these techniques 
and the consequences of use with biodegradable polymers[572]. This review 
concludes that there is no ideal sterilisation technique currently available, so 
one should be selected with the minimal structural effects on the scaffold. 
Gamma or electron beam irradiation could be potentially suitable techniques 
due to the low temperature and the ability to control the lack of residual 
particles from these methods. 
An additional consideration is that sterilisation of polymer scaffolds is 
known to lead to changes in the mechanical properties[572–574]. Therefore, 
following the selection of a suitable sterilisation technique, the mechanical 
properties as well as the resulting degradation and PS release profiles of the 
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post-sterilised scaffolds should be reanalysed to ensure that the scaffolds 
are still suitable for the intended application. 
9.5.1 Additional Use in Chronic Wound Applications 
Chronic wounds are commonly defined as topical skin wounds which 
have not healed after 4-6 weeks[575].  It is estimated that 2.2 million people 
per year in the UK need treatments for chronic wounds, costing the NHS 
£5.3 billion[576]. Infection in chronic wounds is a frequent complication, and 
prevents the wound from healing[575]. As this device aims to regenerate soft 
tissue whilst treating localised infections, the prototype produced from this 
research project could be expanded for use in chronic wounds as well. A 
research project at the University of Bradford has recently been performed 
with the same product concept but with the intended application of skin 
regeneration in chronic wounds. 
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 Conclusions 
To conclude this thesis, the initial table of characteristics (Table 2.1) was 
re-examined to determine whether the development and characterisation of 
a prototype device has been achieved (Table 10.1). 
Scaffold Characteristic Achieved? 
Fibrous and porous Yes – section 6.3.2.2 
Appropriate mechanical properties for the oral 
mucosa (e.g. elastic modulus of 0.9-11 MPa[388]) 
Yes – section 6.3.2.2 
Capable of loading PS and releasing steadily over 
4 weeks 
Yes – section 6.3.2.3 
Demonstrates stability and maintains porous 
structure in aqueous environments 
Yes – section 6.3.2.3 
Maintains integrity up to 8 weeks Yes – section 6.3.2.3 
<30% cytotoxicity to mammalian cells in dark or 
light conditions 
Yes – section 7.3.1 
Minimal bactericidal activity in dark conditions but 
ability to prevent growth of bacteria upon light 
activation 
Yes – section 7.3.2 
Table 10.1 – Summary of scaffold requirements for oral applications 
  
This project has systematically determined a scaffold formulation 
which demonstrates the desirable characteristics which were initially 
identified (Table 2.1). A promising prototype has been developed which, with 
the further research described, has the potential to be developed into a 
commercially relevant medical device capable of improving patient 
outcomes, benefitting the healthcare economy, and minimising the spread of 
AMR. 
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Appendix A 
General Description of University of Sheffield External Placement 
The process of generating the models used during the placement is 
described in detail in the relevant publications[39,567]. Briefly, freeze-dried rat 
tail collagen was dissolved and combined with primary normal oral fibroblast 
cells, added to well inserts and incubated in media for 24 hours. The cell-
embedded collagen gels were then brought to an air-liquid interface and 
FNB6 cells (oral epithelial cells) were added. The oral mucosal models were 
incubated for 10 days with media changes every other day. Following this 
time, the models were either used as controls or infected with S. mutans 
Ingbritt bacteria. After 24 hours, the models were fixed in formalin, 
dehydrated, wax embedded, sectioned, stained with Gram’s stain and 
visualised on a light microscope (Figure A1). 
 
 
(A) (B) 
Figure A1 – Histology slides of Gram-Stained Oral Mucosal Models 
generated during an external placement to Dr Helen Colley’s 
laboratory at the University of Sheffield. (A): Control non-infected 
model; (B): Model infected with S. mutans Ingbritt bacteria. Images 
taken at 20x magnification on a light microscope 
 
